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ABSTRACT 
Iron deficiency anaemia is one of the most prevalent nutritional deficiency disorders 
in the world. Food iron fortification is a widely used strategy to reduce the risk of 
deficiency but presents a major challenge to the food industry. The more 
bioavailable forms of iron, such as ferrous gluconate, cause adverse organoleptic 
changes when added to foods. The primary aim of the work described in this thesis 
was to test whether alginate would bind soluble forms of iron and thereby maintain 
its bioavailability. Initial in vitro studies demonstrated that alginate solutions and 
beads loaded with ferrous gluconate delivered iron in an available form for uptake 
into Caco-2 cells (measured by ferritin formation). A human study was undertaken to 
assess the bioavailability of ferrous gluconate in alginate beads, and it was found to 
be significantly lower than ferrous gluconate on its own, so further in vitro studies 
were undertaken to examine possible reasons for the inhibitory effect of the beads. 
It was concluded that alginate beads, containing calcium as a gelling agent, are not 
an effective delivery vehicle for soluble iron compounds. However, these findings 
should not rule out the potential use of alginates as a delivery system for iron, 
especially in diets containing high levels of phytate. Other related work reported in 
this thesis includes studies of iron availability from two wheat cultivars with varying 
phytate and iron concentrations, potential use of nicotianamine and 2'-
deoxymugineic acid as iron enhancers, and investigations into calcium-iron 
interactions in a Caco-2 cell model, with the use of live cell imaging techniques and 
confocal microscopy. 
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1.1 Iron  
Iron (Fe) is one of the most abundant trace elements in the Earth’s crust. It can be 
found in ten different oxidative states (from –II to +VIII). However in aqueous 
solutions it is only present in either of the two following forms: 
 Fe2+, ferrous form 
 Fe3+, ferric form  
Iron can readily transfer an electron and switch between these two oxidation states, 
thus it is an ideal element to catalyse biochemical reactions, including redox 
reactions1.  
Under aerobic conditions ferrous iron is oxidised to the ferric form. Fe3+ is insoluble 
at physiological pH and therefore not available for mammalian cells2. The problem 
can be overcome with the use of reducing agents or proteins which have evolved to 
reduce iron from the ferric to ferrous form, thus ensuring that iron is soluble and 
bioavailable. The latter are essential to allow iron uptake3, 4, 5, storage6 or haem 
synthesis7. Consequently, reduction reactions of iron are crucial in iron metabolism.  
However, when iron is present in excess it can catalyse reactions in which harmful 
oxygen radicals2 are generated. Reduction of one electron of dioxygen by ferrous 
iron leads to formation of superoxide, which reacts further leading to the sequence 
of reactions known as Haber-Weiss-Fenton chemistry in which hydroxyl radicals7 
are produced from superoxide and hydrogen peroxide. Hydroxyl radicals are toxic 
within biological systems, oxidising proteins, nucleic acid and carbohydrates which 
can result in peroxidation of lipid membranes7. Consequently, oxidative stress 
(elevated levels of reactive oxygen and nitrogen which exceed the antioxidant 
capacity of the organism) occurs in the presence of raised levels of redox-active iron 
leading to enhanced deterioration of tissues2. Therefore, in order for biological 
systems to function optimally, it is crucial that iron concentrations are tightly 
regulated. 
1.1.1 Importance of iron homeostasis in mammalian metabolism 
Unlike other essential metals, there is no specific mechanism for iron excretion from 
the body8. The only loss of iron from the body takes place through shedding 
epithelial cells from the intestine, urinary tract, skin (including hair and nails), via 
blood loss (menstruation or other), urine, bile, semen and sweat9. Nearly 90% of 
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daily iron requirements are covered by recycling from the breakdown of senescent 
red blood cells10. The remaining 10%, which is approximately 1-2mg iron12, needs to 
be acquired from the diet via intestinal iron absorption.  
Nonetheless, according to the World Health Organisation (WHO) around 2 billion 
people worldwide are affected by anaemia12, the reduced capacity of red blood cells 
to carry oxygen. It is caused by impaired or decreased haemoglobin or red blood 
cell concentrations in the blood. Progressive anaemia can lead to hypoxia. By 
contrast, the iron overload disorder, haemochromatosis, affects approximately 1 in 
150 people in populations of Northern European origin10. Thus, tight regulation of 
iron homeostasis (Figure 1.1.1) is fundamental for maintaining health.  
Iron in the ferrous state is a component of haemoglobin and myoglobin. 
Haemoglobin in red blood cells is needed in order to transport oxygen around the 
body. Myoglobin is an oxygen storage and utilisation protein within the muscle 
tissue. Iron is vital for many biochemical processes within the body, such as 
synthesis of DNA, mitochondrial respiration and other crucial metabolic reactions11.  
 
Figure 1.1.1 Schematic diagram showing major pathways of iron homeostasis with 
approximate values of iron content in tissues. From: 
http://ahdc.vet.cornell.edu/clinpath/modules/chem/femetb.htm. Copyright © Cornell 
University- accessed on 02.02.2011. 
 
INTRODUCTION 
26 
 
1.1.2 Iron deficiency in humans  
Iron deficiency anaemia (IDA) accounts for 50% of all anaemias12 with infants, 
children and pre-menopausal women at most risk. Both in developing and 
developed14 countries the consequences of anaemia result in significant health 
problems and economic cost.  
Nutritional iron deficiency is a state of imbalance when the iron content of the diet is 
insufficient to meet physiological needs15. Iron is present in a wide variety of foods, 
so dietary intake usually correlates positively with energy intake16. Depending on the 
presence of dietary enhancers and inhibitors, non-haem (inorganic) iron absorption 
from the diet ranges between 1% and 15%17. Therefore the cause of nutritional 
deficiency is often related to low bioavailability rather than inadequate intake of iron. 
However if body iron requirements exceed intake, the risk of iron deficiency is 
elevated.  
In developing countries instances of iron deficiency are 2.5 times that of anaemia. 
The WHO defines iron deficiency as “a condition in which there are no mobilizable 
iron stores and in which signs of a compromised supply of iron to tissues, including 
the erythron, are noted. The more severe stages of iron deficiency are associated 
with anaemia”14.  
In the United Kingdom according to the National Diet and Nutrition Survey (NDNS) 
iron deficiency affects ≈29% of children below 4.5 years of age, 23.8% of female 
teenagers, 16% of young woman and 14.3% of free-living elderly females (85 years 
and over) with serum ferritin levels in above mentioned groups below 15µg/L14. IDA 
occurs at some stage of pregnancy in 25% of woman and in 33.3% of woman in the 
postpartum period19. Furthermore children below 6 years of age, females aged 15-
18 and 25-34 are also reported to have IDA with a prevalence of 11.5% and 9.1% 
respectively14. According to the NDNS IDA is very common in the elderly, with 
haemoglobin (Hb) concentrations below 130g/L in 37.5% of free-living males and 
below 120g/L in 16.0% of females aged 85 years and over. IDA is even more 
pronounced in institutionalised elderly individuals aged 65 and over with 52.2% of 
males and 38.6% of females being affected. The main reasons for IDA are: 
 Diet with low iron content 
 Diet rich in iron inhibitors thus reducing iron bioavailability 
 High iron demand due to physiological state  
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Other causes of anaemia include: 
 Acute and chronic infections (malaria, HIV, tuberculosis, cancer) 
 Helicobacter pylori infection20 
 Heavy blood loss 
 Parasite infections 
 Other micronutrient deficiencies (riboflavin, folate, copper, vitamin A, B12) 
 Haemoglobinopathies affecting African, Southeast Asia and Mediterranean 
populations.  
 Impaired iron absorption 
Often more than one factor contributes to the development of anaemia. Although it 
is continuously being addressed through food fortification programmes across the 
world, eradication of the condition remains challenging. 
The physiological demands for iron determine how efficiently iron is absorbed, but 
the iron must be present in the gut lumen in a form that is available for absorption, 
therefore dietary factors play a key role in delivering the required amount of iron to 
maintain balance. Requirements are increased in the following situations: 
 Pregnancy 
 Infants and young children (rapid growth) 
 Menstruating teenagers (growth plus iron losses)  
 Menstruating woman (iron losses) 
The symptoms of anaemia are varied. In adults iron deficiency decreases the 
capacity for physical activity, affects work performance and causes tiredness and 
lethargy12,18. IDA adversely affects the immune system, increasing the possibility of 
upper respiratory tract infections in children, and leads to prolonged recovery 
times21. The health consequences of not meeting body iron requirements depend on 
the physiological state: 
 During pregnancy, due to placental growth and the increase in red blood cell 
mass, iron requirements increase three fold22. IDA during pregnancy can 
result in preterm labour, low birth weight, and increases the risk of anaemia 
in infants after 4 months of age. In severe instances it can lead to maternal 
and infant mortality23,24. 
 Very rapid growth during infancy quickly drains iron reserves accumulated 
by the fetus during gestation, frequently resulting in iron deficiency15. At 
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birth, a significant proportion of iron is in the form of fetal haemoglobin; 
however this is depleted by approximately 6 months of age with adult 
haemoglobin being produced from around 10-12 weeks onwards25. This can 
lead to compromised cognitive and motor development, which might not be 
reversible. However, reported findings are conflicting; with a lack of 
convincing evidence that IDA causes any impairment in children less than 2 
years old26. Nonetheless, there are data demonstrating that cognition, motor 
activity, social attention and overall school performance in school age 
children are affected in a state of IDA27.  
 Imbalance between energy intake and increased iron needs occurs during 
female adolescence due to rapid growth and the onset of menstrual iron 
loss. Instances of iron deficiency occur more frequently in individuals with 
heavy blood losses during menstruation28. 
As the lifespan of the population on the whole is increasing the elderly are 
another group at risk of IDA (as supported by the above NDNS figures14). 
Reasons for anaemia in the elderly may be due to number of following factors: 
 Poor and monotonous diet 
 Loss of appetite associated with lower physical activity  
 Chronic diseases and inflammation29,30 
 Impaired efficiency of iron absorption31 
 Decreased functionality of erythrocytes32  
 Regular intake of medications (such as aspirin)30  
 Occult blood loss31 
 Institutionalisation31 
Anaemia in the elderly is related to several health implications, including a 
decline in physical performance and strength, cognitive impairment, increased 
susceptibility to falling, frailty, and mortality33,34,35 (for more detailed review 
please refer to Appendix- A). 
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Finally there is evidence in the literature (for details please see Appendix- B) 
that genotype is a major determinant of body iron content. Latest information in 
twins demonstrate that the genetic contribution to iron status is around 50%36,37. 
 
 
1.2 Mechanisms of iron absorption and influence of dietary 
factors 
Dietary iron can be present as haem (organic) and non-haem (inorganic) iron. 
Animal meat is a rich source of haem iron due to the presence of the iron-containing 
proteins, haemoglobin and myoglobin. Non-haem iron can be found mainly in plant-
based food and meat11. Haem iron is better absorbed than non-haem iron, partly 
due to metalloporphyrin (in which haem iron is incorporated) being less susceptible 
to inhibitors than non-haem iron. In addition, haem iron is taken up by the enterocyte 
via a pathway distinct from inorganic iron38. To date, only the haem iron transporter, 
haem carrier protein 1 (HCP1) has been identified as being involved in haem 
uptake, but the exact process of haem iron uptake remains unclear39,40. It is reported 
that HCP1 is upregulated in situations of iron deficiency or hypoxia, and that it is 
also transports folate39.  
The absorption of haem iron from the diet is estimated to be between 15% to 40% in 
populations where meat is regularly consumed41,42. In comparison, non-haem iron 
absorption ranges between 1% and 15%17, depending on the iron status of the 
individual and on the presence of dietary enhancers and inhibitors to iron 
absorption.  
The mechanism of inorganic iron uptake and metabolism is much better 
characterised and it will be described in a greater detail later in this Chapter.  
1.2.1 Iron inhibitors 
1.2.1.1 Phytate  
Phytic acid (myo-inositiol hexakisphosphate (IP6), Figure 1.2.1 ) or phytate when in 
salt form is the main storage form of phosphate and inositol, which accumulates 
within plant grains and seeds during maturation43. The chemical structure of phytic 
acid allows it to chelate with calcium, iron, magnesium, potassium and zinc cations. 
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Consequently, phytate is a significant inhibitor of inorganic iron absorption in plant-
based foods such as legumes or cereals.  
 
Figure 1.2.1 Phytic acid structure, (Kumar et al43).  
The basis of the inhibitory interaction with mineral ions such as iron is through 
formation of insoluble phytate-mineral complexes43 which are not freely available for 
absorption, thus reducing the availability of iron or other minerals. The human gut 
lacks the enzyme phytase, which if not present in consumed foods or if inactivated 
by food processing (such as heating, or extrusion) results in phytate degradation in 
the upper GI tract of around 0-28%44. However if dietary phytate is consumed with 
foods rich in plant food phytases, phytate can be, at least in part (37-66%), 
degraded in the stomach and small intestine44,45,46. Furthermore, animal research (in 
pigs) showed that phytate hydrolysis reaches a plateau at around 66% and cannot 
be improved further by increasing the phytase content of foods47. This may be due 
to the incomplete release of phytate from foods44,48. In addition pH plays an 
important role in phytate solubility; with a pH increase from ≈2 in the stomach to ≈5-
7 in the small intestine, phosphates, particularly IP6, precipitate and adversely affect 
availability of metal ions such as iron49. On the contrary, less phosphorylated inositol 
phosphatases (IP3, IP2) remain soluble at duodenal pH thus keeping iron in 
solution49. However, the major site for phosphate hydrolysis is the large intestine 
where microbial phytase plays a major role50. 
The effect of phytate on iron absorption is apparent at concentrations as low as 2-
10mg/meal and is dose dependant. However the inhibiting effect of phytate on iron 
absorption can be diminished by addition of ascorbic acid51,52. The molar ratio of 
phytate to iron needs to be below 0.4:1 to prevent inhibition of iron uptake53,10. 
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1.2.1.2 Calcium 
Calcium (Ca) is an unusual inhibitor of iron absorption because it is able to influence 
both non-haem and haem iron uptake in a dose-dependent manner54. It has been 
proposed that the inhibition of iron uptake occurs at the basolateral membrane10 of 
the enterocyte. Research suggests that calcium down-regulates iron uptake by 
translocating divalent metal transporter 1 (DMT 1) at the apical membrane55. For 
more details please refer to Chapter 6. 
1.2.1.3 Polyphenols 
Polyphenols can be found in plant-based foods such as vegetables, fruits and 
cereals as well as in tea, coffee and wine. However, their inhibiting effect on non-
haem iron absorption is greater when originating from black tea rather than from 
herb tea or wine56. The inhibitory effect of polyphenols and phytate is cumulative if 
present together in the diet41. 
1.2.1.4 Milk, egg and soy proteins 
Bovine milk proteins including casein (mainly β-casein A1 and β-casein A2) and 
whey (β-Lactoglobulin and α-Lactalbumin), egg white (albumen) and the conglycinin 
fraction in soy are the main protein groups which are reported to inhibit inorganic 
iron absorption57,58. 
1.2.2 Enhancers of iron absorption 
1.2.2.1 Ascorbic acid 
Ascorbic acid (AA) is one of the best described enhancers of non-haem iron uptake. 
Its effect is attributed to its abilities to both chelate iron and reduce ferric iron, thus 
increasing intestinal absorption59. It has also been shown that AA has the potential 
to diminish the effects of iron inhibitors such as phytates and polyphenols51. 
However, during food processing the positive influence of AA on iron absorption is 
decreased, mainly due to the losses resulting from heat treatment and food storage. 
Erythrobic acid, an epimer of L- ascorbic acid, has an enhancing effect and is able 
to withstand cooking and is used as an antioxidant in food processing60,61. It has 
been reported that erythrobic acid has 1.6 fold the capacity of ascorbic acid to 
enhance iron uptake at 4:1 (erythrobic acid to iron) ratio61. 
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1.2.2.2 Meat 
There is evidence in the literature that addition of meat, poultry or fish to meals has 
an enhancing effect on non-haem iron absorption (2 to 4 fold increase in iron 
absorption)62,63. The enhancing effect of muscle tissue on iron absorption may be 
due to the many small peptides present in the tissue rather than to a single peptide 
fraction64 and is often referred to as the ‘meat factor’. 
1.2.2.3 Nicotianamine.  
Nicotianamine (NA) is involved in intra- and intercellular transport of metal cations in 
the plant. When it is present at elevated levels in the grain it has been reported to 
enhance iron uptake in both cell and murine models65,66. Please refer to Chapter 7 
for more details. 
There is a well-justified use of iron fortification as a strategy to prevent iron 
deficiency anaemia. Food fortification with iron is recognised as a sustainable and 
realistic way to reduce the occurrence of iron deficiency67. Mainly because when 
iron is added to foods that are commonly consumed, iron status of the whole 
population can be improved.   
1.2.3 Iron fortification strategies  
Iron compounds commonly used in food fortification programmes can be divided into 
the following categories68: 
 Water soluble (ferrous sulphate, ferrous gluconate, ferrous lactate, ferric 
ammonium citrate) 
 Poorly water soluble but soluble in dilute acid (ferrous furmarate, ferrous 
succinate, ferrous saccharate) 
 Water insoluble and poorly soluble in dilute acid (ferric orthophosphate, ferric 
pyrophosphate, elemental iron powders) 
 Iron compounds that are protected (sodium-iron EDTA complex)68 
Food fortification can be challenging to the food industry, mainly due to organoleptic 
changes that may occur during storage or preparation69.  Water soluble forms of iron 
are considered highly bioavailable. However they often cause sensory problems 
when added to foods (undesirable colour and flavour changes)68,69. Forms of iron 
that are poorly water soluble but soluble in gastric juice are also well absorbed14. 
Water insoluble and poorly acid soluble forms of iron have the lowest bioavailability 
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but cause fewer organoleptic problems. However because they are generally not 
well absorbed they are therefore ineffective as fortificants68,69.The main advantage 
of using sodium EDTA is that when iron is bound to sodium EDTA it will no longer 
form complexes with phytate present in cereal based foods68. 
In the UK, mandatory enrichment of white and brown wheat flour was introduced in 
195370 in order to restore it to the levels found in wholemeal flour. Since then, other 
foods such as wheat bread, breakfast cereals, infant food formulas, infant cereals 
and other low moisture what products such as  pasta and noodles70 have been 
fortified with iron on a voluntary basis. In developing countries fortification of sugar, 
soy sauce, curry powder and fish sauce is also quite common14.  
Recently, more challenging strategies to fortify foods in iron were employed, such as 
fortification of fresh cheese with glycine stabilised ferrous gluconate71; finger millet 
flour fortification with iron EDTA and folic acid72; addition of ferrous sulphate to 
germinating brown rice73 and dephytinisation of West African cereal (fonio) with 
intrinsic wheat phytase coupled with addition of ferrous sulphate74, all with promising 
potential in relation to preventing iron deficiency.  
 
1.2.4 Intestinal iron absorption 
 
Iron absorption in humans takes place mainly in the enterocytes of the duodenum 
and proximal jejunum. Intestinal enterocytes have a unique pathway of iron uptake 
which is not found in other tissues. Prior to uptake into the enterocyte via DMT175, 
iron, if present in the ferric form, needs to be reduced to the ferrous state by 
duodenal cytochrome b (DcytB)3. Once within the enterocyte, iron can either be 
transported through the basolateral membrane (in the presence of hephaestin), via 
ferroportin 1 into the bloodstream76, or it can be stored within the labile iron pool as 
the protein ferritin77. When iron is exported from the enterocyte, it binds to transferrin 
and is transported to the sites of iron utilization,15 where it is taken up by cells via 
either transferrin receptor 1 (TfR1) or the less expressed transferrin receptor 2 
(TfR2). As iron is liberated from the transferrin-transferrin receptor complex, it is 
reduced from the ferric to ferrous form, and DMT1 transports iron from endosomes 
to the cytosol9. Further information regarding each of the key proteins involved in 
iron homeostasis is given below. 
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1.2.4.1 Iron transport (uptake and export) proteins 
 Duodenal cytochrome b (DcytB) 
The role of DcytB is to reduce iron from the ferric to the ferrous form thus 
enabling it to be taken up by DMT1 into the enterocyte3. In addition, Wyman 
et al. showed in Madin-Darby canine kidney (MDCK) cells that DcytB is not 
only a ferric reductase, but also a cupric reductase78. DcytB is located in 
mature enterocytes of the duodenal brush border and uses intracellular 
reducing cofactors to undertake reduction3. However, research carried out in 
genetically modified mice, where DcytB was not expressed, revealed that 
uptake of iron from the duodenum was reduced, but not entirely blocked79. 
These findings suggested that in addition to DcytB, other reducing mediators 
could be present. As a result, two further mammalian ferrireductases have 
been identified: cytochrome b 561 (Dcytb is a member of this family)
80,81, and 
Steap metalloreductase4. An additional candidate for the role of a reducing 
agent as well as an electron donor is AA8. AA has also been shown to 
enhance iron absorption in humans59, 82.  
 
 Divalent metal transporter 1 (DMT1) 
In the duodenum, inorganic iron, in the ferrous form, enters intestinal 
absorptive cells from the intestinal mucosa75 via DMT1. DMT1, which was 
first identified in rats83, is a natural resistance associated macrophage 
(Nramp2)75 situated in microvilli on the brush border of mature enterocytes8.  
The slightly acidic environment on the mucosal surface of the duodenum84 is 
thought to provide the potential energy for the proton electrochemical 
gradient85. DMT1 is able to use the energy to transport ferrous iron through 
the membrane into the duodenal enterocyte in addition to other divalent 
metal ions (Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, Pb2+)75. However, other 
research suggests that whilst DMT1 shows reactivity with these metals, 
further investigation is needed to characterize the affinity and specific nature 
of the transport processes of each metal86. DMT1 is also expressed in the 
proximal intestine, thymus, kidneys, brain and other organs75. Moreover, this 
twelve transmembrane domain protein not only mediates iron transport from 
the duodenal lumen, but is also involved in cellular uptake of iron. When iron 
is liberated from the transferrin-transferrin receptor complex (see ‘Transferrin 
receptor’ Section below for more details) and reduced from the ferric to 
ferrous form, DMT1 transports iron from endosomes to the cytosol9.  
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 Metal transporter protein Ferroportin 1 (MTP1/IREG1) 
Once iron enters the enterocyte it enters the labile iron pool and can either 
be stored as the protein, ferritin (discussed in further detail in Section 1.2.4.2 
below), or it can be directed through the basolateral membrane into the 
circulation via metal transporter protein (MTP1)/ Ferroportin 1/IREG1 in the 
presence of ferroxidase87. Ferroportin 1 is an iron regulated, multidomain 
transmembrane protein88 localized at the basolateral membrane of polarised 
epithelial cells. Its mRNA contains an iron responsive element (IRE) (refer to 
Section 1.2.5.1 for further details). It is involved in exporting iron from 
macrophages89 and is expressed in kidney, liver and testis87. Once iron is 
exported from enterocytes via ferroportin, it needs to be oxidised to the ferric 
state in order to bind to transferrin (primary iron transport protein) and enter 
the circulation90.  
 
 Hephaestin  
Hephaestin (Hp), a transmembrane multicopper ferroxidase oxidises ferrous 
iron at the intracellular basolateral membrane of the enterocyte91, and 
facilitates iron efflux into the blood stream. Studies carried out in sex-linked 
(sla) mice, where expression of hephaestin was disrupted, showed that 
despite unaffected uptake of iron and a consequent overload in the 
enterocyte, mice developed moderate to severe anaemia due to the impaired 
egress of iron from intestinal enterocytes into the circulation5. Hp is also a 
caeruloplasmin homologue, which is a ‘multicopper ferroxidase found in 
plasma92. Caeruloplasmin is involved in the oxidation of iron, which is 
distributed from the mononuclear phagocyte system into the plasma93.  
 
 Transferrin (Tf)  
Once iron is exported from the enterocyte via ferroportin 1 and hephaestin, it 
is subsequently bound to plasma transferrin (Tf) and either distributed to the 
erythroid cells15 or other tissues. Serum transferrin is a glycoprotein 
consisting of a single polypeptide chain, which is synthesised in the liver and 
from there is released into the bloodstream54 (Figure 1.2.2)  
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Figure 1.2.2 Schematic diagram showing intestinal iron uptake through the 
enterocyte. Adapted from Zimmermann et al.15. 
 
This metal ion binding protein can bind two ferric ions in the presence of 
other anions, such as carbonate. The function of these anions may be to 
prevent water from binding thus “locking the metal firmly to the protein and 
avoiding hydrolysis”85 enabling transport of iron to the cells in depletion64,65. 
1.2.4.2 Iron storage proteins 
 Ferritin  
Following uptake into the enterocyte, iron which is not exported through the 
basolateral membrane into the circulation is stored as ferritin, mainly in the 
cytosol. A small proportion of ferritin can also be found in serum, thus 
making it a useful marker of iron storage6. Ferritin is anoligomeric protein 
composed of 24 chains (4 helix bundle) containing light (L) and heavy (H) 
subunits (Figure 1.2.3). Due to the presence of H subunits, the protein is 
capable of oxidising ferrous iron to the ferric form, which occurs when ferrous 
iron binds to the ferroxidase centre where it is oxidised and subsequently 
moved to the central cavity. An increased number of L subunits allows the 
cell to expand its iron storage capacity within the ferritin molecule. L subunits 
also facilitate iron nucleation in the presence of acidic residues at the cavity 
surface, which increases ferroxidase activity 6.  
HO 
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Figure 1.2.3. Diagram showing spherical shape of ferritin and iron stored as a 
mineral within it. From: Iron in Biology: Study of the Iron Content in Ferritin, The 
Iron-Storage Protein, Rachel Casiday and Regina Frey Department of Chemistry, 
Washington University, St. Louis, MO 63130-accessed on 27.02.2011. 
 
On average, ferritin is able to store 2500-3000 atoms of ferric iron in the core 
of the molecule. However, the number can be as high as 4500 of ferrihydrite 
85, 96. Higher numbers of L subunits are present in ferritin in storage tissues, 
such as liver or spleen. Thus, they contain greater amounts of iron than 
ferritins with a higher proportion of H subunits which are expressed in heart 
and brain77.  
 
How iron is released from ferritin is the subject of ongoing research. Based 
on in vitro studies, there are two main hypotheses. One is that due to 
chelation or reduction, iron release from ferritin occurs preceding its 
degradation97. The other suggestion is that iron is released when cytosolic 
ferritin undergoes degradation within the lysosome98. In a more recent study, 
De Domenico et al. showed that overexpressed ferroportin mediates iron 
release from cytosolic ferritin prior to its degradation by proteasome99. 
Degradation of iron deplete ferritin is performed by ubiquitin which 
disassembles ferritin nanocages99. Nonetheless the precise mechanism of 
iron release from ferritin in humans needs further investigation. 
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 Haemosiderin 
Haemosiderin accumulates mainly in liver lysosomes. It is a water-insoluble 
iron storage protein, which is derived from ferritin degradation products. 
Thus, it has greater iron content than the latter85. However attempts to 
produce haemosiderin in vitro, using purified lysosomes, failed, suggesting 
that additional reactions occur during its formation 100. 
Storage of iron in the haemosiderin complex only occurs in states of iron 
excess, and consequently it can be found in iron overload conditions such as 
haemochromatosis85,101. This may be a response to the fact that iron locked 
within haemosiderin, unlike iron in ferritin, is water insoluble, thus limiting its 
availability102. Moreover, iron stored in haemosiderin does not participate in 
lipid peroxidation103 or the formation of free oxygen radicals to the same 
extent as iron in the form of ferritin104. In addition, due to much greater 
variability in the phosphate content and mineralised structure of the iron core 
in comparison to ferritin, it was shown in vitro that haemosiderin releases 
iron from its core twice as slowly as H-ferritin105, 106. However, this does not 
fully explain the differences in the rate of iron release between haemosiderin 
and ferritin, and it has been suggested that differences in the structure of the 
mineralised iron core between haemosiderin and ferritin have an impact on 
iron release107. 
 
1.2.5 Iron uptake into non-intestinal mammalian cells 
As described in the above section iron acquisition by enterocytes is a unique 
mechanism. The uptake of iron in other cell types is briefly described below.  
Having entered the bloodstream, iron is acquired from transferrin by cells via either 
transferrin receptor 1 (TfR1) or the less expressed transferrin receptor 2 (TfR2). The 
abundance and affinity of TfR1 to bind diferric transferrin is much greater than that 
of TfR2108. Moreover, TfR2 mRNA has been shown not to contain iron responsive 
elements (IRE), as opposed to TfR1 and as a result, TfR2 cannot be down-regulated 
in response to iron overload109. However, other research demonstrated that TfR2 is 
unable to maintain sufficient intracellular iron in the absence of TfR1110.  
Both TfR1 and TfR2 are cell surface glycoproteins consisting of two polypeptide 
chains85. The transferrin-transferrin receptor complex is taken up by the cell via 
clathrin coated endocytic vesicles. Within the endosomes a proton pumping ATPase 
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lowers the pH and in the presence of STEAP metalloreductases, ferric iron is 
reduced to the ferrous form and transported by DMT1 into the cytosol4,111. TfR and 
apotransferrin, assisted by the trafficking protein Sec15l1, migrate to the cell surface 
where apotransferrin is released into the circulation awaiting iron, whilst TfR is 
bound to the cell membrane. The concentration of TfR at the cell surface reflects 
cellular iron requirement9, 111 (Figure 1.2.4). 
Transferrins play a vitally important role in the erythroid cycle as they are required to 
fulfil the demand for iron needed by erythroid precursors in bone marrow in order to 
produce red blood cells. Iron resources are tightly regulated, thus when aged red 
blood cells are utilized by macrophages, iron is recycled and returned to the system 
ready for transport by transferrin15. 
 
Figure 1.2.4 Schematic diagram of the transferrin cycle. From: Anderson et al.112. 
TfR1-mediated uptake of differic transferrin (high affinity uptake) applies to the 
majority of mammalian cells. Apart from TfR1 mediated uptake, non-receptor 
mediated uptake by which cells can acquire diferric trancferrin has also been 
described113. Hepatocytes, for example, can acquire iron via low and high affinity 
uptake processes. The proposed route for low affinity uptake is via TfR2 receptors, 
which are expressed in high numbers in the liver114. Research conducted by Trinder 
and Morgan in hepatocyte cells suggest that uptake of diferric transferrin occurs via 
proteoglycans or fluid phase endocytosis115.  Also macrophages are capable of 
taking up diferric transferrin as well as phagocytosing senescent red blood cells in 
order to recycle the iron112  
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However, when uncontrollably high dietary iron uptake takes place (in iron overload 
disorders) there are elevated levels of iron entering the plasma. When the binding 
capacity of circulating transferrin is exceeded, non-transferrin-bound iron is found in 
the plasma and it can be taken up by the cells116.  The exact mechanism by which 
non-transferrin-bound iron enters the cell is uncertain112.  Also in particular 
pathological conditions iron from free haemoglobin or haem can be taken up by 
hepatocytes and other cells via a haem/haemopexin complex117 through both low 
and high affinity pathways112.  
 
1.2.5.1 Systemic iron regulation protein 
 Hepcidin  
Hepcidin is an antimicrobial, liver-derived, 25 amino acid peptide. It is 
secreted by hepatocytes into the plasma and excreted in urine118. In the 
mature form, hepcidin coordinates iron efflux from the basolateral membrane 
of intestinal enterocytes into the bloodstream. Hepcidin regulates iron 
absorption by direct influence on ferroportin (present in enterocytes or in the 
plasma membrane of macrophages), the only iron protein exporter identified 
to date85. When body iron levels are high, or in a situation of inflammation, 
hepcidin binds to iron loaded ferroportin as it exits the enterocyte or 
macrophages, causing its internalisation and degradation. Consequently iron 
efflux into the circulation is abolished119. Conversely, in a situation where the 
body is depleted, for example during pregnancy, hypoxia, and elevated 
erythropoiesis, hepcidin synthesis is reduced, thus allowing ferroportin to 
transport iron from the enterocyte into the bloodstream119 allowing iron to 
become available for sites of iron utilization (Figure 1.2.5). 
Regulation of hepcidin expression is coordinated by the following hepatocyte 
plasma membrane proteins: TfR2, haemojuvelin (HJV) and 
haemochromatosis protein (HFE)112. It has been shown that HFE binds to 
TfR1, thus making it impossible for transferrin to bind to the receptor, 
whereas TfR2 can simultaneously bind HFE and transferrin. The TfR2-HFE 
complex stimulates hepcidin expression120,121. However further investigation 
is required in order to establish the extracellular signals by which these 
proteins trigger hepcidin synthesis122. Nonetheless, the mechanism by which 
HJV stimulates hepcidin is better understood. HJV acts through the bone 
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morphogenetic protein (BMP6)/SMAD pathway, which is thought to be the 
main route of hepcidin regulation123,124. 
 
Figure 1.2.5. Schematic diagram of hepcidin regulation of iron efflux. From: 
Pantopoulos K.125. 
 
1.2.5.1 Summary of systemic and cellular regulation of iron 
Cellular iron homeostasis is post-transcriptionally mediated by the RNA binding iron 
regulatory proteins (IRP1 and IRP2) and iron responsive elements (IRE)126. In 
instances of iron deficiency, IRP1 and IRP2 bind to the iron responsive elements 
found in mRNA encoding proteins involved in iron metabolism, namely DMT1, TfR1, 
ferroportin and ferritin. Depending where IREs are located in the untranslated region 
(UTR) of mRNA (in the 5’ or 3’ of UTR), the binding of IRPs can either block or 
upregulate the translation 127,112. Ferritin mRNA contains one IRE in the 5’ UTR, 
while mRNA of TfR1 contains many IREs in 3’ UTR128. Therefore the process by 
which IRP/IRE orchestrates ferritin and TfR1 in a situation of increased iron demand 
is as follows: the translation of the message to collect iron for ferritin storage is 
blocked by IRP, and simultaneously the TfR1 is upregulated causing increased iron 
uptake. Similarly to TfR1, in a situation of iron deficiency the mRNA of DMT1 is 
regulated by the IRE/IRP system75. Interestingly, ferroportin is controlled by both 
cellular and systemic iron regulation. Intracellular regulation of ferroportin is 
performed via the 5’ UTR IRE of its mRNA, whereas systemic regulation is 
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maintained by hepcidin as described earlier. This cross talk between cellular and 
systemic iron metabolism is crucial for controlled iron efflux9,129. 
 
1.3 Methods of estimating iron status 
Biomarkers by which ID or anaemia are usually measured in serum/plasma samples 
are:  
 Haemoglobin (Hb) concentration. Hb lacks sensitivity and specificity and 
therefore is only useful for diagnosing severe iron deficiency (anaemia)130, 
but due to its relatively low cost and diagnostic availability it is often used12. 
An important factor which needs to be considered in establishing appropriate 
cut-offs for Hb are ethnic and gender differences. Whilst the latter is well-
characterised the former is a controversial issue, despite the fact that it has 
been identified in the literature since 1975131,132,133. On the other hand there 
is also evidence in the literature that ethnic difference in Hb between Blacks 
and Whites was not significant134. More recent reports suggest applying a 
reduction in the Hb cut-off from 12.0g/dL to 11.5g/dL for black populations. 
The reduced cut-off was established in response to observing no change in 
the relationship between haemoglobin concentration and transferrin 
saturation, whilst still observing different distributions in Hb concentrations135. 
Another factor which needs to be considered in establishing appropriate Hb 
cut-offs is living at high altitude. In order to retain oxygen supply during 
hypoxemia, Andean highlanders (at high altitude) have higher Hb levels 
compared to those at sea level 136. But, this is not necessarily a trait found in 
all populations living at high altitudes (3200-4000m)137; another adaptation is 
reduction in affinity between Hb and oxygen to ensure that Hb bound oxygen 
is more accessible for tissues138.  
 Serum/plasma ferritin concentration is a relatively good estimate of iron 
status139 as there is a quantitative relationship between circulating ferritin in 
the plasma and iron stores in the liver140. Phlebotomy studies have shown 
that a circulating ferritin value of 30µg/L is equivalent to 300mg of storage 
iron141,142. Nevertheless there are some limitations in the use of ferritin as an 
iron biomarker. It may not be appropriate in the presence of acute and 
chronic inflammation or infections because ferritin is an acute-phase 
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protein143 and increases in response to infection/inflammation, no longer 
reflecting body iron stores. In this case the usual ferritin cut-off to estimate ID 
of <15µg/L would no longer be relevant144. 
 Soluble transferrin receptor (sTfR) has also been used as an early indicator 
of iron deficiency145,146 as it is increased when the supply of iron is insufficient 
for optimal erythropoiesis, and this increase is observed before Hb levels 
start to fall18,111. sTfR is not considered to be an acute phase protein 
therefore its fluctuations in inflammatory states are considerably smaller than 
those of ferritin147. However there is evidence that in the presence of malaria 
sTfR levels may increase considerably148. Furthermore in HIV positive 
populations sTfR may be lacking sensitivity145. Therefore, both ferritin and 
sTfR should be interpreted with caution in populations where malaria or HIV 
are prevalent.  
 More recently, the body iron method presented by Cook et al.149 has been 
introduced as a more accurate measure of iron status. Body iron takes into 
account two biomarkers of iron status, ferritin and sTfR, and combines them 
into the following equation:  
Body iron(mg/kg)=- [log(sTfR/Ferritin ratio)-2.8229]/0.1207. However, this 
equation is only valid when the method for sTfR is the same one as that 
used by Cook.  
The relationship between ferritin and sTfR was obtained through repeated 
phlebotomy of 14 healthy subjects150. The body iron method was further 
evaluated by examining iron status in three studies149. Later this approach 
was evaluated to measure iron status in the US population in the National 
Health and Nutrition Examination Survey (NHANES)151. This method is more 
informative than Hb, ferritin or sTfR as it allows individuals to be placed at a 
specific point in the iron status spectrum, ranging from positive values 
representing iron sufficiency to negative values indicating iron deficiency, 
rather than using a cut-off value. However the adjustment for inflammation 
status is not considered in this method. Another limitation has been the use 
of different assays without any standardised samples (although the WHO 
reference reagent has recently become available152), to determine levels of 
sTfR, thus making results from the assays incomparable153,154.  
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In addition, in developing countries the main difficulties in estimating iron status are 
subclinical, acute and chronic infections (such as malaria, HIV, tuberculosis, 
helicobacter pylori infection, parasite infections, cancer)155,156,20; other coexisting 
micronutrient deficiencies (folate, vitamin A, B12)130, 157 and genetic disorders 
(haemoglobin disorders such as sickle-cell disease or thalassemia affecting mainly 
African, Southeast Asia and Mediterranean populations)158, 159.  
Inaccurate diagnosis of IDA could result in the underestimation of iron deficiency in 
a population or inappropriate provision of iron therapy in individuals whose 
underlying cause of anaemia is not iron deficiency. 
1.3.1  Approaches used for addressing the confounding effects of 
inflammation when measuring iron status 
 
Three different strategies have been suggested in order to estimate iron status in 
populations with widespread presence of inflammation160. These are: 
 Determination of the presence of inflammation with the use of inflammation 
biomarkers: C-reactive protein (CRP) and alpha acid 1 glycoprotein(AGP) 
and exclusion of the data obtained from participants with elevated 
inflammation biomarkers. 
 An increased ferritin cut-off for identifying ID from the commonly used 12-
15µg/L111 to 30 or even 70µg/L in the presence of HIV161. 
 Utilisation of inflammation biomarkers (CRP and AGP) to adjust the data to 
allow for the degree of inflammation162. 
Exclusion of data is not a desired solution as a large number of samples may be lost 
(which could cause studies to be underpowered). Ferritin is an acute phase protein 
and its values increase with inflammation, therefore increasing ferritin cut-offs to 
identify individuals with ID is a possible solution. However application of an 
increased cut-off for one population may not necessarily be appropriate for another 
due to potential population differences and variances in analytical 
techniques144.Therefore the use of inflammation biomarkers to adjust ferritin values 
is potentially the most appropriate approach and will be described in greater detail 
below.  
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Thurnham et al.162 suggested adjusting ferritin values with the use of two biomarkers 
of inflammation: CRP and AGP. The rationale for using these inflammation 
biomarkers is as follows: at the start of an infection there is an observed sharp 
increase in CRP levels with the peak occurring at approximately 24-48 hours. After 
that time CRP levels fall, however they stay elevated compared to levels prior to the 
infection for up to 7 days. Ferritin increases during inflammation and has similar 
characteristics to CRP163 although it is not as rapid and it remains elevated for 
longer. On the other hand, AGP levels start to increase after 1 day of acquiring an 
infection, peaking at day 3 and staying at that level for at least a further 4 days162, 163. 
Analysis and use of the above 2 inflammation biomarkers in populations where 
infections are common could be the tool to capture individuals with current or very 
recent infections, thereby allowing for either exclusion of the individuals in question 
from the dataset or adjustment for inflammatory state (please refer to Appendix-C 
where the above correction for inflammation was used).  
There is a clear need to employ the most appropriate methods available to estimate 
the true extent of ID in the most vulnerable population groups, such as those from 
developing countries, as well as pregnant woman, toddlers and woman of 
childbearing age. 
 
1.4 The Caco-2 cell model 
The development of a reproducible model of the small intestine that can be used to 
predict iron availability has been the goal of researchers for decades. Trials to 
culture epithelial cells of rodent origin were not successful, mainly due to the short 
lifespan of cultured cells and morphological changes that occur in early passages164. 
Human gastrointestinal tumour cells isolated from a colon adenocarcinoma in 
1974165 were found to have a much longer viability under culture conditions. One cell 
line in particular, Caco-2, has been shown to share many characteristics of normal 
small intestine absorptive cells166,167. Due to these properties Caco-2 cells have 
been used in various nutritional studies as a model for the human small intestine. 
As reported by Vachon and Beaulieu168 cultured Caco-2 cells are present in 3 
states:  
 Homogeneously undifferentiated (at sub-confluence). 
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 Heterogeneously polarized and differentiated (from day 0 to day 20 after 
confluence). 
  Homogeneously polarized and differentiated (more than 30 days after 
confluence).  
Once differentiated, Caco-2 cells demonstrate several biochemical and 
morphological properties of small intestine enterocytes169. Stierum et al.102 showed 
by proteome examination that once Caco-2 cells undergo differentiation, their 
protein phenotype modifies from adenocarcinoma towards the cells of small 
intestine phenotype170. Under ideal culture conditions the cells grow to form a 
polarized monolayer, display cylindrical morphology with tight junctions between 
adjacent cells, and the development of microvilli on the apical side. They also 
express hydrolase enzymes (i.e. sucrase-isomaltase, lactase, aminopeptidase and 
alkaline phoshatases167). However, these are associated with transient human 
fetal171 small intestine enzymes and are not expressed in adult human colon.  
To highlight the usefulness of the Caco-2 cell model as a tool for investigating iron 
availability and uptake, it is important to mention that once those cells 
spontaneously differentiate172, among the features of mature small intestinal 
enterocytes which they express as mammalian cells, are: DMT1 173, DcytB174, Hp171, 
IREG1175, transferrin receptor171 and ferritin173. As discussed in the previous Section 
1.2.3 these proteins are crucial for iron uptake and storage to take place in 
enterocytes. Due to changes occurring in Caco-2 cells upon differentiation, the 
following proteins have been shown to be up-regulated: 
 Ferric reductase activity was found to be increased in differentiated cells in 
comparison with proliferating cells176.  
 DMT1 has been showed to be upregulated at 15 days post seeding177,178. 
However in Caco-2/TC7 subclones this up-regulation occurred between day 
7 and 21 from seeding179. 
 Hephaestin mRNA has been shown to increase nearly 3 fold upon 
differentiation on day 15 from seeding177. 
 TfR mRNA was also reported to progressively increase with the maximum 
value on day 15 from seeding177. 
  Ferroportin has been shown to increase 3 fold in days 8 to 18 
postconfuence175.  
Furthermore Caco-2 cells have also been used as an intestine model to explore 
calcium transport (transcellular- across cell membranes, and paracellular- 
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through intercellular spaces) into and across the enterocyte under various 
conditions180,181. Once differentiated, Caco-2 cells express vitamin D 
receptors182; with the active form of vitamin D coordinating the efficacy of 
intestinal calcium absorption (in animals and in humans)183. Additionally Caco-2 
cells also express low levels of epithelial calcium channel mRNA (CaTI, 
mediators of calcium influx when expressed in Xsemopus oocytes) which has 
been shown to be upregulated by vitamin D183. Hence it is also possible to 
investigate vitamin D dependant transcellular uptake of calcium by the cells184. It 
has been reported by Chirayath et al.185 that this upregulating effect of vitamin D 
in the cell model, at least in part, may be due to a rise in paracellular ion 
permeability. However as noted by Artursson et al.186 the transmembrane 
resistance of the small intestine epithelium is quite low in comparison to the 
resistance of colon epithelium (≈60ohms/cm2 and ≈280ohms/cm2 respectively). 
Nonetheless differentiated Caco-2 cells possess many fundamental features to 
study calcium transport187. 
1.4.1 Advantages and limitations of the Caco-2 cell model 
The main advantage of using Caco-2 cells to investigate transport of micronutrients 
and their bioavailability is that they are derived from a human source unlike other 
techniques using rodent models164. However, the fact that they originate from a 
tumour means that they express glucose transporters (GLUT1, GLUT3), as 
observed in colonic or cancer cells188 rather than in normal duodenum enterocytes. 
Conversely, peptidase activity in Caco-2 cells is more similar to small intestinal 
epithelia than colonic epithelia166. 
A number of Caco-2 characteristics are inconsistent and they are observed to 
transform with passage of the cells. It has been reported that expression of sucrase-
isomaltase, fructose transporter GLUT5, trans-epithelial electrical resistance189 as 
well as proliferation rate increase in line with the increase of cell passage number190. 
In contrast, alkaline phosphatase activity decreases with increasing passage 
number190.  
Additional factors which have been demonstrated to influence Caco-2 cells growth 
and biology are the culture conditions such as choice of seeding surface (plastic 
surfaces versus porous membranes191), cell seeding density and alteration of the 
media composition171. In order to exploit the potential of the cell system and to 
establish valuable and comparable results it is important to use passages of Caco-2 
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cells which have the desired properties and to use modifications of culture 
conditions as an additional tool if required. 
1.4.2 Incorporation of simulated digestion phase 
The purpose of using a simulated digestion phase before applying the food matrix to 
the dialysis membrane192 in the Caco-2 cell model is to simulate the enzymatic 
phase of human digestion in the stomach and duodenum and associated changes in 
the pH193. 
In this technique (Figure 1.4.1) samples under investigation need to be first exposed 
to pepsin digestion for 1 hour in an acidic environment (pH 2) at 37ºC on a rolling 
table to represent stomach conditions. Once the first phase is completed, gradual 
adjustments of pH need to be made to reach a value of 6.7194. Then, to mimic 
duodenal conditions, pancreatin bile solution is added to the samples. Prepared 
digest is applied onto dialysis membranes which are placed above the Caco-2 
monolayer and the intestinal model is ready for incubation for 2 hours at 37ºC. The 
role of the membrane (12.000-14.000 molecular weight cut off) is to imitate the 
mucus layer107 present in the digestive tract and to protect cells from the destructive 
activity of enzymes192. After 2 hours the digestate is removed from the upper 
compartment and the Caco-2 cells are incubated for a further 22 hours prior to 
harvesting and analysis of ferritin levels193.  
 
Figure 1.4.1. Schematic diagram of in vitro digestion, a Caco-2 cell model adopted 
from Glahn et al.192. 
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It should be emphasised that the Caco-2 cell system, even when combined with 
simulated digestion cannot be considered an ideal duodenal model. In addition to 
the limitations stated in Section 1.4.1 there are other weaknesses: absence of 
peristaltic movements, mucus, micro-flora and digestive secretions. Furthermore, 
the influence of food composition on transit time and enzyme release, as well as 
interactions with other food components cannot be investigated using this model 
system196.  
Nevertheless, Caco-2 cells combined with simulated digestion is a useful model 
system that attempts to imitate small intestinal conditions and is a valuable tool for 
screening different iron sources in order to rank them for potential bioavailability and 
for investigating mechanisms of nutrient absorption in humans197,198. 
The simulated digestion process involves increasing the pH associated with gastric 
conditions (pH2) to that found in the duodenum (pH7). The increase in pH is a major 
determinant of iron solubility in solutions in the presence of oxygen. With the 
increase in pH both ferrous and ferric iron hydrolyse forming polymers and these will 
ultimately precipitate as insoluble complexes, thereby reducing the proportion of iron 
that is available to cells/humans194,199. Ferric iron forms insoluble hydroxides more 
readily than ferrous iron69. In order to avoid the formation of insoluble hydroxides 
iron chelators such as ascorbic acid is normally added prior the start of the 
digestion.  
The iron compounds used in experiments reported in the thesis are summarised in 
Table 1.4.1. All of the iron compounds used in this study are freely soluble in 
water68,200. FeG and FAC are also used as food fortificants and are classified as 
highly bioavailable15,68,69,201 
Studies conducted by Thompson202 using atomic absorption spectroscopy (AAS) 
revealed that the solubility in water of FAC and FeCl3 decreased from 92.6% and 
95.4% at pH 2 to 10.5% and 4.4% pH 6.5 respectively.  
The quantification of % free iron in post experimental digests (which underwent 
simulated digestion as described in Chapter 2, section 2.2.2) was quantified using 
bathophenanthroline colorimetric assay (also described in detail in Chapter 2, 
Section 2.2.2).  The % of free ferrous iron quantified after the simulated digestion 
was 1.7% for ferrous gluconate and ferric ammonium citrate and 1.2% for ferric 
chloride and not 4.4% as quantified by Thompson202 with the use of  AAS. Low iron 
solubility and the discrepancy between the 2 methods might be due to the use of 
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hydroxylamine solution in the colorimetric assay which probably further increases 
the pH of tested samples, thus potentially reducing the solubility of iron. It is also 
worth mentioning that only pre-frozen digest were analysed and the effect of 
freezing on iron solubility was not investigated. 
 
Table 1.4.1 Characteristics of iron compounds  
Iron 
compound 
Molecular 
weight 
Chemical 
formula 
Solubility in water 
Ferrous 
gluconate 
(FeG) 
482.2 C12H22FeO14 
* 2H2O 
10g in 100g 
Ferric 
ammonium 
citrate (FAC) 
265.0 C6H11FeNO7 100g in 100g 
Ferric 
chloride 
(FeCl3) 
162.2 FeCl3 92g in 100g 
.  
Kapsokefalou et. al.203 investigated % total soluble iron in water digests and reported 
that it was significantly higher when ferrous gluconate was used than when ferrous 
lactate, ferrous bis-glycinate or iron EDTA were used. Ferrous gluconate has been 
reported to be a successful food fortificant of specific foods (in that it is not 
associated with adverse organoleptic changes) in combatting iron deficiency 
anaemia68,201,204.  
Different iron compounds with various chemical properties have differing solubility 
and complexation at pH7 or higher, as reported by Minihane when comparing iron 
ascorbate and iron citrate complexes205. 
As mentioned earlier, when using the Caco-2 cell model ferritin is measured as a 
surrogate of iron availability. Therefore if during the simulated digestion all of the 
iron present in solution forms insoluble hydroxides or if it precipitates at 
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physiological pH in the presence of oxygen, then there would be no iron available for 
the cells and there would be no ferritin response.  
The general methods Chapter (Chapter 2) contains a more detailed experimental 
protocol based on the method described by Glahn et al.193 which is a 3 day 
procedure that starts 12 days post seeding of Caco-2 cells in collagen coated 6 well 
plates.  
 
 
1.5 Characteristics of Alginate  
Alginates (sodium alginate, E401) are natural copolymers present in the cell walls of 
brown seaweed as sodium, potassium, calcium and magnesium salts of alginic acid. 
Through the process of extraction (which is comprised of ion exchange in an 
alkaline medium, precipitation, purification and extraction of alginic acid) dry sodium 
alginate powder is obtained206. Alginates are comprised of varying ratios of two 
different acids: D-mannuronic (M) and L-guluronic acid (G), and due to the variable 
length of the polymer chains they exhibit differing physiochemical properties207 
(Figure 1.5.1).  
 
Figure 1.5.1 Schematic diagram of D-mannuronic (M) and L-guluronic acid (G).From 
http://www.btinternet.com/~martin.chaplin/hyalg.html- accessed on 12.09.2010. 
Alginates are used in a wide variety of applications, including drug delivery systems 
(anti-reflux preparations)208 and the food industry (as thickening, gelling, emulsifying 
and stabilising agents in food products (used in ice cream, sauces, fruit pies, onion 
rings etc.)206. They have been shown to bind divalent and trivalent cations209,210, with 
better iron binding capacity at lower alginate concentrations (when calculated as mg 
Fe/g alginate)211, and therefore might be a useful vehicle for soluble iron compounds 
used to fortify foods. 
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1.5.1 Alginate gelation 
The best described gelling mechanism of alginate solutions is through addition of 
calcium ions (Figure 1.5.2 and Figure 1.5.3). Grant et al.212 and Morris et al.213 
proposed a Ca-alginate junction zone model called the ‘egg box’ model which forms 
through calcium ion induction of chain-chain association (2/1 zigzag helix 
conformation) with a 1:4 ratio between Ca2+ and G units in alginate gel. 
 
Figure 1.5.2 Schematic formation of the ‘egg box’ by calcium ion chelation to poly-L-
guluronate sequences (Morris et al.213). 
 
 
Figure 1.5.3 Schematic formation of the ‘egg box’ model sourced from Braccini et 
al.214. Dark dots are oxygen atoms taking part in the coordination of calcium ion. 
 
However, more recent investigations with advanced X-ray scattering techniques 
suggested that the ‘egg box’ dimer is not the only possible conformation. It has been 
suggested that not only GG blocks (and their length), but also MG blocks215 (Figure 
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1.5.4) contribute to the junction zone through Ca2+ binding216 supporting the theory 
of 3/1 and 2/1 helix conformation coexistence. Moreover, the Ca-alginate gelation 
rate has a direct influence on junction zone conformation. According to Li et al.216 a 
fast gelation (such as spinning fibers in calcium chloride solution) process promotes 
2/1 helix conformation, whereas slow gelation (through diffusion) results in 3/1 helix 
conformation.  
 
Figure 1.5.4 Schematic representation for three possible junctions in alginate gels : 
a)GG/GG; b) MG/MG and c) GG/MG junctions as described by Donati et al.215. 
The aforementioned variations in alginate structure and calcium binding properties 
ultimately underline why alginates are so versatile and commonplace in multiple 
industrial processes and are of valuable use both in medicines and the food 
industry. 
 
1.5.1.1 Alginate gelation in presence of iron  
 
It has been demonstrated that alginates can form a stable complex with ferric and 
ferrous iron over a range of different pH values210, 217. Nonetheless, it has been 
reported that binding of iron by alginates increases with decrease in pH211. This 
increase should not occur if the mechanism of binding solely has an ionic basis, 
because then binding of iron should increase with increase in pH211. A potential 
explanation for this phenomena may be that alginates form gels at low pH and the 
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aggregation of polymers may then trap iron211. Brenel et al.211 also showed that pH 
changes during in vitro digestion interrupt binding between alginate and iron. 
Conversely, if alginates bind iron in the lumen of the large bowel they may offer 
positive health benefits by restricting iron supply to cells in individuals with polyps 
who are at increased risk of colorectal cancer218,219. In support of this hypothesis, 
studies carried out in rodents220,221 and humans222 have shown that alginates can 
inhibit iron absorption by up to 40%.  
 
The overall aim of the research project was to develop potential delivery systems for 
fortification iron in order to contribute to strategies for preventing iron deficiency. 
Consequently, it was essential that food grade materials were used that could 
potentially protect the iron through digestion in the stomach and deliver it in soluble 
form to the site of absorption. 
Investigations were undertaken to determine whether alginates could be used as a 
delivery system for iron. Specifically, Caco-2 cell studies were carried out to 
determine the effects of varying ratios of mannuronic and guluronic acids within 
alginate on iron uptake from ferric ammonium citrate (FAC) and ferrous gluconate 
(FeG) in the presence of an iron enhancer, ascorbic acid (AA), and iron inhibitors, 
namely tannic acid (TA) and calcium. The results of the in vitro investigations were 
used to inform the design of a human study investigating the effectiveness of using 
an alginate barrier to deliver FeG to the duodenum, thus maximising its availability 
for absorption. 
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2. GENERAL METHODS 
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2.1 Routine Caco-2 cell culture procedures  
Unless otherwise stated all reagents were purchased from Sigma Aldrich, UK. Caco-
2 cells (HTB-37®) were obtained from American Type Culture Collection (Manassas, 
VA) at passage 20 and stored in liquid or vapour nitrogen (at a temperature of -
1960C). When resuscitated, the cells were grown in Dulbecco’s modified Eagle’s 
media (DMEM) from Gibco UK, supplemented with 10% fetal bovine serum (FBS), 
25mM HEPES solution, 4mM L-glutamine and 5ml 5000u/ml 
Penicillin/Streptomycillin solution (Gibco, UK). The cells were maintained at 370C in 
an incubator with humidified atmosphere consisting of 5% carbon dioxide and 95% 
air. Routinely, cells were resuscitated (frozen Caco-2 cells were allowed to thaw at 
room temperature for one minute followed by re-suspension in DMEM 
supplemented media) at passage 26 in 25cm2 cell culture flasks (Nunc, UK) and 
sub-cultured at 80% confluence into 75cm2 cell culture flasks (Nunc, UK) with media 
changes every three days. 
2.1.1 Cell resuscitation 
Ampoules of Caco-2 cells, stored in liquid or vapour nitrogen were allowed to thaw 
at room temperature for one minute. The cells were then placed in a water bath at 
37C for 1-3 minutes until fully defrosted. The ampoule of cells was wiped with 70% 
ethanol and the cell suspension transferred to a 25 cm2 cell culture flask (Nunc, UK) 
containing DMEM supplemented media.  
2.1.2 Growing and sub-culturing procedures 
Once resuscitated, the cell media was replaced 24h following resuscitation and 
every 2 days thereafter. Cells were sub-cultured at 80% confluence in 75cm2 culture 
flasks. Briefly, the media from sub-confluent cells was removed and the cells 
washed with 6ml of Dulbecco’s Phosphate Buffered Saline (DPBS). Cells were then 
detached with the addition of 1ml of trypsin (incubated at 370C for 4-6 minutes). The 
trypsin was neutralised with the addition of 4ml DMEM supplemented media. The 
cells were transferred to 75cm2 culture flasks, suspended in an additional 8ml of 
DMEM supplemented media, and grown (with media changes every 2 days) until 
80% confluence. The cells were grown (with media changing procedure every 2 
days) in 75cm2 flasks until they reached 80% of confluence, then they were sub-
cultured (as above). The cell suspension was transferred into 10x75cm2 flasks in a 
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volume of 1ml per flask. Each flask was topped up with 11ml of DMEM 
supplemented media. Caco-2 cells were grown (with a media change every 2 days) 
in 75cm2 flasks until they reached 80% confluence, and then sub-cultured (as 
above), counted using a microscope and haemocymeter and finally seeded in 6 well 
collagen plates at density of 4.75x105 per well. 
However, due to issues associated with cell adherence the culturing and sub-
culturing techniques of cells grown in flasks were modified as follows: when 
harvested cells were initially centrifuged at 600rpm for 5min (Eppendorf, UK) in 
order to remove trypsin residues, counted using a haemocytometer, then a constant 
number of cells (7.5x105 or 2.25x106) was seeded into 25cm2 or 75cm2 culture flasks 
respectively and cells were grown for 7 days to full confluence. The change in 
culturing techniques avoided the pre-selection of faster growing cells within the 
Caco-2 monolayer and assured more uniformity between cell passages. This 
modified cell culture technique was used to grow cells for experiments reported in 
Chapters 5, 6 and 7. 
2.1.3 Freezing procedure 
Cells were harvested, counted, transferred to a 50ml tube and centrifuged for 3 
minutes at 1000g. Cells were then re-suspended in 90% fetal bovine serum and 
10% Dimethyl sulfoxide (DMSO) to give a final concentration of 2-4x106cells/ml. The 
cells were then aliquoted into cryovials and frozen at a cooling rate of 1-30C/min 
using a ‘Mr. Frosty’ (Nalgene, UK), which contained isopropanol. After 24 hours the 
ampoules were stored at -800C until use. 
2.1.4 Seeding of 6 well plates 
The Caco-2 cells were seeded onto collagen coated 6 well plates (Greiner, UK) at a 
density of 4.75x105, and suspended in 2 ml of supplemented DMEM, which was 
replaced every 2 days. Cells were used at 13 days post seeding between passages 
28-40 for all experiments. Supplemented DMEM was removed from cell monolayers 
in 6 well plates after 24 hours prior to experimentation and replaced with serum free 
media consisting of DMEM (Gibco, UK) supplemented with 25mM HEPES solution, 
4mM L-glutamine and 5ml 5000U/ml Penicillin/Streptomycillin solution (Gibco, UK).  
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2.1.5 Harvesting of Caco-2 cells 
After 24 hours post experiment, the treatment media was aspirated from the 6 well 
plates and the cells were gently washed twice with 2 ml DPBS (Gibco, UK). 
However, if the experiment was carried out following a simulated digestion 
procedure, then the cells were washed with 130mM sodium chloride, 5mM 
potassium chloride and 5mM PIPES buffer at pH6.7 instead of DPBS. 
Subsequently, deionised water was applied to each well and the Caco-2 cells were 
scraped off using an inverted 10µl pipette tip. The cell suspension from each well 
was then transferred into 5ml sample tubes and stored at -200C.  
2.1.6 Sonication 
Sonication in order to lyse the cells was carried out 24 hours after cell freezing. 
Briefly, 5ml tubes containing cell lysates were defrosted at room temperature and 
subsequently kept on ice. Cell suspensions were sonicated 3 times for 5 seconds on 
ice using a probe sonicator. Following sonication, cell suspensions were transferred 
to pre-labelled 2ml sample tubes and stored at -200C. 
 
 
2.2 Simulated digestion experimental protocol 
2.2.1 Procedures prior to experiment day (12 days post seeding) 
Preparation of media: 1 litre of minimum essential media (MEM) was prepared by 
dissolving the following compounds in 700ml of MilliQ water: 3.5g D-glucose, 
3.6684g PIPES, 2.2g sodium bicarbonate, 1 packet of MEM (Gibco, UK), 4mg 
hydrocortisone. 10ml of antimicrobial/antibiotic solution was added, followed by the 
addition of 5mg of insulin dissolved in 2ml of acetic-dH2O (pH dH2O to pH2 with 
acetic acid) at pH2. 10l of 0.5mg/ml sodium selenite solution, adjusted to pH7, was 
then added and the volume brought up to 1000ml with dH2O. The media was 
completed with the addition of 1.7ml of 20g/ml tri-iodothyronine solution and 1ml of 
Epidermal Growth Factor solution. The resulting solution was filter sterilized using 
filters with cellulose nitrate membrane 0.2µm filters, (Millipore, UK) and aliquoted 
into 50ml sterile tubes and refrigerated at 4oC until use. Prior to the application onto 
Caco-2 cell monolayers, the MEM was warmed to 37ºC in a water bath. 24 hours 
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prior to the experiment all wells were washed once with 2ml of MEM to remove 
residual amounts of DMEM (containing fetal bovine serum) and replaced with a 
further 2ml of MEM. All plates were incubated for a further 24 hours. 
Preparation of inserts: Dialysis membrane (15kDa MWCO, Fisher, UK) was cut into 
pieces approximately 5cm in length and soaked in 18.2M (MilliQ) water for a few 
minutes and subsequently rinsed several times. The membrane was mounted onto 
inserts by cutting along one of the folds and fixed using silicone O-rings. Excess 
membrane was carefully trimmed using scissors. Inserts were immersed in 18.2M 
water and refrigerated until use. 
2.2.2 Experiment day (13 days post seeding) 
Experiments were undertaken at 13 days post seeding. In all plates, MEM was 
replaced with 1ml of fresh media and inserts with mounted membranes were 
incorporated onto wells. Enzyme solutions: pepsin to imitate the gastric phase and 
pancreatin and bile solution to imitate the duodenal phase were prepared. A suitable 
number of 20ml tubes (Sterilin, UK) (for control samples, positive controls and 
treatment samples) were labelled and their weight without the lids noted. The 
appropriate amount of alginate beads or other samples (to match the required iron 
concentration) were weighed into the tubes. 10ml of sodium chloride and potassium 
chloride solution at pH 2 was added to each tube, and the pH adjusted to 2 to 
provide an optimal environment for pepsin to work; 0.5ml of pepsin solution was 
added to each tube and the tubes were incubated for 1 hour on a rotating table at 
37ºC. Once the gastric phase was completed, the pH was adjusted to 5.5-6 using 
1.0M sodium bicarbonate to inactivate pepsin digestion and 2.5ml of pancreatin/bile 
solution was added to each sample. The pH was further adjusted to 6.7 with sodium 
bicarbonate and the volume (by weight) of each tube readjusted to tube weight plus 
15g using sodium chloride and potassium chloride solution at pH 6.7.  
Each tube was well mixed using a vortex during sampling and 1.5ml of sample from 
each tube was transferred onto appropriate inserts on the plates. Plates were then 
moved onto the plate shaker (slow setting, 20oscilations/min) and incubated at 37ºC 
for 2 hours to imitate the duodenal phase. After 2 hours the inserts were removed, 
and each well supplemented with an additional 1ml of MEM and the plates 
incubated for a further 22 hours.  
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The iron content of the digests was quantified using a bathophenanthroline 
colorimetric assay. Briefly, 1.5ml of sample digestates from the in vitro digestion was 
centrifuged at 10000g for 5 min, then 380μl of the resulting supernatant was 
transferred to a fresh tube, and 20μl of hydroxylamine hydrochloride solution was 
added. Ferrous standards ranging from 0 to 2.0 μg/ml were prepared by diluting a 
5μg/ml stock solution of iron (High-Purity Standards,USA) in 0.1M HCl in the 
presence of 20μl of 0.1g/ml hydroxylamine hydrochloride (Sigma, UK) dissolved in 
10M HCl, then 100μl of each standard and sample was added to a 96-well plate, in 
triplicate, and 50μl of chromagen solution (0.0156g of bathophenanthroline 
disulfonic acid disodium salt (Sigma, UK) dissolved in 50ml of 2.0M sodium acetate) 
was added. The plate was incubated on a plate shaker at 200 oscillations per 
minute at room temperature for 10min. Once incubation was completed the 
absorbance was measured at 562 nm using a microplate reader (Omega, BMG 
Labtech, UK). 
2.2.3 Post experiment day procedures (14 days post seeding) 
24 hours after the start of the duodenal phase, MEM was removed from the cells, 
each well was washed twice with sodium chloride and potassium chloride buffer, 
and cells from each well were suspended in 2ml of MilliQ water, frozen and kept at -
20ºC until sonication. Further analysis was performed as described in Sections 2.1.6 
and 2.3. 
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2.3 Analysis of Caco-2 cell lysates 
2.3.1 Spectroferritin ELISA assay 
Sonicated cell lysates were defrosted at room temperature and kept on ice and a 
spectroferritin ELISA assay (Ramco, USA) was carried out 24 hours post-sonication, 
according to the manufacturer’s instructions. The spectroferritin kit was left to 
equilibrate at room temperature for a minimum of 20 minutes and the microplate 
wells were dried and placed on a 96 well grid. Standard solutions containing 0.3ml 
human spleen ferritin calibrated to concentrations of 6, 20, 60, 200, 600 and 
2000ng/ml were applied in duplicate to obtain a standard curve. Test samples were 
applied in duplicate at a volume of 10µl. Once all the samples were applied to the 
microplate wells, 200µl of conjugated anti-human ferritin was applied to each well. 
The plates were then incubated for 2 hours at room temperature with agitation. After 
2 hours, all wells were washed three times with deionised water. The plate was then 
incubated for a further 30min at room temperature in the presence of 200µl 
substrate. Following incubation, 100µl of potassium ferricyanide was added and 
mixed for one minute on a rotating plate shaker set at 180rpm. Absorbance was 
measured using an absorbance microplate reader (Omega, BMG Labtech, UK) at 
490, 570 and 630nm. Absorbance at 570-630nm was subtracted from absorbance 
at 490nm.  
2.3.2 BCA protein assay 
In order to adjust for well-to-well cell number variability (which results in variations in 
ferritin) the ferritin measurements were standardised to allow comparisons within 
and between experiments. This was achieved by measuring the protein content and 
expressing the ferritin content per mg of total protein. Total protein was quantified 
using a bicinchoninic acid (BCA) protein assay (Pierce, USA), carried out in parallel 
with the spectroferritin assay. A BCA working solution and standard solutions (0, 
125, 250, 500, 1000 and 2000µg/ml Bovine Serum Albumin (BSA)) were prepared 
according to the manufacturer’s instructions. The assay was performed with the 
addition of 10µl protein standard (in duplicate) or 10l experimental samples (in 
duplicate) to 200µl of BCA working solution in a 96-well microplates. The plates 
were mixed on a rotating plate shaker for 1 minute at 180 rpm and then incubated at 
370C for 30min. Absorbance was read at 562 nm using a microplate reader (Omega, 
BMG Labtech, UK) 
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2.3.3 Statistical analysis 
Unless otherwise stated, all statistical analysis was performed using SPSS Inc, 
USA, (version 16.0.0). ANOVA general linear model with Tukey post-hoc testing 
was used to examine pair wise differences. Data are presented as mean ±SD.  
 
2.4 Analysis of iron and calcium content of alginate beads 
Atomic absorption spectroscopy (AAS) was used to determine the iron content of 
the alginate beads or the filtered liquid resulting from the digestion. Briefly, alginate 
beads were first separated from the liquid in which they are dispersed by filtration 
using a filter paper (Whatman 4). Then, a minimum of 0.5 g of wet beads or liquid 
were transferred to a crucible and dried overnight in an oven at 60ºC before being 
placed in a muffle furnace (Vulcan Box Furnace, NEY Dental International, USA) 
and heated with a two-step temperature program (20ºC - 250ºC for 2h followed by a 
fast ramp and hold for 24h at 550ºC). Once cooled, a known volume of 20% (v/v) 
nitric acid was added to each crucible to dissolve the ashes including the metal ions. 
The acidic solution was then transferred to a tube and the amount of iron and/or 
calcium measured by AAS using a Perkin Elmer Atomic Absorption 
Spectrophotometer 3300 (Perkin Elmer Ltd., Beaconsfield, UK). 
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3.1 Introduction 
As a part of a joint project between the IFR, Norwich, Norfolk, UK and the University 
of East Anglia (UEA), funded by Biotechnology and Biological Sciences Research 
Council, and Diet and Health Research Industry Club (BBSRC, DRINC, Grant 
Reference Number BB/G53015X), a food grade sodium alginate was selected as a 
potential delivery system for iron and was the subject of further investigation using 
the Caco-2 cell model. 
The use of iron fortification as a strategy to prevent IDA is widespread as it is 
recognised as a sustainable and realistic way to reduce the occurrence of iron 
deficiency67. Nonetheless, fortification is challenging to the food industry, mainly due 
to organoleptic changes during food storage or preparation69 brought about by the 
addition of iron. Water soluble forms of iron are generally more bioavailable than 
non-soluble iron compounds but they often cause adverse sensory changes when 
added to foods. A potential strategy to overcome this problem is the use of water 
soluble iron compounds protected by a water resistant barrier which will prevent any 
organoleptic changes in the fortified food products. When combined with AA FeG is 
an iron compound that has been reported to be an effective food fortificant223, which 
may reduce the prevalence of anaemia.15 In order to maximise iron absorption in 
vivo, it would be advantageous to employ a delivery system that will reduce 
organoleptic problems in food and also protect the iron from adverse interactions in 
the gut lumen and deliver iron directly to the duodenum where it is absorbed. 
Physico-chemical studies of alginate beads (with the use of different alginates), 
starch,  water-in-oil-in water emulsions (W/O/W) and gel in water in oil emulsions 
(G/O/W) were performed at IFR. Four iron compounds (divalent salts: iron (II) 
gluconate and iron (II) sulphate and trivalent salts ammonium (III) citrate and iron 
(III) chloride) were used for the preparation of iron containing alginate beads. Once 
optimal conditions for the preparation were selected, the most promising materials 
were tested using Caco-2 cells as a screening tool.  
The hypothesis tested in this chapter was that iron-containing alginate beads would 
remain intact during the gastric digestion phase and that iron would be released 
under duodenal conditions, thus delivering soluble iron for cell uptake.  
The primary objective of these experiments was to determine whether alginates 
would interfere with iron uptake into Caco-2 cells, to assess whether AA would 
demonstrate its usual enhancing effect on iron uptake in the presence of alginate 
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and if alginate beads subjected to simulated digestion would deliver available iron to 
be taken up by the cells.  
 
3.2 Methods 
3.2.1 Development of iron containing materials 
Iron containing materials were developed by scientists at IFR, with lab work 
undertaken by Dr Natalia Perez-Moral. 
3.2.1.1 Preparation of alginate beads 
 As empirically tested at the Institute of Food Research (IFR) by Dr Natalia Perez-
Moral alginate gelation in the presence of FeG with the use of Encapsulator 
(EncapBioSystemS Inc, Switzerland) resulted in amorphous gel and not bead 
formation. Thus, in order to obtain reproducible morphology and uniformity in bead 
shape, calcium had to be introduced to the system. For experimental details please 
see the details further down this Section.  
Perez-Moral et al.217 used four alginates differing in M/G acid ratio (characterised in  
Table 3.2.1) and investigated their cross-linking capacity with FeG in the presence 
of calcium chloride (Figure 3.2.1). The researchers wanted to test the hypothesis 
that there is competition between calcium and iron for binding sites of alginate gel224. 
Their results showed that the highest amount of FeG incorporated into alginate 
beads was observed at the lowest calcium chloride concentration (5mM) used 
(Figure 3.2.1; graph a) across all alginates used. However, in alginate with the 
highest guluronic acid content (35/65 M/G ratio) iron loading was approximately 2 
fold higher than in the alginate with the lowest guluronic acid ratio (60/40 M/G).   
In fact, increasing iron content of alginate beads was found to be consistent with 
increasing guluronate content of alginates. This observation suggests a potentially 
distinct guluronate and iron interaction. Nevertheless, as calcium concentrations 
were increased, the differences between iron loading in alginate beads containing 
varying guluronate content was negligible. The latter supports the hypothesis of 
competitive binding between Fe2+ and Ca2+ in alginate gel beads. Interestingly, when 
only calcium (5mM) was used, alginate with the highest guluronic acid content 
resulted in the highest calcium concentration (Figure 3.2.1;graph b). When a range 
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of calcium concentrations were used (between 5 and 50mM), calcium content of 
alginate beads was increased until it reached a plateau at a concentration of 40-
50mM of calcium.  
 
 
Figure 3.2.1 Graphs of 0.5% (w/v) alginate beads with following M/G ratios: ◊ 
((60/40); ∆(50/50); □ (45/55); ○(35/65) with FeG (a) or without (b) in presence of 
increasing calcium concentrations as described by Perez-Moral et al.217.  
 
Iron containing alginate beads (Figure 3.2.2) were prepared from 4 different 
alginates (Danisco, DK;  
Table 3.2.1) using an encapsulator. Three different routes of bead synthesis were 
evaluated:  
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 Route 1: by mixing iron and alginate solutions (0.5% (w/v)), which were then 
transferred to an encapsulator (to form drops) and collection in a calcium 
bath where crosslinking (with calcium) took place225.  
 Route 2: use of 0.5% (w/v) alginate solution to form beads with an 
encapsulator with collection of the beads into a calcium and iron bath for 
crosslinking (calcium and iron ions competition; approximately 20 hours of 
loading). 
 Route 3: use of 0.5% (w/v) alginate solution to form beads with an 
encapsulator, which were crosslinked in a calcium bath and subsequently 
soaked in an iron bath (exchange process, 35 days of loading). 
      
Figure 3.2.2 Microscopic photograph of beads containing 178mg Fe/g dried beads 
prepared via route 2 after 31 days of loading. Black bar represents 100µm. 
 
Table 3.2.1 Composition (M/G) ratio, molecular weight (MW) and the solution 
viscosity of the alginates. Data supplied by manufacturer. 
Alginate M/G MW(kDa) Viscosity of 1%w/w 
solution (mPa s) 
A1 60/40 350 520 
A2 50/50 350 520 
A3 45/55 320 370 
A4 35/65 315 350 
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Preparation of the beads via route 1 caused technical issues regardless of the type 
of alginate and iron compound used. Due to an increase in viscosity of the iron and 
alginate solution (caused by the interaction of iron with alginate) the flow in the 
encapsulator was often disrupted resulting in faulty bead shapes. Therefore, 
formation of beads via route 1 was discontinued.  
The best iron loading of the beads using route 2 was obtained with FAC regardless 
of type of alginate used. Ferric chloride loading was the most successful when 
alginates A1 and A4 were used, whereas loading with divalent salts was not as 
effective. FeG loading was not dependent on the type of alginate used. 
Conversely, FeG combined with alginate A2, A3 or A4 led to the best loading when 
route 3 was applied; followed by FAC when combined with alginate A1 or A4. 
Differences in iron loading with routes 2 and 3 could have been due to different 
incorporation processes. In route 2, loading with iron occurred through a competitive 
process between iron and calcium ions whereas in route 3 iron loading arose 
through the exchange process217. 
From an analysis of the bead morphology and iron content the most effective 
methods to prepare the beads were shown to be routes 2 and 3. Microscopic 
examination revealed that bead uniformity in shape, lack of adhesiveness or 
aggregation was higher with increased guluronic acid content of the alginates. Once 
loading time and iron content of the beads was taken into account the following 2 
bead preparations were investigated further: alginate A4 loaded with FeG or FAC 
prepared via route 2; and alginate A2 loaded with FeG and FAC prepared via route 
3217. 
Application of a simplified simulated in vitro digestion procedure described by Perez-
Moral et al.217 demonstrated that approximately 4.7g of wet beads prepared via 
route 2 and route 3 survived gastric digestion (Figure 3.2.3), and would deliver 
nutritionally relevant amounts of iron (approximately 10mg of iron) into the 
duodenum. However beads loaded with FeG via route 3 showed a progressive 
decrease in iron content (starting at day 5 and continuing until the end of the 
experiment on day 30) which was not the case when FAC was used. Because FeG 
is considered to be more bioavailable than FAC, beads prepared via route 2 with 
FeG were selected for further screening using Caco-2 cells and simulated digestion 
as a model to predict iron bioavailability.  
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More specific details of the bead preparation process are given in Perez-Moral et 
al.217.  
 
Figure 3.2.3 Microscopic photograph of beads after simplified simulated digestion 
which contain 39mg Fe/g dried beads prepared via route 2. Black bar represents 
100µm. 
3.2.1.2 Preparation of emulsions and starch particles 
In addition to alginate beads other materials tested were: W/O/W emulsions; gel in 
oil in water (G/O/W) emulsions and starch particles. 
 G/O/W emulsions 
G/O/W are multiple emulsions were oil globules containing small alginate droplets 
are dispersed in an aqueous continuous phase226. G/O/W emulsions are prepared 
as follows: the inner aqueous phase consisted of 10ml of 1% sodium alginate 
solution mixed with 2ml of FeG 0.2M and 0.34ml of a 5% slurry of calcium tartrate. 
Prior to that, the oil phase was prepared in a separate beaker by melting 48g of 
inter-esterified palm kernel oil, chocotan (donation by Macphie, Glenbervie, 
Scotland) at 40ºC and mixing it with 1g of PGPR (the oil soluble emulsifier 
poliglycerol polyricinoleate PGPR, Palsgaard 4125, Healy Group, UK). The aqueous 
inner phase was added to the oil phase in a high speed blender and mixed at a low 
shear position (up to 18000rpm) for 30 seconds, then 1ml of acetic acid was added 
and after 30 seconds the emulsion was mixed again for 30 seconds at high shear 
position (up to 22000rpm). After 1 min 200ml of a 2% whey protein isolate (Bipro, 
Danisco, UK) aqueous solution was added before starting another mixing cycle 
consisting of 30 seconds at low speed, 30 seconds rest and another 30 seconds at 
low speed. 
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 W/O/W emulsions  
W/O/W emulsions (Figure 3.2.4) were prepared using chocotan. Briefly, 12ml of 
water containing the iron compound (ferrous sulphate or FAC) was blended at low 
power (up to 18000rpm) with 48g chocotan and 1g PGPR for 30 seconds at 44ºC, 
rested for a further 30 seconds and blended again at high power (up to 22000rpm) 
for 30 seconds to establish water in oil droplets. These droplets were then 
suspended in water containing 200ml of 2% whey protein isolate by high power 
blending for 30 seconds. 
 
Figure 3.2.4 Microscopic photograph of W/O/W emulsion. 
 
 Preparation of starch particles 
20g of starch (Sigma, UK) was mixed with 180ml of deionised (DI) water in a round 
bottomed flask equipped with a mechanical stirrer and immersed in an oil bath to 
control the temperature at 85ºC. Then a solution containing 9.44g of FeG in 25ml of 
water was added and the mix was stirred at approximately 500rpm. After 30 minutes 
the temperature was increased to 85ºC and stirred for a further two hours. The 
resulting mixture was poured on two plastic Petri dishes (13.5cm diameter) and 
placed in an oven at 50ºC. Once the starch film was dried, it was grounded and 
sieved in order to get a range of different sized particles.  
3.2.2 Preparation of alginate solutions  
 Four alginate formulations with different ratios of mannuronic (M) to guluronic (G) 
acid were used in this study: A1 (M:G ratio 60:40), A4 (M:G 35:65) from Danisco, 
Copenhagen, Denmark (Table 3.2.2); A5 (Manucol®DH,M:G ratio 60-70:30-40) and 
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A6 (Manugel®GHB, M:G ratio 30-40:60-70) from FMC BioPolymer, Haugesund, 
Norway.  
Table 3.2.2 Characteristics of alginates used to make up alginate solutions. 
Alginate M/G ratio Supplier  
A1 60/40 Danisco, Denmark 
A4 35/65 Danisco, Denmark 
A5  
(MANUCOL® DH)  
60-70/30-40 FMC Biopolymer, Norway 
A6 
(MANUGEL® GHB) 
30-40/60-70 FMC Biopolymer, Norway 
 
All glassware and magnetic stirrers were washed in 10% hydrochloric acid (HCl) and 
rinsed with MilliQ water prior to use to eliminate iron contamination. The alginate 
solutions were prepared by dissolving 3g of alginate powder in 300ml in serum free 
media to obtain 1% (w/v) stock solutions. The solution was covered with sterilized 
para-film and left overnight at room temperature with stirring. If needed, the stock 
solutions were diluted further in serum free media in order to obtain working 
solutions of 0.5% (w/v) or 0.1% (w/v) alginate concentrations which were applied to 
the Caco-2 cells in media containing FAC (30µmol/L), with or without L-ascorbic 
acid (AA) (600µmol/L) or tannic acid (TA) (molar ratio of 1:0.1 FAC:TA).  
3.2.3 Preparation of ascorbic acid and ferric ammonium citrate solutions 
Shortly before use, AA was prepared at a concentration of 0.06M (1/100 dilution of 
concentrated stock). A working solution of 600µM was prepared in treatment 
medium. FAC was prepared at a concentration of 3mM (1/100 dilution of 
concentrated stock) in 0.1M HCl. A working solution of 30µM was prepared in 
relevant treatment media. Both solutions were filter sterilised using hydrophilic 
0.2µm syringe filters (Sartorius Stedim Biotech, Germany). 
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3.2.4 Preparation of treatment media 
Shortly before use, 1% (w/v) alginate solution and serum free media were heated to 
370C. Subsequently, treatment media were prepared as described below (Table 
3.2.3) in 50ml tubes under sterile conditions.  
Shortly before the start of an experiment, serum free media was aspirated from the 
Caco-2 cell monolayer and 2ml of required treatment media was applied to each 
well and incubated (37C, 5% CO2) for 24 hours. After that time the cells were 
harvested and sonicated according to the procedure in Chapter 2, Section 2.2.3. 
Table 3.2.3 Example of treatment media description. 
Tube (50ml) Serum 
free 
DMEM 
(ml) 
1% alginate  
solution in 
serum free 
DMEM  (ml)  
FAC  
3mM   
(ml) 
AA 
0.06M  
(ml) 
Total vol 
(ml) 
1. Control (Blank) 50  ---- ---- 50 
2. 1% alginate ---- 50 ---- ---- 50 
3. 1% alginate 
+AA 
---- 49.5 ---- 0.5 50 
4. FAC  49.5 --- 0.5  --- 50 
5. FAC +AA 49 --- 0.5 0.5 50 
6. FAC + 0.1% 
alginate 
44.5 5 0.5 --- 50 
7. FAC + 0.1% 
alginate+AA 
44 5 0.5 0.5 50 
8. FAC + 0.5% 
alginate 
24.5 25 0.5 --- 50 
9. FAC + 0.5% 
alginate+AA 
24 25 0.5 0.5 50 
10.FAC + 1% 
alginate 
--- 49.5 0.5 --- 50 
11.FAC + 1% 
alginate  +AA 
--- 49 0.5 0.5 50 
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Uptake of FAC by Caco-2 cells was measured from the ferritin content 24h post-
exposure (ng/mg total protein), as this reflects the quantity of iron entering the cell, 
and is therefore a surrogate index of iron availability. 
3.2.5 Statistical analysis 
Unless otherwise stated, all statistical analyses were performed using SPSS Inc, 
USA, (version 16.0.0). 2-factor ANOVA with Tukey’s post-hoc or Dunnett (2-sided) t-
test were conducted to examine pairwise differences on log-transformed data. Data 
are presented as mean ±SD. Differences were considered significant at p<0.05. 
Each table or figure represents data from one experiment. The number of replicates 
in each experiment performed is indicated and is provided in figures/tables legends.  
 
3.3 Results 
3.3.1 Iron in presence of alginate solutions  
As described earlier four types of alginate (A1; A4 from Danisco, UK and A5 
(Manucol); A6 (Manugel) from FMC bioPolymer, Norway) with different ratios of 
mannuronic to guluronic acid (Table 3.2.2), were applied to the Caco-2 cells at 
various concentrations in media solution containing FAC.  
There was no effect of 0.1% (w/v) A1 (Figure 3.3.1), A5 and A6 with the exception of 
A4 (Figure 3.3.2) alginate on FAC-induced ferritin formation in Caco-2 cells exposed 
to the same dose of iron. Higher concentrations of alginates resulted in a 
significantly higher ferritin expression (p=0.002, p<0.0005 and p<0.0005 for 0.5% 
(w/v) alginates A4, A5 or A6 respectively; p=0.004 for 1% (w/v) A1 alginate and 
p<0.0005 in case of remaining 1% (w/v) alginates used) together with FAC 
compared to cells treated with FAC alone. In cells exposed to FAC (30 µmol/L) there 
was a 10-fold increase in cell ferritin concentrations when compared to untreated 
control cells (data not shown, ferritin concentration 4.7ng/mg protein). These data 
demonstrate that alginates can increase iron bioavailability in this in vitro system. 
There were no major differences between the effects of 4 different alginates tested 
on ferritin formation in Caco-2 cells. There was a similar trend in cell response 
(Figure 3.3.1; Figure 3.3.2), when treated with 4 different types of alginate (A1, A5 
and A6), with the exception of A4 alginate at 0.1% concentration in the presence of 
FAC, (however when the experiment was repeated (Figure 3.3.3), the results were 
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different, suggesting that it was not a reproducible effect) indicating that the different 
M:G ratios in the alginates tested had a similar effect on ferritin formation. 
  
Figure 3.3.1. Ferritin concentration in Caco-2 cells exposed to FAC and different 
alginate concentrations and AA. Ferritin concentration (ng/mg total protein) after 
treatment with 30μmol/L FAC (n=6), FAC plus A1 at 3 concentrations (0.1, 0.5 and 
1% w/v) (n=4 for each alginate concentration used, black bars), FAC and AA (at 
600μmol/L) (n=3), or FAC and A1 and AA (n=4 for each alginate concentration 
used, white bars). Cell ferritin response to control (blank) was 1.4±SD 0.2. Data 
represent mean ±SD. Bars without a common letter (a, b, c, d) are significantly 
different, p<0.05.  
 
Figure 3.3.2 Ferritin concentration in Caco-2 cells exposed to FAC and different 
alginates. Data combined from 2 separate experiments. Ferritin concentration 
(ng/mg total protein) after treatment with 30μmol/L of FAC, FAC plus A4 or A5 or A6 
at 0.1%; 0.5% and 1% (w/v) concentration. Data represent mean ±SD (n=4, except 
FAC where n=6). Bars without a common letter (a, b, c, d, e) are significantly 
different, p<0.05.  
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3.3.2 Iron and ascorbic acid in the presence of alginate solutions  
As predicted, cells exposed to FAC plus AA had a significantly higher ferritin 
concentration than cells incubated with FAC alone (p<0.0005 Figure 3.3.1; Figure 
3.3.3). Interestingly, ferritin formation was increased further in the presence of 0.5% 
and 1% A1 alginate when compared to AA alone (p=0.01 and p=0.041, 
respectively), (Figure 3.3.1). However this was not the case when A4 alginate was 
used (Figure 3.3.3).  
 
Figure 3.3.3 Ferritin concentration in Caco-2 cells exposed to FAC and different 
alginate concentrations and AA. Ferritin concentration (ng/mg total protein) after 
treatment with 30μmol/L FAC (n=6), FAC plus A4 at 3 concentrations (0.1, 0.5 and 
1% w/v) (n=4 for each alginate concentration used, black bars), FAC and AA (at 
600μmol/L) (n=3), or FAC and A4 and AA (n=4 for each alginate concentration 
used, white bars). Cell ferritin response to control (blank) was 2.0±SD 0.9. Data 
represent mean ±SD. Bars without a common letter (a, b, c) are significantly 
different, p<0.05. 
3.3.3 Iron and tannic acid in presence of alginate solutions  
It has previously been reported that at 1:0.1 (Fe:TA molar ratio) TA inhibits iron 
uptake into Caco-2 cells by 92%227. Co-addition of TA significantly inhibited ferritin 
formation induced by FAC at 30µmol/L or at 100µmol/L (p=0.044, Figure 3.3.4; and 
p=0.002; Figure 3.3.5 respectively). When 0.5% A5 alginate was added with iron 
(30µmol/L or at 100µmol/L) and TA, the ferritin formation was restored to levels 
obtained in samples treated with iron alone, resulting in significantly higher ferritin 
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concentrations than in cells treated with iron and TA alone (p=0.042 and p<0.0005 
respectively). However the inhibitory effect of TA was not blunted at low or high 
(0.1% or 1% w/v) alginate concentrations (Figure 3.3.4). These results suggest that 
an alginate concentration of 0.5% (w/v) was the most favorable in terms of negating 
the inhibitory effect of TA.  
It is also worth commenting that as in previous experiments a dose-response effect 
was noted in samples treated with increasing amounts of alginate in the presence of 
iron, with a significant increase in ferritin formation in samples at 0.5% (w/v) alginate 
concentration in comparison with a lower (0.1% w/v) concentration (p=0.013 in 
experiment where 100µmol/L FAC was used). 
 
Figure 3.3.4. Ferritin concentration in Caco-2 cells exposed to FAC, alginate and 
TA. Ferritin concentration (ng/mg total protein) after treatment with 30µmol/L FAC, 
or FAC and A6 at 0.1%; 0.5% and 1% (w/v) concentration, with or without TA at iron: 
TA molar ratio 1:0.1. Cell ferritin response to control (blank) was 1.5±SD 1.3. Data 
represent mean ±SD (n=4). Bars without a common letter (a, b, c, d) are significantly 
different, p<0.05. 
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Figure 3.3.5. Ferritin concentration in Caco-2 cells exposed to FAC, alginate and 
TA. Ferritin concentration (ng/mg total protein) after treatment with 100µmol/L FAC, 
or FAC and A6 at 0.1% and 0.5% (w/v) concentration, with or without TA at iron: TA 
molar ratio 1:0.1. Cell ferritin response to control (blank) was 5.2±SD 0.5. Data 
represent mean ±SD (n=4). Bars without a common letter (a, b, c) are significantly 
different, p<0.05. 
 
Based on the above results, alginate solutions at concentrations more than 1% (w/v) 
were prepared to investigate if the ameliorating effect of alginate on TA was greater 
at higher concentrations of alginate. However, due to very high viscosity of the 
alginate solutions it was impossible to undertake the planned experiments to test the 
above hypothesis. 
3.3.4 Iron containing alginate beads 
Experiments were performed to examine the stability of alginate beads containing 
varying levels of alginate (Table 3.3.1) but a constant amount of FeG at the level of 
8.38µg in each treatment (apart from ‘blank’ control) when subjected to simulated 
digestion. Iron (III) chloride in the presence of AA was used as a positive control 
(Fe:AA ratio 1:10). The beads were loaded with two iron compounds: FeG and FAC.  
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Table 3.3.1. Composition of the beads. 
Beads Iron 
compound   
added 
Weight 
of beads, 
g 
Iron: AA 
ratio 
Total iron 
content,  
µg 
Total 
calcium 
content 
µg 
 
--- FeCl3+AA --- 1:2  8.38 --- 
B1   FAC1 0.049 --- 8.38 Data not 
available 
B2 FeG2 0.044 --- 8.38 Data not 
available 
B3  FeG 0.174 --- 8.38 Data not 
available 
B4  FeG 0.419 --- 8.38 Data not 
available 
--- FeCl3+AA --- 1:10 8.38 --- 
B5  FeG 0.044 --- 8.38 16.7 
B6 FeG 0.093 --- 8.38 65.1 
B7 FeG 0.175 --- 8.38 85.8 
B8 FeG 0.419  --- 8.38 289.1 
B9 FeG 0.209 1:10 8.38 108.7 
B10 FeG 0.419 1:10  8.38 217.9 
 
1FAC -ferric ammonium citrate; 2FeG- ferrous gluconate 
To ensure identical iron concentrations for each treatment, varying weights of 
alginate beads were used. The results showed that FeG was more effective in 
inducing a ferritin response in the Caco-2 cells than FAC (Figure 3.3.6) with 
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significantly higher ferritin values for beads B3 and B4 (p=0.04 and p=0.024 
respectively). 
In addition, the design of an experiment presented in Figure 3.3.7 also enabled the 
evaluation of ferritin formation in Caco-2 cells in response to increasing weight of 
alginate beads but to a constant amount of iron (Table 3.3.1). However, with higher 
weights of alginate beads the calcium content per treatment also increased.  
 
 
Figure 3.3.6 Ferritin concentration in Caco-2 cells treated with iron (III) chloride in 
presence of AA, alginate bead formulations (B1-B4) containing either FAC (B1) or 
FeG (B2, B3 or B4). Cell ferritin response to control (blank) was 5.9 ±SD 0.7. Data 
represent the mean ±SD (n=4). Means without a common letters (a, b) are 
significantly different (p<0.05). 
 
Ferritin formation in cells treated with digestates of B6 beads (containing 0.093 g 
alginate) was similar to the positive control (FeCl3:AA) (Figure 3.3.7). Increasing the 
alginate content of the beads (B7, B8) inevitably increased the calcium content, and 
this resulted in a significantly lower ferritin concentration. However, addition of AA 
during bead formation (i.e. B9, B10) counteracted the inhibitory effects observed in 
B7 and B8 (p<0.0005 for both comparisons, Figure 3.3.7; Table 3.3.1). Furthermore, 
AA containing beads B10 produced a significantly greater ferritin response than AA 
alone (p=0.013), suggesting a synergistic effect between AA and alginate.  
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Figure 3.3.7 Ferritin concentration in Caco-2 cells treated with iron (III) chloride in 
presence of AA (at 1:10 ratio and alginate bead formulations (B5-B10) containing 
either FeG (B5- B8) or FeG in presence of AA at 1:10 Fe to AA ratio (B9-B10). Cell 
ferritin response to control (blank) was 1.7 ±SD 2.0. Data represent the mean ±SD 
(n=4). Means without a common letters (a, b, c, d) are significantly different 
(p<0.05). 
3.3.5 Iron containing starch and emulsions 
W/O/W) described earlier in Section 3.2.1 loaded with 16µM, 33µM, 80µM or 160µM 
of FAC and subjected to simulated digestion (described in paragraph 2.2) did not 
deliver iron in an available form and therefore there was no ferritin response in 
Caco-2 cells (experiment was performed twice with the same findings, data not 
shown).  
As a result of these experiments, further analysis was undertaken at the IFR. More 
detailed microscopic examination revealed that although emulsion droplets 
remained intact at physiological temperatures (37ºC) for several hours, they did not 
withstand the addition of 0.15M sodium chloride solution. Osmotic pressure caused 
the diffusion of iron from the W/O/W particles; hence the emulsions did not provide a 
protective barrier. Based on the above evidence, no further experiments using 
W/O/W emulsions were undertaken. 
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3.3.6 Comparison of iron availability from iron (III) chloride, iron (II) 
gluconate, iron containing alginate beads, starch and G/O/W 
In previous cell experiments iron (III) chloride was used as a positive control but 
since FeG was being used to load alginate beads it was appropriate to use FeG as 
a positive control in order to investigate the effect of alginate beads on FeG uptake 
in cells. In addition, use of FeG and ferric chloride in one experiment allowed for 
comparison between these two forms of iron in the Caco-2 cell model. An 
experiment was undertaken to examine the effect of simulated digestion on FeG, 
iron (III) chloride (Figure 3.3.8) as well as dried beads, wet beads, G/O/W emulsion 
and 2 types of starch. The exact quantities of iron-loaded materials are shown in 
Table 3.3.2 
Table 3.3.2. Composition of iron loaded materials. 
Iron loaded 
material 
Iron compound   
added 
Weight of iron 
loaded materials 
used (g) 
Iron content 
per well  (µg) 
---- Iron (III) chloride ---- 8.5 
--- FeG --- 8.5 
Wet beads 
(B11) 
FeG 0.0945 8.5 
Dry beads 
(B11) 
FeG 0.00289 8.5 
Wet beads 
(B12) 
FAC 0.00233 8.5 
G/O/W FeG 4.83g 23.1* 
Starch SN14 FeG 0.00289 8.5 
Starch SN 15 FeG 0.00289 8.5 
*Iron content of G/O/W was 2.5 fold higher than other materials used because (as 
revealed by the IFR team) G/O/W’s in their in vitro test showed a small release of 
iron.  
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Results presented in Figure 3.3.8 suggest that iron as FeG is more available to the 
cells than iron delivered as iron (III) chloride when assessed by ferritin formation 
(p=0.001). However, when the cell ferritin response to wet beads B11 and dried 
beads B11 was compared with the cell ferritin response to ferric chloride and FeG 
there were no significant differences between the beads and the two iron 
compounds. 
 
 
Figure 3.3.8 Ferritin concentration in Caco-2 cells treated with iron (III) chloride, 
FeG, alginate beads containing either FeG (B11 wet or B11 dried beads) or FAC 
(B12); G/O/W containing FeG and 2 starch samples also containing FeG. There was 
no ferritin response in untreated cells control (blank). Data represent the mean ±SD 
(n=4) except control, FeCl3 and FeG treatment where n=6. Means without a 
common letters (a, b, c, d) are significantly different (p<0.05). 
 
Beads loaded with FAC (B12), G/O/W as well as starch SN14 and SN15 gave a 
significantly lower ferritin response than unprotected FeG (p<0.0005 in all 
instances). These results suggest that alginate beads loaded with FeG are the most 
promising (wet or dried) vehicle. However, ferritin produced by the cells when 
treated with beads containing FeG was at a similar level to unprotected FeG.  
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3.4 Discussion 
Caco-2 cell models have been developed as a rapid tool for investigating iron 
availability, and when combined with a simulated digestion procedure they are 
considered to mimic more closely the in vivo situation. However, seeding the cells at 
very high density and culturing them for 12 days post-confluence in 6 well plates is 
technically challenging. There may be non-uniform distribution of cells which can 
reduce the cell monolayer by 30 to 40% in some parts of the well and across many 
plates which will result in a low cell response for iron treatments. For example the 
cell ferritin response to ferric chloride treatment in the presence of AA (Figure 3.3.6) 
was six fold lower than the cell ferritin response to ferric chloride treatment 
presented in Figure 3.3.8. These problems were encountered on several occasions 
and a significant amount of time was spent trying to determine the cause of the 
growth problems and changing the culturing and sub-culturing conditions. These 
issues illustrated the importance of accurate seeding procedures for obtaining 
uniform cell distribution, and this was more difficult to achieve in a round culture 
dish.  
In experiments performed using W/O/W emulsions as a carrier of iron, there was no 
ferritin response, indicating that either iron was not released from W/O/W emulsions 
or G/O/W emulsions did not provide an adequate barrier to protect iron from 
precipitation as ferric hydroxide at high (duodenal) pH, therefore preventing it from 
being in an available form for uptake by Caco-2 cells.  
The mechanism by which alginates enhance iron uptake into Caco-2 cells remains 
uncertain. Based on the fact that alginates bind calcium cations209,228 and that 
alginates have a higher affinity with calcium in the presence of iron211, one of 
potential hypotheses is that when alginates are added to the culture media they form 
a complex with calcium, a recognized inhibitor of iron absorption54, which is present 
in the media as calcium chloride (at a concentration of 200mg/L). High 
concentrations of calcium can act as a non-competitive inhibitor of iron absorption 
via DMT1229 and, in addition, can induce translocation of DMT1 away from the cell 
surface of Caco-2 cells55. A limitation of our model system is that calcium (an 
essential component of cell culture media) cannot be removed without deleterious 
effects to the cell monolayer. Furthermore, attempts at increasing the calcium 
content in culture media in the presence of alginate failed due to the immediate 
formation of a thick gel.  
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Additionally, alginate beads loaded with FeG resulted in a greater response than 
FAC in terms of ferritin formation. Thus, FeG was used in the subsequent human 
study (Chapter 4) as this compound appears to be the more promising than FAC 
and has the benefit of already being used in food fortification.  
The experimental procedures employed in these studies had some weaknesses. All 
the ferritin results (ng/mg total protein) presented Figure 3.3.6 are relatively low 
(ferritin values are low across all treatments) which suggests that the cells were not 
responding sensitively to the iron treatments. Thus, these results should be treated 
with caution. Furthermore the ELISA assay used to quantify ferritin (S-22, Ramco, 
USA procedure described in detail in Chapter 2) measured ferritin in the range 
between 6 and 2000ng/ml, therefore results presented in Figure 3.3.6 are at the 
lower end of the standard curve.  
The simulated digestion procedure (described in Chapter 2) was designed to 
investigate food samples which have lower iron concentrations (w/w) than the iron 
containing alginate beads and therefore higher weights (e.g. 0.5g) could be tested in 
each treatment. The Caco-2 cell system works best with solutions of iron ranging 
from 10-100µmol/L230. At higher values the response is no longer linear, and at 
lower values, the ferritin response is low and the sensitivity of the assay is greatly 
reduced230. The weight of alginate beads that contained iron within this range was 
relatively low, increasing the possibility of errors when weighing of the samples. To 
minimize these errors the iron loading conditions and consequently the iron content 
of the beads was reduced, but this inevitably increased the calcium content of the 
beads.  
In addition, enzymes that are involved in the digestion of fat (lipase and lecithin) and 
starch (duodenal amylase) were not included in the standard simulated digestion 
procedure (designed specifically for screening iron availability, Glahn et al.230). 
Therefore the low release of iron from starch or G/O/W may be the result of 
incomplete digestion. This was tested by adding egg lecithin enzyme to the gastric 
phase of digestion and duodenal amylase to the duodenal phase of digestion. 
However, despite the use of a membrane during the digestion step, the Caco-2 cells 
did not survive the experimental conditions. 
In conclusion, the results from the in vitro experiments demonstrate that alginates 
increased the uptake of iron into Caco-2 cells, whilst not modifying the effect of AA; 
thus having a positive effect on iron bioavailability. Alginates also protected iron from 
the inhibitory effects of TA under the conditions tested. Furthermore, from all the 
IN VITRO STUDIES OF ALGINATE 
85 
 
materials tested (W/O/W, starch, G/O/W, alginate beads) the alginate beads 
provided the highest ferritin response in Caco-2 cells suggesting that these may be 
a promising vehicle for iron fortification. However it has to be noted that cell 
response to FeG containing alginate beads was at similar level to unprotected FeG. 
The efficiency of iron uptake from alginate beads into Caco-2 cells was dependent 
on the calcium content and chemical form of iron in the alginate beads. Overall, the 
results therefore suggest that alginate beads could be considered as a suitable food 
delivery vehicle for iron in food fortification programs. The performance of the iron-
loaded alginate beads was subsequently examined in a human study (Chapter 4). 
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4.  IN VIVO STUDIES OF ALGINATE 
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4.1 Introduction 
The aim of the human study was to investigate the effectiveness of using an alginate 
barrier to deliver FeG to the duodenum, thus maximising its availability for 
absorption. The technique employed was to give the test material to volunteers who 
had fasted overnight and measure iron appearance in the serum over 6 hours231 and 
to use compartmental modelling to calculate percentage iron absorption232. Based 
on previous reports in the literature, measurements of serum iron increase were in 
good agreement with iron absorption measured by whole-body counting233. 
The hypothesis tested in this study was that the absorption of iron from FeG loaded 
alginate beads (Figure 4.1.1) would be higher than from unprotected FeG 
(administered in a capsule). This hypothesis was based on the results of the in vitro 
experiments, and the proposed mechanism was that the alginate provided 
protection for the water-soluble FeG by keeping it in a bioavailable form. 
 
Figure 4.1.1 Iron containing alginate beads. 
 
The primary objective of this human study was to determine if iron absorption from 
FeG incorporated into alginate beads was greater than from unprotected FeG. The 
secondary objective was to investigate the modulating effect of calcium by 
comparing iron absorption from FeG incorporated into alginate beads with that from 
unprotected FeG when both were given with calcium. 
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4.2 Methods 
A human study entitled: ‘Study to measure the absorption of iron from FeG 
incorporated into alginate beads’ was approved by the UEA, Faculty of Medicine 
and Health Research Ethics Committee on 31st November 2011 (reference number 
2011/2012-05). The study was also registered on a publicly accessible clinical trials 
database (www.clinicaltrials.gov), registration number NCT01528644 
4.2.1 Subjects  
A total of fifteen apparently healthy subjects completed the study (Figure 4.2.1, for 
consort checklist please see Appendix-D). Participants were selected from 
populations with a higher prevalence of low iron stores; these were women of child-
bearing age (18-45y) and men who were regular blood donors (aged 18-65y). 
Underweight and obese individuals were excluded and the BMI inclusion range was 
>18.5< 30kg/m2. Iron absorption is up-regulated when iron stores are low to 
moderate (ferritin stores <60µg/L6), thus selecting individuals with a ferritin <60μg/L 
increases the sensitivity of the absorption test. Volunteers were recruited from the 
Norwich Research Park (NRP) and the surrounding Norwich area. Advertisements 
were placed on the UEA website, NRP newsletters, and distributed via email to UEA 
staff and students.  
Volunteers who expressed an interest in taking part in the study, and who met the 
basic inclusion criteria (listed below) were sent participant information sheet (PIS) 
and invited to attend a meeting where full details of the study were explained. A 
10ml screening blood sample was taken to exclude subjects whose serum ferritin 
was ≤15 or ≥60µg/L. 
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Assessed for eligibility 
(n= 34) 
Excluded (n=14) 
*Not meeting inclusion criteria (n=14) 
   Declined to participate (n=1) 
Analysed (n=15) 
*Excluded from analysis (n= 0) 
Lost to follow-up (n= 1, due to relocation) 
Allocated to intervention (n=19)         
* Received allocated intervention (n= 
15) 
* Did not receive allocated 
intervention: n=1 withdrawn due 
to relocation; n=2 were withdrawn 
during first study day due to 
difficulties in keeping the cannula 
patency. Total withdrawn n= 3 
Lost to follow-up (n=0) 
Allocated to intervention (n= 9) 
*Received allocated 
intervention (n= 9) 
Analysed (n=7) 
*Excluded from analysis 
(n=1) due to high CRP levels 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=19) 
Enrolment 
Figure 4.2.1 CONSORT 2010 flow diagram describing stages of the study with 
number of participants at every stage.  
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 The exclusion criteria for study were: 
 Serum ferritin concentration ≤15μ/L or ≥60μg/L. 
 Blood pressure (measured in the Clinical Research and Trials Unit (CRTU) 
at the screening visit) >160/100mmHg  
 Previous diagnosis with a long-term illness requiring active treatment, e.g. 
diabetes, cancer, cardiovascular disease 
 Currently smoking or stopped smoking in the last 12 months  
 Previous or current gastrointestinal disease 
 Any significant co-morbidity 
 Previous gastrointestinal surgery 
 Blood donation within the previous 3 months assuming that volume taken is 
above 500ml in a 4-month period 
 Blood transfusion within the last 3 months 
 Relation of someone in the study team i.e. spouse, partner or immediate 
family member 
 Regularly prescribed medication that may interfere with iron metabolism 
 Regular use of antacids and laxatives (at least once a week) 
 Women who are pregnant or less than 12 months since giving birth 
 Women who are breast feeding 
 Vitamin supplements with or without minerals if taken more than once a 
week, and unwillingness to discontinue occasional use for the duration of 
study  
 Unwillingness to discontinue use of herbal supplements for the duration of 
study  
 Unwillingness to consume jelly prepared with animal source gelatine 
 Use of antibiotics within four weeks prior to study start 
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 Parallel participation in another study which involves dietary interventions or 
sampling of blood that may increase the volume taken above 500ml in a 4-
month period  
 Asthma requiring treatment within the last two years 
4.2.2 Study design 
The study design and outline are presented in Figure 4.2.2. The study was a 
randomised, single blinded, cross-over trial with participants randomly allocated into 
two groups: A (n=8 volunteers) and B (n=15 volunteers). Group A underwent 4 tests, 
whereas group B underwent 2 out of the 4 tests. For each test meal (cola jelly) an 
oral dose of iron (on its own or incorporated into alginate beads) of approximately 
21mg, sufficient to perturb normal serum iron concentration2, with or without calcium 
was given to apparently healthy adult volunteers after a 10 hour (overnight) fast.  
All appointments (initial interview, screening visit and study days) were carried out 
by the study scientist and took place in the CRTU based in the UEA Norwich 
Medical School. The CRTU provided all the required facilities and resources to 
undertake the study. A trained research nurse based in the CRTU undertook all 
study-related clinical procedures, details of which are described in the following 
Sections.  
4.2.1 Study day procedures 
4.2.1.1 Initial Interview 
Interested individuals who responded positively to the advertisements and the PIS 
were asked to visit the CRTU for an individual informal meeting to receive further 
information about the study. During the meeting the study scientist explained the 
purpose of the study and encouraged the potential volunteer to ask questions to 
ensure that he/she understood the requirements of study participation. Volunteers 
who met the basic inclusion and exclusion criteria (outlined in Section 4.2.1) and 
expressed an interest to take part in the study were given a minimum of 72 hours (3 
days) to further consider whether they wanted to participate in the study. 
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VISIT 1. Initial interview  
VISIT 2. Consent, detailed health questionnaire, 
blood sample for screening 
VISIT 3. Both groups A and B (Test meal 1). Cannulation, 
baseline blood sample (t=0). Test meal 1, followed by blood 
sample collection at 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 
and 360 min. Removal of the cannula. 
VISIT 4. Both groups A and B (Test meal 2): Cannulation, baseline 
blood sample, Test meal 2. Further procedures as VISIT 3 
Min. 7 day wash-out  
Eligibility to take part in the study. 
Volunteers randomly allocated 
into 2 groups (A and B) 
VISIT 6. Group A only (Test meal 4): Cannulation, baseline 
blood sample, Test meal 4. Further procedures as VISIT 3 
Food record for 24h prior visit 3, overnight fast. 
Repeat 24h diet as prior to visit 3, 
overnight fast. 
VISIT 5. Group A only (Test meal 3): Cannulation, baseline blood 
sample, Test meal 3. Further procedures as VISIT 3 
Min. 7 day wash-out  Repeat 24h diet as prior to visit 3, 
overnight fast. 
Repeat 24h diet as prior to visit 3, 
overnight fast. 
Min. 72h  
Min. 7 day wash-out  
Figure 4.2.2 Study design. 
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During this period the volunteers were not contacted by any member of the research 
team. If, following the period of consideration, the volunteer expressed an interest in 
participating in the study, a clinical screening visit at the CRTU was arranged.  
4.2.2.1 Consent and screening 
Volunteers were invited to attend a clinical screening visit at the CRTU after an 
overnight fast of at least 8 hours. On arrival, the study scientist presented the 
consent form and encouraged the volunteer to ask any questions they had at this 
stage. Volunteers were then asked to sign a consent form agreeing to participate in 
the study. A copy of this form was given to the volunteer to keep. Subsequently, a 
researcher along with an experienced CRTU nurse completed a basic health 
questionnaire and collected information about weight and height. The CRTU nurse 
obtained and recorded blood pressure measurements, pulse and BMI. A single 
venous blood sample (10ml) was also taken by a CRTU nurse to measure full blood 
count: WBC, RBC, Hb, HCT, MCV, MCH, platelets, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils, fasting glucose and ferritin. The blood was 
analysed at an accredited pathology laboratory at the Norfolk and Norwich 
University Hospital (NNUH), Norwich, UK. Once all clinical procedures were 
completed, the volunteers were offered and encouraged to have a meal provided by 
the study team.  
Blood screening results were examined by an experienced CRTU nurse and study 
medical advisor (Dr Phyo Myint, Norwich Medical School, UEA) who informed the 
study scientist if all screening parameters were within the normal range for sex and 
age, and therefore whether the participant could take part in the study. If any of the 
parameters (apart from ferritin values of ≤15 ≥ 60µg/L, study specific requirement) 
fell outside the normal range the study medical advisor was contacted by a study 
scientist and asked whether the results could affect the study data or have 
implications for the health of the volunteer, and therefore whether inclusion, 
exclusion or re-screening was appropriate. 
During the screening interview the study scientist also provided instructions on 
keeping a 1-day food diary to record the “pre-test diet” in preparation for the first 
experimental day (visit 3 on Study flow diagram, Figure 4.2.2). Volunteers were 
asked to repeat the same pre-test diet prior to each experimental day. Where there 
were any deviations, volunteers were asked to note them down in the Record of 
Differences Diary. During the meeting participants also received instructions with 
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regard to undertaking a 10 hour overnight fast. They were asked to have a meal no 
later than 9pm on the night prior to each experimental day and to arrive at the CRTU 
at around 8:00 am the next morning.  
4.2.2.2 Confidentiality  
Personal data was handled in line with the regulations of the Data Protection Act 
1998. Once recruited onto the study, volunteers were assigned a three digit code 
number with only the named study scientists approved by the Ethics Committee 
having access to allow them to link codes to volunteers. All personal data and 
biological samples were coded with this number to ensure confidentiality. All 
personal information was kept confidential and the information linking codes to 
participants had restricted access known only to the chief investigator, academic 
supervisors, CRTU research nurses, and the volunteer’s GP. It was not possible for 
an individual to be identified solely from their code number. 
4.2.2.3 Randomization  
Randomization was undertaken by a third party unconnected with the study using 
the randomization generator available at www.randomization.com website. The 
study was single-blinded so participants were unaware to which group they were 
allocated and which test meal they received on each experimental day. Volunteers 
were assigned randomly to group A or B and were asked to complete 4 study days 
in group A and 2 study days in group B. Volunteers were unaware (until the 
completion of the first 2 study days) to which group they had been assigned. After 
completing 2 study days, volunteers from group B were thanked for their 
involvement and informed that their participation in the study was complete. At the 
same time participants from group A were asked to continue their participation for 2 
further study days.  
Thirty four volunteers were screened, of which 20 were eligible to take part in the 
study (based on health questionnaire and screening results). Out of 20 eligible 
participants one did not respond to the study invitation, one withdrew prior to the first 
experimental day (due to relocation), one withdrew after the first study day (due to 
relocation) and two were withdrawn during the first study day due to difficulties in 
finding an appropriate peripheral vein and maintaining cannula patency. In addition, 
one participant had elevated CRP levels on the 4th study day; therefore data from 
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that day were excluded from the final analysis. The remaining 15 participants 
completed all study days as planned (Figure 4.2.1).  
4.2.3 Iron Dose Administration 
For each test meal an oral dose of iron (mean=21.6mg ±SD 2.1mg of iron as FeG), 
sufficient to perturb the normal serum iron concentration235, was given, either 
incorporated into alginate beads or weighed into a gelatine capsule (Distinctive 
Medical, UK). 
4.2.4 Test meal composition and preparation 
All test meals were prepared in the CRTU kitchen at the University of East Anglia. 
The composition of each of the four test meals was as follows: 
 Test meal 1 (study day 1) for all volunteers (groups A and B): 200ml cola 
jelly (as described below) into which alginate beads were mixed 
(mean=21.77g ±SD 0.14g)) containing iron (mean=21.6mg ±SD 2.1mg) as 
FeG (mean=0.187g ±SD 0.019g) followed by 3 placebo capsules (each filled 
with 50mg commercially available dextrose powder, ‘Glucose Dextrose 
Powder’, (Pharmacy Near U, Huddersfield, UK) acting as placebos for 
calcium, an iron capsule and 200ml of diet cola drink.  
 Test meal 2 (study day 2) for all volunteers (group A and B) consisted of 
200ml cola jelly. The jelly was stirred with a plastic spoon prior to 
administration. The test meal also included administration of one FeG 
capsule (prepared exclusively for each volunteer to match the iron content in 
the alginate beads administered in test meal 1), two dextrose (approximately 
50mg of dextrose in each capsule) placebo capsules and 200ml of a diet 
cola drink. 
 Test meal 3 (study day 3) for 8 volunteers only (group A): 200ml cola jelly 
with the addition of FeG in alginate beads (mean=21.77g ±SD0.14g) 
followed by 200ml of a diet cola drink and two capsules containing calcium 
phosphate, (Freeda vitamins, USA) (300mg of calcium in each capsule)3 and 
one placebo capsule (50mg of dextrose). 
 Test meal 4 (study day 4) was prepared in exactly the same way as 
previously with the exception of the alginate beads which were replaced by 1 
FeG capsule (prepared exclusively for each volunteer to match the iron 
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content in the alginate beads administered in test meal 3) and 2 calcium 
phosphate capsules (each containing 300mg of calcium phosphate) followed 
by 200ml diet cola drink.  
Results of previous human intervention studies have shown that the consumption of 
a cola drink has no effect on iron absorption and study participants find it a more 
palatable way of consuming a solution of iron than in water alone237. 
4.2.5 Preparation of iron-containing alginate beads 
Iron-containing alginate beads were prepared in the kitchen of the Human Nutrition 
Unit (HNU) at IFR using a specially purchased encapsulator (Figure 4.2.3) 
designated for the sole preparation of beads for human consumption. Beads were 
prepared by either the study scientist or a scientist from the IFR, Natalia Perez-
Moral. 
Alginate (Flavicans HV; 315KDalton, M/G 35/65 and viscosity 1% 350 cp; Danisco, 
DK) solution was prepared by dissolving alginate in distilled water for 12 hours to 
obtain a concentration of 0.5% (w/v). Once dissolved, the solution was put through 
the encapsulator in order to produce beads. The beads were collected into an FeG 
(0.1M) and calcium chloride (0.1M) (Cat. No. 1.72570.1000; VWR International LTD, 
UK) solution at 50/50 ratio and left to soak for 20h at 4ºC in order to load them with 
iron. Once the beads were fully saturated with iron they were washed with distilled 
water and then filtered for 5 minutes with Whatman (grade 4) filter papers. 
Appropriate quantities of sample (≈22g for an experimental day and ≈5g for atomic 
absorption analysis) were weighed and stored in a fridge in the HNU (at 4ºC). The 
beads were subsequently transported to the CRTU at the UEA ready to be used in 
an experiment on the same day.  
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Figure 4.2.3 Encapsulator. 
 
The preparation of iron-containing alginate beads was a long process taking 
approximately 32h, including 12h for dissolving the alginate, followed by a further 
20h for loading with iron in the iron and calcium bath. Preparation of the beads was 
timed such that the beads were ready for consumption by the participants on the 
morning of the experimental day. Sub-samples of every batch of beads administered 
to each volunteer were analysed for iron content using AAS (see Chapter 2, Section 
2.4 for method details). During the study, the development of the iron-containing 
beads was on-going research, and consequently their preparation imposed certain 
limitations on the study design. Iron incorporation into the alginate beads was 
generally found to be within 15% of that predicted (with average iron content of 
1.03mg/g wet bead ±SD 0.11 and average calcium content 1.96mg/g wet bead ±SD 
0.12 as analysed by AAS; however, analysis of the iron content of the alginate 
beads was a two day procedure. This latter time constraint, coupled with the 
absence of an established long term storage method for the beads, meant that the 
sequence of test meal administration could not be randomised. Consequently, every 
batch of the beads needed to be analysed in order to obtain an accurate measure of 
the iron content. Once the exact iron content of the beads administered to each 
individual volunteer in test meals 1 and 3 was known (and recorded), exactly the 
same amount of FeG was weighed into a coloured gelatine capsule (Distinctive 
Medical, UK) and administered to that volunteer in a subsequent test meal (test 
meals 2 and/or 4 respectively) after a minimum 7 day wash-out period. 
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4.2.6 Capsule preparation 
Preparation of the FeG, placebo and calcium capsules was undertaken in the 
kitchen of the HNU at the IFR.  
- FeG capsule preparation: approximately 0.187g (±SD 0.019g) of food grade FeG 
powder (Cat.No. 1.03868.5000; VWR International LTD, UK) was weighed into 
empty gelatine red and white coloured capsules, size ‘00’ (Distinctive Medical, UK). 
- Placebo capsule preparation: approximately 50mg of ‘Glucose Dextrose Powder’, 
(Pharmacy Near U, UK was weighed into empty gelatine red and white coloured 
capsules, size ‘00’ (Distinctive Medical, UK). 
- Calcium capsule preparation: approximately 300mg of calcium phosphate (Freeda 
Vitamins, USA) was weighed into empty gelatine red and white coloured capsules 
(Distinctive Medical, UK). 
4.2.7 Preparation of cola jelly 
The cola jelly was prepared in the CRTU kitchen the day before each study day. 
200ml of Coca-Cola® was heated in a microwave, 10ml of Diet Cola flavoured drink 
concentrate (Sodastream, Lakeland) and 5g of gelatine (Dr. Oetker, UK) were 
added and mixed until the gelatine was fully dissolved. Once cooled, 200ml of the 
liquid jelly was poured into a disposable plastic cup and allowed to set in a 
refrigerator at 4ºC. 
 
On the morning of the experimental day and depending on the test meal (with or 
without alginate beads) an average of 21.77g (±SD 0.14g, approximately 5 
teaspoons) of iron-containing alginate beads were stirred into the jelly in an attempt 
to mask the presence of the beads, or if the test meal was without alginate beads, 
the jelly was just stirred to look similar to the bead-containing jelly. In addition to the 
jelly, participants were given 200ml coca cola® drink (poured directly from a newly 
opened 330ml can) in a disposable plastic cup along with 3 capsules (depending on 
the test meal: placebo or/and calcium or/and iron capsule).  
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4.2.8 Experimental day procedures 
On the day before the first study day, participants recorded all food and drink 
consumed (pre-test diet) in a food diary provided by the study team. On the same 
evening volunteers began a 10 hour overnight fast from 10:00pm, and subsequently 
attended the CRTU at approximately 8:00am the following morning. During the 
fasting period volunteers were advised to drink water. All clinical procedures were 
carried out by a fully trained nurse in the CRTU.  
 
Prior to cannulation the volunteer's blood pressure was measured and if it was 
<90/50mmHg, or <95/55mmHg if symptomatic, or >160/100mmHg three further 
measurements were taken and recorded at 5 minute intervals. The approved 
protocol stated that if the blood pressure measurement remained outside these 
ranges after the third measurement, the volunteer would be excluded from the 
study, referred to their GP and the study day cancelled. However, there were no 
exclusions from the study based on blood pressure measurements. 
If the blood pressure was within the acceptable range a CRTU nurse inserted an 
intravenous (i.v.) cannula into an appropriate peripheral vein in one of the 
volunteer's arms. No more than two attempts were made to insert the cannula on 
any one experimental day. After the cannula was appropriately sited and the first 
blood sample taken, the volunteers received test meal 1 (as described in Section 
4.2.4). 
When there were problems with the cannula during the 6 hour sampling period 
either it was removed and a second cannula inserted or, if there were no more than 
two blood samples remaining, they were taken by venepuncture. The cannula was 
flushed with sterile normal saline between blood samples to maintain its patency. 
During the 6 hour cannulation period volunteers had access to a drinking water 
dispenser (Aquarius, UK). Any adverse events were recorded by the nurse on the 
experimental day record sheet and dealt with in accordance with Good Clinical 
Practice and National Research Ethics Service guidelines. 
After the final blood sample was collected, volunteers were offered and encouraged 
to consume lunch which they had pre-selected from a menu during their screening 
visit. Lunch was prepared by Catering Direct at UEA and consisted of: a sandwich 
filled with ham, cheese or tuna mayonnaise, 1 piece of fresh fruit, 1 cake bar, 1 
packet of crisps, and a fruit juice drink.  
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Following a minimum seven day “wash-out” period, the volunteers were asked to 
repeat their experimental day 1 pre-test diet, prior to the second experimental day. 
All remaining experimental days: day 2 and if required day 3 and 4 were carried out 
in exactly the same manner as experimental day one with the exception of the 
administered test meal. 
For taking part in the study participants received inconvenience payments (£85 per 
study day) and travel expenses were reimbursed on production of a receipt for 
public transport or at 40p per mile rate for private cars. If the volunteer withdrew 
from the study before completion inconvenience payments were paid pro rata. 
Data Storage 
Electronic study data stored at UEA was account password protected and only study 
scientists and appointed nurses had access to the coded information.  
4.2.9 Analytical methods 
4.2.9.1 Serum sample preparation 
Serum samples were prepared for total iron, ferritin and soluble transferrin receptor 
analysis. Following collection into trace element and EDTA free tubes (BD 
Vacutainer, UK) blood samples were allowed to stand at room temperature for a 
period of 30-45 minutes prior to centrifugation at 500g. The serum (approx. 2ml 
supernatant) was removed and aliquoted into pre labelled screw-top micro tubes 
(Sarstedt, DE, product code: 72.694.006) and stored at -80ºC prior to analysis.  
4.2.9.2 Serum sample analysis 
Total serum iron  
Total serum iron was measured in duplicate using the QuantichromTM (BioAssay 
Systems, USA) iron assay kit, a colorimetric assay which utilizes a chromogen that 
forms a blue coloured complex with iron (II). Iron (III) is reduced during the 
incubation of the assay. Briefly, Fe (III) is converted to Fe (II) using AA. Then, Fe (II) 
forms a colored complex with TPTZ (2,4,6-tripyridyl-s-triazine). The change in 
absorbance is directly proportional to the concentration of Fe in the sample, 
therefore the intensity of the colour at 590nm is proportional to the total iron content 
of the analysed sample. 
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Serum ferritin receptor analysis 
Ferritin measurements were performed using a Spectro ferritin enzyme 
immunoassay (Cat. No. S-22), Ramco, USA following the assay procedure provided 
by the supplier (described in detail in Chapter 2). Duplicate measurements of ferritin 
resulted in average %CV 10%. 
Soluble transferrin receptor analysis 
Soluble transferrin receptor (sTfR) concentration in plasma samples was performed 
in duplicate using TfR enzyme immunoassay (Cat. No. TFC-94, Ramco, USA), 
following the assay procedure provided by the supplier. Briefly, samples and 
controls were diluted with sample diluent (1/100) then 50µl of samples, standards, 
controls and WHO Reference reagent (Recombinant rsTfR, 303nmol/L; NIBSC 
code:07/202) were loaded into pre-coated (with polyclonal antibody to sTfR) micro 
wells of 96 well plates, then 150µl of horseradish peroxidase (HRP) conjugated 
murine monoclonal antibody (specific for sTfR) was added to the wells and the 
plates were incubated for 2 hours at room temperature. During the 2 hour 
incubation, the sTfR binds to the polyclonal antibodies adsorbed to the wells and the 
HRP-conjugated second antibodies bind to the sTfR adsorbed to the wells. After 2 
hours the content of the wells was removed (removing any unbound sTfR and HRP 
conjugate), plates were washed three times with washing buffer and 200µl of 
enzyme substrate (chromogen tetramethylbenzidine) was added to the wells and 
incubated for 30min. A blue product is formed through the action of HRP enzyme 
substrate. In order to stop the colour reaction 50µl of an acid stop solution (2.5M 
sulphuric acid) was added converting the product from a blue to a yellow colour. 
Yellow colour intensity was measured in a plate reader set at 450nm. 
 In addition to controls provided in the TfR kit WHO Reference reagent was 
reconstituted (according to the supplier procedure) and run with each plate in 
duplicate and at 2 different concentrations. The values obtained were transformed 
with the conversion equation published by WHO in 2009238 with a mean value of 
306.7mol/L (11 measurements in total, ±SD 45.5). Average %CV for serum sTfR 
was 4%.  
C-reactive protein (CRP) 
CRP concentration was performed on each experimental day in all baseline samples 
in order to establish whether the iron concentration might be elevated due to 
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inflammation/infection. CRP measurements were performed at an accredited 
pathology laboratory at the Pathology Department of the NNUH, Norwich, UK. 
According to the NNUH the normal CRP range is defined as 0-10mg/L however for 
the purpose of this work if values of CRP were above 6mg/L, samples were 
excluded from the analysis in case there was any low grade inflammation that might 
reduce iron absorption and elevate serum ferritin concentrations.  
Visual examination of serum samples revealed that 8.8% (52 out of the total of 588 
of all collected samples) were haemolysed. In order to assure high quality of the 
analysis and to eliminate the possibility that haemolysed samples would be included 
in the analysis (providing unreliable results due to haemoglobin interfering with the 
Quantichrom iron assay) the optical densities of all serum samples were compared 
at the following haemoglobin peak wavelengths 415; 417; 540; 570; 575nm239,240 
with a standard serum (normal mixed pool) sample obtained from TCS Biosciences 
Ltd, UK, product code:CR100. 
In addition, any interference of haemoglobin with the Quantichrom assay was 
assessed by constructing a ten point standard curve ranging from 0.03125 to 
16.0mg/ml with the use of haemoglobin from human red blood cells (product code: 
338-10, Lee Biosolutions, USA), reconstituted in phosphate buffered saline 
according to the manufacturer’s instructions. A separate analysis was also 
conducted in which haemoglobin was reconstituted in standard serum. 
4.2.10 Statistics  
Statistical power 
The initial assumption made for the power calculation in order to estimate the 
number of required study participants was that a difference of 2.5% in iron 
absorption (primary outcome measure) between the 2 tests (test meal 1 and test 
meal 2) would be nutritionally significant.  
Since absorption is related to iron stores it would be expected that there would be a 
good correlation between iron absorption from the iron loaded alginate beads and 
FeG in its native form i.e. volunteers who absorb higher amounts of one form will 
also absorb higher amounts of the other form. With each volunteer acting as his/her 
own control, this reduced the number of subjects required. Consequently, a 
minimum of 12 volunteers was required to complete the study to detect a difference 
of 2.5% at a significance level of 0.05 for 80% power. 
IN VIVO STUDIES OF ALGINATE 
103 
 
For the secondary objective, a minimum of 8 volunteers was required to detect a 
significant difference in iron absorption of 3.3% between a test meal containing 
20mg of iron as FeG with calcium, and a test meal containing 20mg of iron as FeG 
with calcium and alginate beads (test meals 4 and 3). This assumes a power of 
80%, a level of significance of 0.05 and standard deviation of differences (within 
pairs) of 2.8% 
Statistical analysis 
The primary outcome measure for the study was percentage iron absorption. 
Estimating the difference in iron (FeG) absorption when consumed in a form of iron 
incorporated into alginate beads compared with the same amount of iron in an 
unprotected form i.e. not in alginate beads was the main objective of the study. The 
secondary objective of the study was to establish the difference in iron (FeG) 
absorption when consumed in the presence of calcium in a form of iron incorporated 
into alginate beads compared with the same amount of iron not in alginate beads, 
also in the presence of calcium. 
Paired, two-tailed Student’s t test was used to assess any significant differences in 
iron absorption. This method was found to be appropriate when assessing iron 
absorption in previous studies conducted at the IFR231. In addition, a mixed effects 
model was used for Group A to determine whether there was an effect of treatment 
on iron absorption. Pairwise comparisons (with multiple test correction) were then 
carried out using contrasts. Repeated measures ANOVA analysis was carried out in 
R version 3.0. 
  
Data analysis 
Dainty et al.231 have previously shown that the measurement of serum iron 
concentrations for a period of 6 hours following an oral iron dose is a simple and 
effective method for estimating iron absorption which correlates well with stable 
isotope techniques for measuring iron absorption. From the serum iron appearance, 
it is possible to calculate percentage iron absorption from the administered dose 
using the following method: 
Given a time of between 3 and 6 hours post administration of an oral dose (doseoral) 
the rate of infusion R can be calculated from the serum iron concentration 
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(1)      
                             
                          
 
 
 
 
Given a volume of distribution V, and a rate constant of elimination from the 
compartment k, the concentration in the compartment can be approximated to: 
 
(2)      
 
     
           (0<t<T) 
(3)      
 
     
 (      )           (t<T) 
By fitting the equations to the concentration data, M, T and k can be calculated. 
The fractional absorption from the oral dose is then: 
(4)                          
 
         
  
 
This study was single-blinded (the volunteers were blinded as to the treatment). In 
order to ensure that the analysis was blinded, all sample tubes were relabelled by 
someone unrelated to the study prior to the analysis. Once all the samples were 
analysed and the data summarised by the statistician; the code was broken.  
 
 
4.3 Results 
Most of participants who took part in the study were young adult females aged 20-
30y, with the exception of one male participant who was aged 49y at the time of the 
intervention. Table 4.3.1 provides details of the characteristics of the study 
population. 
There was no relationship between body iron values, ferritin values or sTfR and % of 
iron dose absorbed on study day 1 or 2. This is most likely due to the small sample 
size and the fact that the ferritin range was relatively narrow. 
One participant had a raised CRP concentration of 23mg/L suggesting the presence 
of infection/inflammation which could potentially interfere with iron absorption, 
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therefore the whole set of data for this one study day was excluded from the final 
analysis.  
Table 4.3.1 Characteristics of population studied (n=15; 14 females, 1 male). Data 
are means ±SD. 
 Screening 
 
Study day 
1 (beads+ 
Fe) 
Study 
day 2 
(Fe) 
Study day 
3 (beads+ 
Fe+Ca) 
Study 
day 4 
(Fe+Ca) 
Age 
(years)  
     
A (n=9) 24.9±9.5 --- ---- --- --- 
B (n=15) 23.6±7.5 --- ---- --- --- 
BMI      
A (n=9) 22.2±2.0 --- ---- --- --- 
B (n=15) 22.1±1.8 --- ---- --- --- 
Ferritin* 
(µg/L) 
     
A (n=9) 28.8±10.3 22.7±9.9 18.7±9.2 22.3±16.2 24.0 
±17.9∆ 
B (n=15) 27.1±11.7 24.6±10.2 19.8±9.3 --- --- 
sTfR** 
(mg/L) 
     
A (n=9) --- 6.1±2.8 6.3±2.7 6.2±2.2 6.3±1.7∆ 
B (n=15) --- 5.6±2.5 5.9±1.9 --- --- 
BI 
(mg/kg 
body)  
     
A (n=9) --- 3.5±2.4 2.4±2.2 2.5±3.1 2.6±3.4∆ 
B (n=15) --- 3.5±2.4 2.5±2.3 --- --- 
CRP 
(mg/L) 
     
A (n=9) --- 2.0±1.7 1.9±1.5 2.1±1.3 2.3±1.8∆ 
B (n=15) --- 1.7±1.3 1.7±1.4 --- --- 
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*Mean ferritin CV between duplicates on the sample plates was 8.2%. Plate to plate 
inter-assay CV was 17.4 %. The high CV difference is most likely due to the fact that 
most samples were at the lower end of the standard curve hence the lower 
sensitivity of the assay.  
** Average sTfR CV between the duplicates on the same plate was 4.3%. WHO 
reference reagent was run on each plate (used at 2 different concentrations: 30µg/L 
and 90.21µg/L run on 2 plates) and its value of 319.5nmol/L; ±SD 28 was calculated 
using the following WHO conversion241: mean of 2 readings x dilution x 
3.8685+1.3965  
∆(n=8) one data point from one participant removed due to high CRP 
 
Analysis of serum samples for potential contamination by haem iron from 
haemolysed red blood cells revealed that haemoglobin in PBS adversely affected 
the Quantichrom total iron assay at the lowest concentrations tested (0.03mg/ml). 
Furthermore, haemoglobin dissolved in the standard serum sample (at constant 
serum volume) started to interfere with the Quantichrom assay readings at a 
concentration of 0.125mg/ml, giving markedly increased readings at a concentration 
of 1mg/ml. From the above results the percentage of haemolysed samples 
estimated visually to be 8.8% increased slightly to 9.5%. All of these samples were 
excluded from the subsequent modelling. 
Absorption of FeG (Day 2) ranged from 5.7% to 17.9%, (Table 4.3.2), with a mean 
value of 12.6% (n=13), and this was significantly higher (p=0.0025) than absorption 
from FeG incorporated into alginate beads (Day 1), which ranged from 4.6% to 
14.6%, with a mean value of 8.5% (n=13). 
The dose of calcium (600mg calcium as calcium phosphate) administered with 
either FeG (Day 4; n=5) or FeG in alginate beads (Day 3; n=5) significantly reduced 
the % of iron absorbed (from 11.4% to 5.9%, p<0.001 and from 8.4% to 5.0%, 
p=0.0213, respectively) compared to the administration of iron alone. In addition, the 
lower absorption of iron when incorporated into alginate beads in the presence of 
calcium was also significant compared with iron incorporated into alginate beads 
with no additional calcium (p=0.023). 
There was no significant difference in iron absorption between FeG and iron-
containing alginate beads when given with calcium. Therefore, at the doses given, 
alginate did not modify the inhibitory effect of calcium on iron absorption. There was 
also no effect of time on serum ferritin and soluble transferrin receptor 
concentrations. 
IN VIVO STUDIES OF ALGINATE 
107 
 
 
 
Table 4.3.2 Absorption of FeG (% of dose absorbed) with and without alginate 
 % of iron dose absorbed 
Day 1 Day 2 Day 3 Day 4 
Recoded 
Volunteer number 
Fe in alginate 
beads 
Fe Fe in alginate 
beads +Ca 
Fe+Ca 
ALG1 5.4 14.2 --- --- 
ALG2 8.2 15.7 --- --- 
ALG3 12.7 16.1 --- --- 
ALG4 6.3 13.1 --- --- 
ALG5 6.6 15.7 --- --- 
ALG6 ---□ 16 --- --- 
ALG7 6.3 11.9 3.5 4.9 
ALG8 5.7 7.5 5.4 ---* 
ALG9 8.4 8.7 3.2 5.3 
ALG10 ---□ 5.7 ---□ 5.6 
ALG11 10.5 6.3 6.1 ---□ 
ALG12 8.1 8.8 4.8 6.3 
ALG13 4.6 11.4 4.4 6.3 
ALG14 14.6 16.4 9.3 6.6 
ALG15 13.0 17.9 ---□ 4.2 
Mean % of dose 
absorbed for 
complete pairs 
8.5◊(n=13) 
8.4a(n=5) 
12.6∆(n=13) 
11.4b(n=5) 
 
5.0c(n=5) 
 
5.9a, c(n=5) 
±SD (%) (n=13) 
±SD (%) (n=5) 
3.2 (n=13) 
3.8 (n=5) 
4.1(n=13) 
3.1 (n=5) 
 
2.5 (n=5) 
 
0.7 (n=5) 
∆; ◊Different symbols denote statistically significant differences between day 1 and 
day 2 test meals. Different letters denote statistically significant differences between 
day iron treatments Differences were considered to be significant at p<0.05. *Data 
point removed due to high CRP. □Sub-standard, not modelled data 
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Due to the constraints associated with the bead preparation outlined in Section 
4.2.6, their iron content varied from 0.9 to 1.27mg iron per gram wet bead and the 
content of calcium varied from 1.79 to 2.29mg of calcium per gram wet bead. On 
average each participant consumed 21.8g (±SD 0.14g) of beads containing on 
average 21.6mg (±SD 2.1mg) of iron and 42.82mg (±SD 2.71mg) of calcium 
chloride on test days involving consumption of alginate beads. Test meals involving 
the consumption of an iron capsule contained an amount of iron that was equivalent 
to the dose provided in the beads. It did not however contain the quantity of calcium 
that was present in the beads. The absence of calcium phosphate on test days not 
involving beads was intentional; otherwise it would not have been possible to 
investigate the potential protective effect of the beads.  
4.4 Discussion 
There were two main findings from this human study. Firstly, alginate beads 
significantly reduced iron absorption from FeG. Secondly, the beads did not protect 
the iron from the inhibitory effect of calcium (at a calcium dose of 600mg). 
The observed lack of correlation between body iron, ferritin or sTfR and % of iron 
dose absorbed may be due to the fact that participants recruited onto the study had 
relatively low iron stores (in order to maximise iron absorption from the test meal) 
thus the sample did not include individuals with ferritin above 60ng/ml. In addition 
the sample size was low (n=15). 
One of the potential reasons for the beads not demonstrating an enhancing effect on 
iron absorption (as observed in the Caco-2 cell model system242) may have been the 
presence of high levels of calcium in the beads, which was an essential part of the 
production process to maintain their integrity and shape217. Another possibility is that 
alginates, (as reported in earlier Chapter 1, Section 1.5) have the potential to bind 
divalent and trivalent cations210,209, and are able to bind iron ions in the human gut, 
thus limiting iron absorption. Research supporting the latter hypothesis was reported 
by Sandberg et al.222. In their study 6 ileostomy participants were subjected to a diet 
low in fibre, with or without 7.5g sodium alginate (M to G acid ratio: 60:40), dissolved 
in a milk shake and also given as a jam. Mineral absorption was calculated from the 
difference between dietary intake and the quantity excreted in ileostomy fluid. There 
was a reported decrease in apparent absorption of iron and manganese in 5 out of 6 
volunteers. However, as the authors point out, the sample size was too small to 
determine if the effect was statistically significant. Comparison of our study in 
IN VIVO STUDIES OF ALGINATE 
109 
 
healthy subjects with participants from the ileostomy trial may not be appropriate, 
not only due to physiological differences but also due to differences in the design of 
the two studies, alginates used (different M:G ratios), test meals consumed, and 
analyses performed. In addition, considerably less alginate was used in our iron 
absorption study (0.5% alginate solution; approximately 0.58g ±SD 0.11g of alginate 
powder per person per test meal) than in the study involving ileostomy participants 
(7.5g of alginate per volunteer per test meal).  
In contrast, Bosher et al.243 reported that the availability of iron and zinc from infant 
formulas increased with the addition of 2g of alginic acid when investigated with the 
use of an in vitro dialysis model with a preliminary intraluminal digestive phase. 
These observations support the in vitro findings reported earlier in this thesis 
(Chapter 3).  
Differences between the in vivo and in vitro studies reported are as follows: the in 
vitro study did not include a test meal consisting of cola-flavoured jelly (described in 
Section 4.2.7 of this Chapter), the bead preparation was slightly different, and, 
possibly the most important difference was that a rinsing step was introduced to 
make the test meal (in the human study) more palatable, which removed any 
unbound iron from the surface of the beads. All of the above discrepancies between 
the in vitro and in vivo studies have been addressed in the final set of in vitro 
experiments conducted after completion of the human study (see Chapter 5)  
As described in an earlier Chapter 1 alginates are natural polysaccharides occurring 
in brown seaweed which form gels with ions244 producing ‘egg-box’-like structures. 
In industrial use the most common gelling ion is calcium245,246 and to a large extent 
gel rigidity depends on the M:G ratio (in particular guluronic acid residues) and 
stoichiometry of alginate245. Alginate beads used in this human study were prepared 
by soaking in a calcium chloride (0.1M) and FeG (0.1M) bath (50/50) and the final 
content of calcium per gram of wet bead was roughly 2 fold higher than that of iron, 
thus illustrating a higher binding affinity of alginate for calcium than for iron. As 
reported by Perez-Moral et al.217 57% of iron incorporated into alginate beads 
(prepared using the same technique as the beads in this study) was released during 
simulated digestion (43% during gastric and 12% during duodenal phase of 
digestion) leaving the remaining 47% of iron within the beads. It is therefore possible 
that due to the high guluronic acid content of the alginate used, which results in the 
firm structure of the beads when bound with calcium247, and due to the indigestibility 
of alginate in the small intestine248,249, iron remains trapped within the beads 
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throughout the in vivo digestion process and is thus unavailable for absorption. The 
above hypothesis could very well explain the results reported within this study, 
however further research is required to confirm this.  
Since alginates have a strong affinity to bind calcium248 we wanted to test if alginate 
beads would bind calcium consumed with the test meal and thereby ameliorate its 
inhibitory effect on the absorption of iron. The form and dose of calcium selected 
from a previous publication236 was predicted to reduce iron absorption from FeG. 
The Inhibitory effect of calcium phosphate was significant with and without the 
addition of alginate to the test meal. Thus it was concluded that alginate beads did 
not diminish the inhibitory effect of calcium on iron absorption. One potential 
explanation could be the fact that the beads, during their production process, were 
soaked in a calcium and iron bath for approximately 20 hours which could have 
caused saturation with calcium leaving no further capacity for binding with the 
additional calcium administered in the test meal. This hypothesis warrants further 
investigation. 
The human study had the following limitations: The study scientist was not blinded 
when administering the test meals (due to the requirements for alginate bead 
preparation and analysis, as described earlier). However, in order to minimise bias, 
serum samples were relabelled prior the analysis, by a third party not involved in the 
study. The study would have benefitted from more detailed observation of other 
potentially confounding factors which could have influenced iron absorption, such as 
plasma hepcidin concentration. Additionally, it would have been preferable if 
subsequent test days for all participants were at the same, fixed time intervals, but 
this was not feasible. Also, to further increase sensitivity of the total serum iron 
assay future studies may benefit from using a slightly higher dose of iron. 
One of the limitations of measuring changes in serum iron concentration in 
conjunction with compartmental modelling is diurnal differences in serum iron 
concentration. However our study days commenced at approximately the same time 
of the day (±30min) thus minimising the diurnal effect. 
This study has several strengths. The crossover design of the study permitted each 
subject to act as his/her own control and enabled us to use a smaller sample size. 
The self-selected pre-test diet ensured high compliance, maintained the habitual 
diet, and removed any effect of pre-test meal diet on efficiency of iron absorption. 
Furthermore, the number of blood samples collected on the test days resulted in 
good quality data (frequent data points) and allowed us to use single compartment 
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mathematical modelling232 to estimate % absorption of the iron dose. The results 
clearly demonstrate that iron absorption from FeG, administered to participants in 
capsules, was significantly higher than FeG incorporated into alginate beads. 
Alginate beads did not reduce the inhibitory effect of calcium on iron absorption, as 
observed in earlier in vitro Caco-2 cell studies.  
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5. HUMAN STUDY FOLLOW UP- IN VITRO INVESTIGATIONS 
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5.1 Rationale for undertaking further in vitro investigations. 
As described in Chapter 1, Section 1.4 the use of Caco-2 cells in combination with a 
simulated digestion procedure has been shown to be a valuable tool for screening 
different iron sources in order to rank them for potential bioavailability of iron and to 
advance our understanding of intestinal absorption and metabolism192,193,197,227,250–
262. The findings of the in vivo study (Chapter 4) did not support those of the in vitro 
experiments (Chapter 3) in that the iron absorption results were different from what 
was predicted. Consequently, it was decided to conduct follow-up experiments using 
the Caco-2 cell model to try to find out the reason(s) for the differences.  
One important factor that warranted further investigation was the discrepancy 
between test meals administered to participants in the human study and treatments 
which were applied to the cells. The differences were that the beads used for the in 
vitro treatments were not washed with water as part of the production process and 
were not accompanied by cola jelly given as part of the test meal. 
Also, as specified in Chapter 3, small quantities of beads (mostly between 0.002 to 
0.095g) had to be weighed out for the simulated digestion because of the relatively 
high iron content of the beads. Thus any small weighing errors could have 
contributed to variations in response between replicates. The beads had to be 
suspended in a final volume of 15ml and then 10% of this suspension used to treat 
the cells. In order to investigate the possibility of errors in sample weighing and 
application onto the cells, beads B13-B17 (described below in methods Section) 
were prepared in modified conditions to ensure lower iron loading per gram of wet 
beads and by this means, the weight of beads required for each treatment was 
greater and therefore weighing errors were less important. 
The hypothesis tested in this chapter was that when washed and mixed in with cola 
jelly the iron-containing alginate beads would deliver less iron than FeG on its own, 
thus confirming the findings of the in vivo study. 
The aims of the experiments described in this Chapter were to investigate whether:  
 the cola jelly present in the test meal and washing step in the bead 
production could affect iron uptake by Caco-2 cells; 
 FeG is a more bioavailable form of iron than FAC when incorporated into 
alginate beads (confirmation of previous findings);  
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  the use of higher weights of beads would reduce potential weighing 
errors occurring when lower quantities of beads were used; thus 
reducing the variability of results obtained (Chapter 3);  
 alginate beads protected iron during the simulated digestion process, 
thus delivering more bioavailable iron than unprotected iron for the Caco-
2 cell model;  
 the enhancing effect of AA on iron absorption was unaffected by the 
presence of alginate beads; 
  the calcium present within the beads played a role in decreasing iron 
absorption in vivo compared with the administration of unprotected iron  
5.2 Methods  
5.2.1 Cell culture and experimental procedures 
Caco-2 cells were cultured as described earlier in Chapter 2 and for experimental 
purposes they were combined with the simulated digestion procedure described in 
Chapter 2, Section 2.2. However, the following modification to the simulated 
digestion methodology was introduced in some of the experiments described below: 
the duodenal phase of digestion was continued for 2 hours in test tubes (rather than 
over the cells) at 37ºC on a rotating table and once completed all samples were 
centrifuged at 3184g for 10min in order to remove any potential jelly residue, which 
could have resulted in physical blockage of the dialysis membrane. Once 
centrifugation was completed, 10% of the resulting supernatant from each treatment 
was applied onto the dialysis membranes and placed over appropriate wells. Cells 
were incubated with the supernatant for an hour at 37ºC on a rotating table at a 
speed of 20 oscillations per minute. 
5.2.2 Preparation of jelly treatments 
Cola-flavoured jelly was prepared in exactly the same way as in the human study, 
as reported in Chapter 4, Section 4.2.7. The amount of cola jelly used in each in 
vitro treatment was calculated based on the ratio of beads to jelly used in the human 
study, which was 1:6.77 grams of beads to grams of jelly. 
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5.2.3 Preparation of iron containing alginate beads 
5.2.3.1 Beads prepared in altered conditions 
Beads B13-B16 were prepared under different conditions to those of the beads 
previously used in in vitro or in vivo experiments in order to assure lower loading 
with iron. To achieve this, the calcium and iron bath in which the beads were loaded 
contained 0.1M calcium chloride (Fluka, UK) and iron at following concentrations: 
0.1M FeG; 0.015M FeG; 0.01M FeG and 0.005M FeG resulting in the production of 
beads B13, B14, B15, B16 respectively. Beads B17 were prepared with the use of 
FAC instead of FeG at the concentration of 0.01M. The above conditions resulted in 
a range of iron content per gram of wet beads, for details see Table 5.2.1 
5.2.3.2 Conditions for preparation of beads B18 
Alginate beads (Table 5.2.1) used in experiments presented in Figure 5.3.2; Figure 
5.3.3 and Figure 5.3.4 were prepared using exactly the same parameters (dissolving 
time, nozzle size, flow speed, loading time and rinsing step) as those made for the 
human study, and using the same batch of alginate powder, calcium chloride 
solution and FeG powder. However, the beads produced for these in vitro 
experiments contained 1.712mgFe/g and 1.618mg Ca/g wet bead. Whereas 1g of 
wet alginate beads prepared for the human study contained 1.04mgFe/g wet bead 
(±SD 0.08) and 1.96mgCa/g wet bead (±SD 0.12). For more details please refer to 
Chapter 4.  
The final concentration of iron per well was 102.3µM (once accounted for dilution. In 
order to obtain the required amount of iron per well, an appropriate amount of iron- 
containing alginate beads (to obtain a concentration of 238.76µM of elemental iron) 
was weighed into relevant digest tubes.  
FeG (VWR International LTD), UK, from the same batch as the one used in human 
study) solution was prepared at a concentration of 0.00716mol/L in 0.1M HCl, and 
an appropriate volume was used to obtain a concentration of 238.76µM of elemental 
iron (in order to match the same concentration of iron which was incorporated into 
the alginate beads) in a 15ml total volume of digest. One tenth of each digest 
solution was used to treat each well containing cells, resulting in a final 
concentration of 102.3µM per well.  
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Table 5.2.1 Composition of iron containing beads (B13-B18). 
Iron loaded 
material 
Iron compound  
added 
Weight of alginate 
beads used (g) 
Iron content per well 
(µg) 
B13 FeG 0.12 15 
B14 FeG 0.39 15 
B15 FeG 0.53 15 
B16 FeG 0.72 15 
B17 FAC 0.46 15 
B18 FeG 0.117 20 
5.2.4 Preparation of experimental solutions and treatments for beads (to 
replicate the test meals used in the human study) 
In order to replicate the calcium content of the test meals in the human study, 
calcium phosphate (Freeda Vitamins, USA), from the same batch as the one used in 
human study) was applied to the cells. The molar ratio of FeG and calcium 
phosphate was calculated based on the average values used in the human study: 
on average 21.8g of wet beads were administered to each participant with 
approximately 21.6mg iron served together with 150g cola jelly and, where 
appropriate, 600mg of calcium phosphate were added to the test meals. Therefore, 
the FeG to Ca phosphate molar ratio used in the human study was 1 : 11.813. 
Furthermore, the calcium chloride content of the beads was also quantified using 
atomic absorption spectroscopy (described in Chapter 2, Section 2.4) in order to add 
the same amount of calcium chloride (Sigma, UK) to the appropriate FeG positive 
controls. 
5.2.5 Preparation of experimental solutions and treatments for beads B13-
B17 
Iron solutions were prepared and treatments administered in exactly the same way 
as described in the above Section, the only exception being that the final 
concentration of FeG or FAC applied to the cells was 76.9µM per well. 
AA was dissolved in MilliQ water and the final concentration was 1:10 Fe:AA molar 
ratio per well. 
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5.2.6 Optimisation of simulated digestion procedure 
In order to eliminate the possibility of dialysis membrane blockage by the jelly, two 
experiments were performed with the duodenal phase conducted in test tubes, 
followed by sample (digestate) centrifugation at 3,184g for 10 minutes prior to 
application of the supernatant onto the dialysis membrane (Figure 5.2.1.) Caco-2 
cell monolayers were incubated with the supernatants from the digestate for one 
hour at the same conditions as described in Chapter 2, Section 2.2. Further 
digestion procedure steps together with cell harvesting procedures, sonication and 
analysis were also performed as in the standard method described in Chapter 2, 
Section 2.2.3. 
 
Figure 5.2.1 Schematic diagram of in vitro digestion, a Caco-2 cell model adopted 
from Glahn et al.192. 
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5.2.7 Statistical analysis 
Unless otherwise stated, all statistical analyses were performed using SPSS Inc, 
USA, (version 16.0.0). 2-factor ANOVA with Tukey HSD post-hoc tests were 
conducted to examine pairwise differences on power-transformed data. Data are 
presented as mean ±SD. Differences were considered significant at p<0.05. 
 
 
5.3 Results 
5.3.1 Beads B13-B17 with and without ascorbic acid. 
Beads B13-B16 (detailed specification in Table 5.2.1) delivered available iron to the 
cells at a similar level to unprotected FeG (Figure 5.3.1). The only exception were 
beads B17 which contained FAC; these delivered significantly less available iron to 
the cells than unprotected FeG (p <0.0005) or any of the other beads. When cells 
were treated with any of the beads (B13-B17) they produced significantly less ferritin 
than when they were treated with FeG in the presence of AA (p<0.0005 in all 
instances). Cells treated with iron-containing alginate beads in the presence of AA 
(at 1:10 iron to AA ratio) had significantly higher ferritin concentrations than cells 
treated with iron- containing alginate beads only (p<0.0005 in all instances). The 
enhancing effect of AA was maintained in the presence of iron-containing alginate 
beads and was as potent as with unprotected FeG with the exception of beads B16 
(where the highest weight of beads was used) and beads B17 (where FAC was 
used instead of FeG), which resulted in a significantly lower cell ferritin response 
compared to FeG in the presence of AA (p=0.03 and p=0.02 respectively). 
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Figure 5.3.1 Ferritin concentration in Caco-2 cells exposed to unprotected FeG or in 
alginate beads (B13-B16) or FAC containing beads (B17) with or without AA at 1:10 
Fe:AA molar ratio. Ferritin concentration (ng/mg total protein) after exposure to 
107.7μmol/L FeG across all treatments. Data represent mean ±SD. Bars without a 
common letter (a, b, c, d, e) are significantly different, p<0.05. Ferritin concentration 
in cells not exposed to any iron (no treatment) was 4.0±SD 2.4.  
 
5.3.2 Iron uptake from iron-containing alginate beads in the presence of 
cola-flavoured jelly. 
Also, to replicate the human study test meals 3 and 4, Caco-2 cells were treated 
with FeG together with cola-flavoured jelly and calcium phosphate or with FeG-
containing alginate beads together with cola-flavoured jelly and calcium phosphate 
(Figure 5.3.2; Figure 5.3.3; Figure 5.3.4). 
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Figure 5.3.2. Ferritin concentration in Caco-2 cells exposed to FeG unprotected or in 
alginate beads with or without cola jelly test meal or with cola jelly test meal in 
presence of calcium phosphate. Ferritin concentration (ng/mg total protein) after 
treatment with 102.3μmol/L FeG (n=6). Data represent mean ±SD. Bars without a 
common letter (a, b, c, d) are significantly different, p<0.05. Ferritin concentration in 
cells not exposed to any iron (no treatment) was 7.6±SD 1.0, cells exposed to test 
meal only or beads not containing iron did not produce any ferritin. 
 
Additionally, to investigate the hypothesis that calcium chloride present within the 
beads (calcium acquired during the production of the beads, for details see Chapter 
3) was at a high enough level to inhibit iron uptake into the cells (which limits the 
production of ferritin), FeG in the presence of exactly the same amount of calcium 
chloride was applied to the cells with (Figure 5.3.4) and without the cola jelly test 
meal (Figure 5.3.3; Figure 5.3.4).  
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Figure 5.3.3. Ferritin concentration in Caco-2 cells exposed to centrifuged digests 
with FeG unprotected or in alginate beads with or without cola jelly test meal or with 
cola jelly test meal in presence of calcium phosphate. Ferritin concentration (ng/mg 
total protein) after treatment with 102.3μmol/L FeG (n=6). Data represent mean 
±SD. Bars without a common letter (a, b, c, d) are significantly different, p<0.005. 
Ferritin concentration in cells not exposed to any iron (no treatment), cells exposed 
to test meal only or beads not containing iron was 3.8±SD 0.7; 6.8±SD 0.2 and 
6.5±SD 0.2 respectively.  
 
Figure 5.3.4 Ferritin concentration in Caco-2 cells exposed to centrifuged digests 
with FeG unprotected or in alginate beads with or without cola jelly test meal; with 
cola jelly test meal in presence of calcium phosphate or with FeG with calcium 
chloride at the concentration present in the beads. Ferritin concentration (ng/mg 
total protein) after treatment with 102.3μmol/L FeG (n=6). Data represent mean 
±SD. Bars without a common letter (a, b, c, d, e) are significantly different, p<0.006. 
Cells which were not exposed to any iron (no treatment) did not produce any ferritin.  
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All of the above experiments have the following findings in common:  
 FeG on its own triggered a significantly higher ferritin concentration in cells 
than iron-containing alginate beads (p=0.008; p<0.0005 and p<0.0005; 
presented in Figure 5.3.2; Figure 5.3.3; Figure 5.3.4 respectively); 
 cells treated with FeG together with jelly had a significantly lower ferritin 
concentration than cells treated with FeG only (p=0.003; p<0.0005 and 
p=0.006; presented in Figure 5.3.2; Figure 5.3.3 and Figure 5.3.4 
respectively);  
 calcium phosphate provided to the cells with unprotected FeG or with FeG-
containing alginate beads significantly reduced the amount of iron that was 
available to the cells compared with corresponding treatments without 
calcium phosphate (p<0.0005 in all instances) (similar to the results reported 
from the human study); 
 there was no significant difference (results presented in Figure 5.3.2; Figure 
5.3.3 and Figure 5.3.4) between ferritin concentrations in cells treated with 
FeG in the presence of calcium phosphate in the cola jelly test meal and 
iron-containing alginate beads in the presence of calcium phosphate in the 
cola jelly test meal (similar to the results reported from the human study).  
 cells treated with FeG-containing alginate beads together with the cola jelly 
test meal had significantly lower ferritin concentrations than cells treated with 
FeG-containing alginate beads only (p=0.003; p<0.0005 and p<0.0005; 
presented in Figure 5.3.2; Figure 5.3.3 and Figure 5.3.4 respectively).  
 
The results relating to the comparison of iron-containing alginate beads and FeG in 
the presence of calcium chloride (at the same concentration as in the beads) proved 
to be inconclusive. In both experiments there was a lower ferritin concentration in 
cells treated with FeG in the presence of calcium chloride (equal to the calcium 
chloride concentration in beads) when compared with cells treated with FeG. 
However, the reduction was statistically significant in only one of the 2 experiments 
performed; results presented in Figure 5.3.3 (p<0.0005) and Figure 5.3.4;  
Similar inconsistencies were observed in relation to ferritin concentrations in cells 
treated with FeG together with cola jelly and iron-containing alginate beads together 
with cola jelly. The observed difference between the two treatments was either 
significant, with lower ferritin formation in cells treated with iron-containing alginate 
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beads in the presence of cola jelly (Figure 5.3.2 and Figure 5.3.4; p=0.009 and 
p<0.0005 respectively) or not significant (Figure 5.3.3).   
 
5.4 Discussion 
The use of iron containing alginate beads prepared using the technology described 
in Chapter 3 is a novel approach. No in vitro or in vivo studies were found in the 
literature apart from Wawer et. al.242 report which was based on Chapter 3 of this 
thesis.   
Results obtained with beads B13-B18 reported in this Chapter consistently 
demonstrate that alginate beads do not exhibit the expected protective/enhancing 
effect of iron, similar to that conferred by AA, as reported earlier242. There are two 
potential explanations for this observation:  
 increasing the amount of beads used in this series of experiments 
reduced the potential error in weighing of the sample and its application 
onto the cells, however at the same time it inevitably increased the 
concentration of calcium which could have inhibited iron uptake by the 
cells19. 
 not all the iron present within the beads was being released during the 
simulated digestion process, as reported by Perez-Moral et al.217, hence 
there was a lower quantity of iron available to be taken up into cells.  
Alginate beads (B18) used for the cell experiments were prepared in an identical 
manner to those administered in the human study. However, despite this, there were 
differences in both the calcium and iron loading of the beads prepared for the in vivo 
and in vitro experiments. Beads used for the human study contained on average: 
1.96mgCa/g wet bead (±SD 0.12) and 1.04mgFe/g wet bead (±SD 0.08), whereas 
beads B18 used for the above cell experiments contained 1.618mg Ca/g wet bead 
and 1.712mg Fe/g wet bead. The discrepancies in the iron and calcium content of 
the beads, despite the use of the same protocol and reagents, illustrate limitations in 
the preparation technique used for iron containing alginate beads which should be 
addressed in future work. 
When FeG and washed FeG-containing alginate beads B18 were presented to the 
cells, there was a significantly lower cell ferritin response from beads B18 than from 
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unprotected FeG. Furthermore, the cell ferritin concentrations were significantly 
lower when the iron treatments were carried out in the presence of the cola jelly test 
meal, suggesting an interaction between the cola jelly and iron. When washed 
beads B18 and FeG accompanied by the jelly test meal were compared, their effect 
on cell ferritin formation was inconsistent.  
Centrifugation of the digests prior to application onto the dialysis membrane placed 
above the cells did not reduce the apparently inhibitory effect of the cola jelly 
indicating that the pores in the dialysis membrane were not blocked by the jelly. 
Additionally, the effect of the jelly may be more pronounced in the in vitro cell model 
than in the human study, where a small amount of jelly enters the relatively large 
volume of the stomach. However, the possibility of interaction between cola jelly and 
iron occurring in vivo cannot be ruled out. Collings et. al.237 reported that cola 
beverage had no effect on iron absorption in vivo, suggesting that the inhibitory 
effect of cola jelly observed in experiments reported in this Chapter may be due to 
gelatine jelly. However research carried out in rodents suggest that gelatine can 
actually protect iron from the inhibitory effect of tea263 which makes this an unlikely 
explanation.   Due to limited time further investigations on the effect of the jelly on 
iron uptake by the cells could not be carried out.  
The inhibitory effect of calcium phosphate was consistent across all experiments 
and agreed with the in vivo findings reported in Chapter 4 as well as with findings 
reported by others236. However, it was not possible to isolate the effects of calcium 
present in the beads from other potential confounders (such as the jelly or alginate 
itself).  
The findings reported in this Chapter consistently demonstrate that when washed, 
FeG- containing alginate beads result in significantly lower ferritin concentrations in 
cells than unprotected FeG.  
 
 
 
 
 
 
CALCIUM - IRON INTERACTIONS 
125 
 
 
 
 
6. CALCIUM - IRON INTERACTIONS 
 
  
CALCIUM - IRON INTERACTIONS 
126 
 
6.1 Introduction  
Work discussed in this Chapter is a result of a collaborative project undertaken in 
the lab of Professors Kevin Pedley and Jane Coad at the Institute of Food, Nutrition 
& Human Health at Massey University in New Zealand. The research was funded by 
Marie-Curie IRSES (International Research Staff Exchange Scheme) grant funding 
(“REINFORCE” FP7-PEOPLE-2010-IRSES) awarded to UEA. 
Experiments using live cell imaging techniques were performed together with 
immunocytochemistry experiments investigating the localisation of DMT1 and tight 
junctions. However, the latter investigations are still on-going and therefore only live 
cell imaging data are presented here.  
In contrast to other dietary inhibitors of iron absorption (described in Chapter 1, 
Section 1.2.1) calcium affects uptake of both non-haem and haem iron264,54 which 
suggests that the effect is not just luminal (the site where modulators of iron 
absorption exert their effect). 
 Effects of calcium supplementation on iron absorption in humans has been the 
subject of research for decades42,265,266.Seligman et al.265 compared iron absorption 
from prenatal multivitamin-mineral supplements with equivalent amounts of iron 
administered as iron supplements only and reported that iron from the latter was 
significantly better absorbed than the former. Decreased absorption of iron from 
multivitamin-mineral supplements was attributed to the presence of calcium 
carbonate, magnesium oxide and in some instances to ineffective iron release.  
Cook et al.236 investigated the effect of different forms of calcium supplements 
(calcium carbonate, calcium citrate and calcium phosphate) at doses of 300mg and 
600mg on ferrous sulphate absorption used at doses of 37mg or 18mg of iron 
respectively. The results demonstrated that when taken with no food matrix, higher 
doses of calcium phosphate or calcium citrate significantly inhibited iron absorption 
whereas calcium carbonate did not. Moreover, when taken with single meals all the 
above mentioned calcium forms significantly reduced iron absorption from 
supplements as well as dietary iron (present in the test meal). Similar findings were 
reported by Dawson-Hughes et al.266 when 500mg of calcium carbonate or 
hydroxyapatite was administered together with a test meal containing ≈3.6mg of 
iron; thereby, highlighting the issue of potentially ineffective iron supplementation (or 
uptake from meals) with simultaneous administration of calcium supplements. On 
the contrary, Snedeker et al.267 showed no effect of calcium gluconate and 
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phosphorus at three different supplementation levels on biomarkers of iron status. 
However, this lack of effect could be attributed to a small sample size and imprecise 
analytical methods. 
In a study performed by Hallberg et al.54 wheat rolls were supplemented with 
increasing calcium chloride concentrations (40 to 600mg) and the strongest 
inhibiting effect (50-60%) was reported at higher doses in the range 300-600mg. A 
similar effect was also present when the calcium chloride supplement was replaced 
with an equivalent dose of dietary calcium (≈165mg) which inhibited both haem and 
non-haem iron. Interestingly, addition of as little as 40mg of calcium to the dough 
(80g of flour) significantly decreased iron absorption. This observation was attributed 
to the protective effect of calcium on phytate degradation during the baking process, 
thus indirectly impacting on iron availability from the test meal. This hypothesis was 
confirmed later by addition of calcium to wheat rolls after the baking process was 
completed. Another study268 reported an inhibiting effect of calcium carbonate 
(400mg per meal, total daily intake of 1200mg) on iron absorption from a reasonably 
rich iron diet (15mg/day). This inhibiting effect was not present at lower doses of 
calcium (<320mg/day) confirming previously reported findings where calcium 
chloride (178mg dose) did not significantly inhibit iron (4.1mg) absorption from a 
single meal269. Moreover, the long term effect of calcium (6 months, taken daily with 
meals at the dose of 1200mg of calcium per day) was also investigated by Minihane 
et al.268 and no changes in iron status parameters, such as plasma ferritin, 
haemoglobin, zinc protoporphyrin and haematocrit were reported. These findings 
may suggest that some adaptive mechanism of iron absorption to prolonged calcium 
exposure may be present, or perhaps the study was not continued long enough to 
affect its endpoint (measures of iron status). 
 Reallocating the intake of high calcium products (such as cheese or milk) from 
lunch or dinner meals (which are most likely to contain higher percentage of iron) to 
breakfast and /or supper significantly increased total iron absorption (non-haem and 
haem) from reduced calcium meals270 compared with calcium intake spread across 
all main meals during the day. These findings suggest that redistribution and 
separation of calcium and iron rich products into different meals during the day may 
be a way forward to ensure sufficient absorption of both these vital nutrients. 
More recently, calcium chloride (200 to 1500mg) was given to participants together 
with 5mg of haem or non-haem iron with no test meal and an inhibiting effect was 
reported for calcium doses exceeding 800mg (non-haem and haem iron absorption 
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inhibited by ≈50% and ≈38% respectively)271. However this study has been criticised 
for assessing iron absorption on one occasion from a single meal, thus not 
accounting for day to day variations in iron absorption272. Nonetheless contradicting 
results of the effect of calcium from single meals or complete diets on iron 
absorption reported in the literature warrant further investigation273,274. 
In summary, based on the above literature review the inhibiting effect of calcium on 
relative iron absorption may be dependent on: 
 dose of calcium and iron 
 source of calcium and iron (dietary or supplemental), 
 pattern of consumption (single meal-acute studies or studies over several 
months)  
 distribution of calcium (and iron) across different meals/times in the day275 
Caco-2 cell (as reported earlier in Chapter 1, Section 1.4) are commonly used as an 
in vitro model to study iron bioavailability and/or uptake from different iron 
compounds227, foods193,257 and their composition18,19. Overall, published reports 
suggest good agreement between in vitro findings (using this particular cell line) and 
in vivo research estimating iron bioavailability from food in the presence of iron 
enhancers and inhibitors252,258 e.g. AA. In addition it has also been reported that 
calcium inhibits iron uptake in Caco-2 cell line55,254 therefore this model can be used 
to investigate the mechanisms by which calcium inhibits iron uptake. 
As previously discussed (Chapter 1) DMT1 is the only non-haem iron transporter 
identified to date. DMT1 is expressed by Caco-2 cells at levels allowing study of its 
properties and optimal conditions to transport iron (II). One of the most intriguing 
processes in the intestinal epithelium is the occurrence of the ‘mucosal block’ when 
treated with high, prolonged or frequently reoccurring iron doses. Recent literature 
reports of investigations in a murine model276 suggest that this phenomena takes 
place at the apical side of the enterocyte by reduction in expression of Dcytb and 
DMT1(IRE+) mRNAs, thus decreasing iron uptake. Interestingly, in Caco-2 cells iron 
induced (24 hours incubation) translocation of DMT1 into the cytosol occurred prior 
to reduction of DMT1 mRNA levels179,277. It is also worth mentioning that Sharp et 
al.179 demonstrated that total levels of DMT1 within the cells remained unaltered 
supporting the translocation hypothesis. In addition 72 hours of incubation were 
required to reduce DMT1 mRNA by 50%179. 
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The hypothesis tested in this chapter was that the presence of calcium would reduce 
iron uptake into the cell thus confirming previously reports of an inhibitory effect of 
calcium on iron absorption at the apical side. 
The aim of the research reported in this Chapter was to further the understanding of 
complex calcium-iron interactions. Cell imaging techniques using a confocal 
microscope were used in conjunction with the Caco-2 cell line model as an 
investigation tool.  
 
6.2 Methods  
6.2.1 Cell culture procedures 
Cell culture procedures (harvesting and seeding) were identical to the ones reported 
in Chapter 2 with the exception of media composition. For experiments reported in 
this Chapter DMEM media was supplemented with 10% fetal bovine serum, 4mM L-
glutamine, 5ml of 5000u/ml Penicillin/Streptomycillin solution (Gibco, UK) and 5ml of 
100x non-essential amino acids (Sigma, UK). Cells used for these experiments were 
at passages: 30 to 35. 
Cells were seeded onto flame sterilised and collagen coated round glass coverslips 
(25mm, Warner instruments, USA).  Prior to seeding coverslips were washed in 
0.1% Decon solution (Decon Labolatories, UK), washed 10 times in MilliQ water, 
immersed in 96% ethanol, flamed in sterile conditions and placed in 35mm petri 
dish. Collagen coating solution was prepared by mixing 0.02M acetic acid (Sigma, 
UK) and collagen from rat tail (Fisher, UK) to obtain a final concentration of 50µg/ml 
of collagen. Glass coverslips were then covered in collagen coating solution and left 
for 1 hour in sterile conditions. After 1 hour coverslips were washed twice with 
Hank’s balanced salt solution (HBSS, Sigma, UK) and immediately after that the 
cells were seeded. Experiments took place 3 weeks post seeding.  
6.2.2 Preparation of experimental solutions and treatments 
Ferric chloride and calcium chloride (both from Sigma, UK) were dissolved in 0.1M 
HCl to obtain the following stock solutions: 0.125M; 0.25M and 0.5M CaCl2 solutions 
and 0.01M and 0.003M FeCl3 solutions. On experimental days the above solutions 
were diluted further in experimental media to obtain the required concentrations. 
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Earles/HEPES buffer (EH media) composition: 124.0mM of sodium chloride; 5.4mM 
of potassium chloride; 0.8mM of magnesium sulphate; 1.0mM of monosodium 
phosphate; 14.3mM of sodium bicarbonate; 10.0mM HEPES; pH 7.4, 1.2mM of 
calcium chloride and 5.55mM D-(+)-glucose. 
Experimental media was prepared using phenol red free, serum free DMEM (Gibco, 
UK). Media pH was adjusted to 6.5 and HEPES buffer added at a final concentration 
of 25mM in order to stabilise the pH. 
DPD solution was used at the end of the incubation period with iron chloride. DPD 
(2,2′-Bipyridyl, Sigma, UK) powder was dissolved in dimethyl sulfoxide (DMSO, 
Sigma, UK) to obtain 1M stock solution, which was further diluted in experimental 
media to obtain a final concentration of 5mM. 
6.2.3 Phen green loading- optimisation of the technique 
Phen GreenTM SK, diacetate ((PG); Invitrogen, UK)) powder was dissolved in DMSO 
to obtain 1mM and stored at -20ºC in 50µl aliquots. Investigations were undertaken 
to optimise loading conditions into Caco-2 cells. PG concentration, loading time and 
temperature were tested. The best loading conditions for cells (21 days post 
seeding, Figure 6.2.1) were: rinsing coverslip with EH media, 20min loading at room 
temperature with 10µM of PG in EH media and following incubation rinsing the 
coverslip twice with EH media.  
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Figure 6.2.1 PG loaded Caco-2 cells. The length of white bar is 40microns. 
6.2.4 Confocal microscopy  
Images were collected using a Nikon eclipse TE2000-U confocal microscope, lens 
60x1.2, with Nikon EZ-C1 FreeViewer 3.80 software. Fluorescence of PG was 
excited at 488nm (blue excitation) and collected through a 488 nm detector (green 
emission). Images were collected for 100min (at 5min intervals) at 512 resolution. 
The first image collection phase comprised of baseline image collection: 2 images 
collected 5min apart of cells in EH media followed by 2 images collected 5min apart 
(4 images in total) with experimental media (pH 6.5). The second image collection 
phase comprised of images taken of cells exposed to iron alone or in the presence 
of calcium (30 or 100µM FeCl3 with or without 1.25 or 5mM CaCl2). This latter 
collection phase (in which a decrease in fluorescence was expected to be observed 
as iron entered the cells) took 60min with images collected at 5min intervals (13 
images in total). In the final phase which lasted 20min, images were again collected 
at 5min intervals (5 images in total) with iron dequenched from PG using a 5mM 
solution of DPD, which resulted in an observed increase in fluorescence.  
Collected stacks of images were combined using the ImageJ 1.46r; Java program 
and fluorescence values (in arbitrary units) were obtained. 
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6.2.5 Statistical analysis 
Prior to statistical analysis the data were normalised to baseline readings (the time 
point at which iron was added onto the cells). Every experiment considered 10 cells 
(areas; n=10). Data from 2 (Figure 6.3.1 and Figure 6.3.5) or 3 (Figure 6.3.3) 
separate experiments was combined. 
Statistical analysis was performed using SPSS Inc, USA, (version 16.0.0). One way 
ANOVA with Tukey HSD or Games-Howel post-hoc tests were conducted to 
examine pairwise differences on normalized data. Data are presented as mean 
±SD. Differences were considered significant at p<0.05. 
 
6.3 Results 
6.3.1 Cell exposure to 100µM ferric chloride, live cell imaging data  
Three time-points were selected for visual representation of the results: baseline 
(t=0), when iron was applied onto the cells (control); t=60 (incubation with iron for 
60min) and the final time-point (t=80) being 20min incubation with DPD following 
incubation with iron. In total cells were observed for 80min. 
After the Caco-2 cells were loaded with PG they were exposed to either 100µM of 
ferric chloride or 100µM ferric chloride in the presence of 1.25 or 5mM calcium 
chloride (Figure 6.3.1A). A significant decrease (p<0.0005 in all instances) in 
fluorescence was observed after 60min incubation with iron in all 3 treatments when 
compared with baseline (t=0) suggesting that iron was entering the cells despite the 
presence of calcium. There were no significant differences in the rate of 
fluorescence decrease between the three treatments investigated (Figure 6.3.1B). 
An explanation for iron entering Caco-2 cells in the presence of calcium at a similar 
rate to iron alone is the possibility that a 1h exposure to iron may not be long 
enough to observe changes in the rate of iron uptake into the cells. Therefore, in the 
experiment presented in Figure 6.3.3A cells exposed to iron after pre-incubation for 
24 hours with 2.5mM were compared with cells exposed to iron only. 
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Figure 6.3.1A Change in fluorescence in cells exposed to 100µM ferric chloride with 
or without presence of 1.25 or 5mM calcium chloride. Combined data from 2 
experiments (n=20 in each treatment), normalised to control. Data represents mean 
±SD. Bars without a common letter (a, b, c) are significantly different, p<0.05.  
 
Figure 6.3.2B Data as in figure 6.3.1A with additional time points in order to 
investigate decrease in fluorescence (normalized to control) over 60min incubation 
time.  Data represents mean ±SD. Star (*) represent points with significantly lower 
fluorescence than the control (p<0.05). 
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Figure 6.3.3A Change in fluorescence in cells exposed to 100µM ferric chloride or 
pre-treated (24h) with 2.5mM calcium and then exposed to 100µM ferric chloride. 
Combined data from 3 experiments (n=30), normalised to control. Data represents 
mean ±SD. Bars without a common letter (a, b, c, d) are significantly different, 
p<0.05. 
 
Figure 6.3.4B Data as in figure 6.3.2A with additional time points in order to 
investigate decrease in fluorescence (normalized to control) over 60min incubation 
time.  Data represents mean ±SD. Star (*) represent points with significantly lower 
fluorescence than the control (p<0.05). 
 
The decrease in fluorescence in cells pre-treated with calcium (Figure 6.3.3A) after 
60min incubation with iron was not statistically significant when compared with 
baseline, but the decrease in fluorescence in cells exposed to iron was significant 
CALCIUM - IRON INTERACTIONS 
135 
 
when compared to baseline (p=0.001). However, the decrease in fluorescence 
between calcium pre-treated and non-pre-treated cells after 60min of incubation with 
iron was not statistically significant. There were also no significant differences in the 
rate of fluorescence decrease between the two treatments investigated (Figure 
6.3.2B). 
 
6.3.2 Cell exposure to 30µM ferric chloride, live cell imaging data 
In order to investigate if similar trends would be observed in the presence of lower 
iron concentrations, experiments with 30µM ferric chloride were also performed 
(Figure 6.3.5A). There was a decrease in fluorescence after incubation for 60min 
with 30µM iron in both the presence and absence of 2.5mM calcium when 
compared with baseline (p<0.0005 in both cases). These findings are also in 
agreement with findings when 100µM of iron was used.  
When cells were pre-treated with calcium prior to exposure with 30µM of iron a 
significant decrease in fluorescence was also noted when compared with baseline 
(t=0); (p<0.0005). This finding is not in agreement with calcium pre-treated data 
when 100µM of iron was used. 
 
Figure 6.3.5A Change in fluorescence in cells exposed to 30µM ferric chloride or 
30µM ferric chloride in presence of 2.5mM Ca or pre-treated (24h) with 2.5mM 
calcium and then exposed to 30µM ferric chloride. Combined data from 2 
experiments (n=20), normalised to control. Data represents mean ±SD. Bars without 
a common letter (a, b, c, d) are significantly different, p<0.05. 
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Figure 6.3.6B Data as in figure 6.3.3A with additional time points in order to 
investigate decrease in fluorescence (normalized to control) over 60min incubation 
time.  Data represents mean ±SD. Star (*) represent points with significantly lower 
fluorescence than the control, two stars (**) represent the treatment with significantly 
lower fluorescence at a given time point (p<0.05). 
Also there was a significant difference in the rate of fluorescence decrease (p<0.05) 
between the treatment with calcium added at the same time as iron at the 40min 
time point and the two remaining treatments (Figure 6.3.3B). Overall, the rate of 
decrease of phen green fluorescence was more rapid when the cells were exposed 
to 30µM ferric chloride in the presence of 2.5mM Ca than with other treatments. 
 
6.4 Discussion 
As mentioned earlier investigations into calcium and iron interactions reported in this 
Chapter are still on-going. Complementary images using immunocytochemistry 
techniques to stain and fix DMT1 and tight junction proteins (following iron, iron with 
calcium or calcium only exposure for 1, 2 and 4 hours) have yet to be analysed. 
Thus interpretation of the results reported in this Chapter is currently incomplete.  
Thompson et al.55 suggested that the mechanism by which calcium affects non-
haem iron uptake is through translocation of DMT1. The authors used ferritin as a 
surrogate index of iron availability, therefore incubation times with iron and calcium 
solutions were relatively long (16 or 24 hours) and as expected calcium inhibited 
iron uptake into the cell. Thompson et al.55 also showed that DMT1 levels in the cell 
membrane fraction were reduced after a 4 hour exposure to iron, calcium or a 
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combination of both. Similarly, results reported by Johnson et al.277 showed that 
maximal reduction in membrane expression of DMT1 (as well as decrease in 
plasma membrane DMT1(+IRE)) occurred 4 hours post exposure to 100µM of iron, 
whilst there was no difference after a 1hour exposure. Johnson et al.277 also 
reported that DMT1 mRNA (+IRE) expression was unchanged after 4h exposure to 
iron. In addition, a significant reduction in the IRE containing DMT1 was observed 
after 24h179,277. 
Published data indicate that the inhibitory effect of calcium on iron uptake in the 
Caco-2 cell model is observed between the second and fourth hour post exposure to 
calcium and/or a high dose of iron. The observations made in this Chapter were only 
collected for one hour post exposure. Interestingly, when cells were pre-incubated 
with calcium for 24 hours and then exposed to 100µM of iron, the decrease in 
fluorescence after 60min was not significantly lower when compared to the control 
cells. However, when a lower iron concentration was used (30µM) after pre-
incubation with calcium no inhibitory effect was detected. A possible explanation for 
this observed inconsistency may be the confounding effect of calcium which may be 
more pronounced with lower iron concentration (Ca:Fe ratio of 83:1). The possibility 
of calcium binding PG within the cell, thus reducing PG fluorescence, is supported 
by the rate of fluorescence decrease presented in Figure 6.3.3B. This observation 
warrants further investigation. 
One of the limitations of work presented in this Chapter is the lack of images of cells 
exposed to calcium only (1.25, 2.5 and 5mM). These data are required in order to 
investigate whether calcium alone (especially at higher concentrations) can induce a 
reduction in PG fluorescence to distinguish between the effect of iron and that of 
calcium. 
Another limitation which needs to be noted is that the experimental media contained 
1.8mM of calcium, a standard concentration of calcium in DMEM media. Calcium is 
essential for cells to maintain their integrity; therefore complete elimination of 
calcium from experimental procedures is not possible. PG loading however was 
undertaken in EH media which contained a reduced calcium concentration of 
1.2mM. 
Finally, this investigation would have benefitted from extending the incubation time 
from 1h to 4-5h. However due to technical issues (such as PG photo bleaching and 
the inability to keep the cells in 5% CO2 while image collection was taking place) 
ideal experimental optimisation could not take place. Future plans should include 1h, 
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2h 3h and 4h cell pre-incubation with calcium prior to exposure to iron and then 
collection of images. Furthermore, the analysis of experiments undertaken using 
immunocytochemistry techniques would elucidate some of the above uncertainties.  
Nonetheless, despite some experimental limitations, this research permitted a better 
understanding of the kinetics of iron uptake and the inhibitory effect of calcium on 
pre-incubated cells, and further analysis of the data collected (on-going) will add 
further information. 
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7.1 Introduction 
The investigations reported in this Chapter are a result of collaboration between a 
PhD student, Tristan Eagling, based at Rothamsted Research Institute (RRI) and 
myself. Preparation of all samples and speciation of iron within the wheat samples 
used for the experiments was carried out by Tristan Eagling at RRI, whereas 
screening of the samples using the Caco-2 cell line model, coupled with the 
simulated digestion technique described in Chapter 2, was carried out by myself at 
the UEA.  
One of the strategies for addressing iron deficiency is biofortification of food crops. 
By means of selective plant breeding or genetic engineering techniques new 
varieties of staple foods (such as rice, wheat, maize, millet and legumes)278–281 
cultivars are being developed with higher nutritional value. This approach of 
increasing the micronutrient density of foods is useful in settings (remote rural 
areas) where food fortification or supplementation is not feasible281,5.  
If a successful programme of staple food biofortification can be developed in a given 
region, nutrient-rich foods will then be widely available to the majority of the 
population282. In addition, mineral-rich seeds may be more resilient to diseases and 
thus provide higher yields282.  
There are, however, potential issues with implementation of biofortified varieties of 
plants for everyday use by farmers. Namely, breeding must be effective and provide 
high yields, efficacy must be verified in the most commonly consumed foods 
produced from biofortified crops, and, finally, new seeds need to be accepted and 
widely used by both farmers and consumers283. All the aforementioned aspects may 
slow down the introduction of biofortified crops worldwide. 
During the milling process of wheat flour the outer layer of the grain (bran) and 
embryo (germ) is removed leaving endosperm as the main component of white 
flour284 (Figure 7.1.1). However, it is the bran that contains higher concentrations of 
iron, not the endosperm285. Therefore the control (by means of biofortification) of iron 
accumulation at sites within the grain is also of importance286. 
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Figure 7.1.1 Diagram of wheat grain (sourced from Wheat Flour 
Institute:https://dl.sciencesocieties.org/publications/books/abstracts/acsesspublicati/
cropqualitystor/). 
 
The form in which iron is present within the grain and the presence of iron-binding 
complexes such as phytate can influence iron availability. Most of the iron present in 
cereal grain is bound to inositol hexakisphosphate (IP6) or pentaphosphate (IP5) and 
forms phytate salts287. Minerals bound to phytate are not accessible to iron 
transporters in the human gut due to the lack of specific enzymes49, but there is 
evidence that phytates, depending of the nature of the bonding, may be insoluble or 
soluble. Soluble, and thus available for the uptake, salts in the form of monoferric 
phytate (Fe-IP6 or Fe-IP5
287,288) may be a potential source of available iron52. 
Therefore, potential bioavailability of monoferric phytate (MFP) was also the subject 
of investigations reported in this Chapter. 
Metal chelator65- nicotianamine (NA, Figure 7.1.2) formed by NA synthase from 
three molecules of S- adenosylmethionine289, is involved in intra- and intercellular 
transport of metal cations in the plant. When it is present at elevated levels in the 
grain it has been reported to enhance iron uptake in both cell and murine 
models65,66.  
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Figure 7.1.2 Chemical structure of NA adopted from Von Viren et al.290. 
Another chelator and potential enhancer of iron uptake is 2'-deoxymugineic acid 
(DMA, Figure 7.1.3) which is synthesised via NA aminotransferase in graminaceous 
plants291,292. DMA is a phytosiderophore and thus has a high affinity with ferric iron, 
and plays an important role in the solubilisation and acquisition of the iron (III)-
phytosiderophore complex by the plant from the rhizosphere292,293 . Therefore, an 
increase in both NA and/or DMA is another potential avenue of improvement with 
the use of transgenic technologies. 
 
Figure 7.1.3 Chemical structure DMA adopted from Von Viren et al.290. 
Finally, there are large natural genetic variations between (commercially used) 
cultivars of wheat grain with respect to total iron concentration, ranging from 19-
58mg/kg294–296, suggesting that biofortification as a method of producing nutrient rich 
crops has the potential for success. However, it is not known if similar variations in 
iron content are present when white flours are produced from grains that are low 
and high in iron.  
The hypothesis tested in this chapter was that the cell ferritin response would be the 
highest in cells treated with chapattis made of the white flour that had the highest 
iron content; that DMA (similarly to NA) would enhance iron uptake into the cell, and 
that MFP would not prevent iron from being taken up by the cells, compared with the 
strongly inhibitory effect of phytate in the inositol hexakisphosphate form.  
USE OF CACO-2 CELL MODEL AS A TOOL TO INVESTIGATE IRON 
AVAILABILITY FROM TWO WHEAT CULTIVARS 
143 
 
The main aim of this collaboration was to investigate if there are differences in iron 
availability between wholegrain and white flours made out of two commercially 
available wheat cultivars selected by Rothamsted team: Rialto (high in iron) and 
Riband (low in iron), with and without AA and additional iron (II) sulphate. Iron 
availability was tested in the Caco-2 cell model combined with a simulated digestion 
procedure. In addition, the availability of iron from MFP and the effect of NA, DMA 
(the two iron transporters present in graminaceous plants) and AA on iron uptake by 
the cells was also investigated.  
7.2 Methods 
7.2.1 Sample preparation 
7.2.1.1 Grain materials and unleavened flatbread preparation 
Analyses were performed on two wheat cultivars selected to represent high (Rialto) 
and low iron (Riband) cultivars296. Growing conditions (soil and climate) were 
described by Shewry et al.297. Based on these analyses the two cultivars were 
grown in field trials at Rothamsted Research in 2010.  
Milling, extraction, iron and phytate analysis in flour samples and unleavened 
flatbread (chapattis, from Rialto and Riband wholemeal and white flours) was 
undertaken by Tristan Eagling and are described in detail in his thesis entitled 
‘Understanding the amount and availability of iron in bread wheat cultivars to 
prevent global iron deficiency’ submitted in September 2013. Characteristics of flour 
and flatbread samples are summarised in Table 7.2.1 
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Table 7.2.1 Specification of flours and chapattis. 
Flour 
type 
Total Fe1 
(mg/kg) in 
flours 
Total Fe1 
(mg/kg) in 
chapattis 
Phytic acid2 
(g/kg dw) in 
chapattis 
Rialto 
White 
16.98 11.85 1.0 
Rialto W-
meal 
46.7 46.7 6.4 
Riband 
White 
6.83 6.65 0.4 
Riband 
W-meal 
30.3 30.25 4.5 
1 Total Fe determined by ICP-MS 
2Analysis of phytic acid was performed using a commercially available kit (K-PHYT 
12/12 Megazyme, Ireland), as per the manufacturer’s instructions. Briefly, either 1g 
or 0.5g of samples were extracted with 10ml of HCl followed by an enzymatic 
dephosphorylation step with phytase and alkaline phosphatase and precipitation 
using a colour reagent prepared from AA in sulphuric and ammonium molybdate. 
The absorbance (655 nm) of free phosphorous and total phosphorous were then 
compared to phosphorus standards using a Varioskan spectrometer (Thermo, 
Finland). 
 
7.2.1.2 Preparation of experimental solutions- AA, NA, DMA, MFP (work 
undertaken by Tristan Eagling) 
Ascorbic acid (AA).  
The usual practice is to add AA to obtain an AA:Fe molar ratio in the range of 10-
20:1. Therefore the AA final concentration is determined by the amount of iron in the 
samples257,298. However, there were large variations in total Fe in the chapatti 
samples (6.65-46.7mg/kg) and an identical amount of 132µM AA solution (AA 
dissolved in MilliQ water) was added per gram of flatbread used. Although this 
meant that some samples would have a higher AA:Fe ratio than the others (Table 
7.2.2), the amount of AA chosen was sufficiently high to ensure that it achieved 
maximal effect as observed in previous studies299 . 
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Mono-ferric phytate (MFP).  
A solution of 100ml of 0.5M acetic acid with 10g of sodium phytate and 1g FeCl3-
6H2O was stirred for 2 hours until all the sodium phytate was completely dissolved. 
The resulting solution was allowed to stand briefly, then 100ml of 95% ethanol was 
added and the solution left overnight. The precipitate was then collected by 
centrifugation (5000g for 10min) (Medowrose scientific LTD, Oxford , UK), washed 
three times with acetone, allowed to air dry, and stored in a desiccator. The final 
product underwent inductively coupled plasma atomic emission spectroscopy 
analysis to verify the expected structure300. 
Table 7.2.2 Iron and AA concentrations of treatments containing 3g of Chapatti’s. 
Chapatti 
treatments 
containing 3g of: 
Fe content 
(µg) per 
digest 
Fe (µM) 
per 
digest 
AA (µM) 
per 
digest 
Fe:AA 
molar ratio 
Riband White 19.95 23.82 396 1 : 16.6 
Rialto W-meal 35.55 42.44 396 1 : 9.3 
Riband W-meal 90.75 108.34 396 1 : 3.7 
Rialto W-meal 140.10 167.25 396 1 : 2.4 
 
Fe-DMA and Fe-NA.  
Both DMA and NA form 1:1 molar complexes with iron. Fe (II)-NA was prepared 
from ferrous sulphate and Fe (III)-DMA was prepared from ferric chloride (both from 
Sigma Aldrich, Austria). DMA/NA were dissolved in MilliQ water and iron was 
dissolved separately also in MilliQ water. Appropriate solutions were then mixed 
immediately to avoid oxidation. Both NA and DMA were purchased from Toronto 
Research Chemicals Inc. 
 
7.2.2 Cell culture procedures 
All cell culture procedures with Caco-2 cells were identical to those reported in 
Chapter 2 with the exception of media composition and supplier. For experiments 
reported in this Chapter DMEM media (0.5L) was sourced from LGC, UK and 
supplemented with 10% fetal bovine serum, 2mM L-glutamine, 5ml of 5000u/ml 
Penicillin/Streptomycillin solution (Gibco, UK) and 5ml of 100x non-essential amino 
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acids (Sigma, UK). Caco-2 cells used for these experiments were at passages: 27 to 
34 
7.2.2.1 Simulated digestion procedures 
Initially the simulated digestion procedures were identical to those reported in 
Chapter 2, Section 2.2. However, due to the low iron content of the flour samples 
the following changes were made to the simulated digestion: sample volume was 
increased from 0.5g to 1g and subsequently to 3g which produced a thick digestate, 
so the duodenal phase of the simulated digestion was performed in a test tube for 2 
hours and not above the Caco-2 monolayer (usual procedure). Once completed, the 
tubes with the digestates were centrifuged at 21,000g for 10min (as described in 
Chapter 5, Figure 5.2.1, with the exception of centrifuge force) and the resulting 
supernatant was flash frozen in liquid nitrogen and stored ready for the Caco-2 cell 
experiments. The supernatant was warmed to 37°C, then applied to the inserts with 
dialysis membranes and placed above the wells containing Caco-2 cells for 2 hours. 
After that time the inserts with dialysis membranes were removed and the cells were 
incubated for a further 22 hours. In order to increase the cell response further AA 
and/or iron (II) sulphate was added to all treatments. 
 
7.2.3 Experimental procedures without a simulated digestion phase with the 
use of MFP, NA, DMA and AA 
Experiments performed with the use of NA, DMA and MFP were performed without 
a simulated digestion phase due to the limited quantity of material available for the 
experiments.  
Solutions containing NA, DMA and MPF were prepared by Tristan Eagling in MilliQ 
water (at approximately 1:9 Fe to AA molar ratio across all treatments), the pH was 
adjusted to 2 and the samples were incubated for 1 hour at 37 ºC. After that time the 
samples were frozen and sent to UEA where they were stored at -18 ºC. 
On the experimental day samples were thawed, diluted with MEM media (Gibco, 
UK, complete composition is described in Chapter 2) to the desired iron 
concentrations (1.6 or 3.11µg Fe/ml) and kept in water bath at 37ºC for an hour. 
Because small concentrated volumes of NA, DMA or MFP solutions were used 
(600µl were diluted in 6ml) it did not markedly affect the pH of solutions (final pH 
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was in a range of 6.9-7). Before adding onto the cell monolayer all treatment 
solutions were filtered with 0.22µm syringe filters (Merck Millipore, UK). The cells 
were incubated with the experimental solutions for 24h and after that time they were 
harvested, sonicated and analysed (as described in Chapter 2).  
7.2.4 Protein and ferritin analysis 
Protein and ferritin analyses were performed as described in Chapter 2, Section 2.3. 
7.2.5 Statistical analysis 
Unless otherwise stated, all statistical analyses were performed using SPSS Inc, 
USA, (version 16.0.0). 2-factor ANOVA with Tukey post-hoc to examine pairwise 
differences on power-transformed data. Data are presented as mean ±SD. 
Differences were considered significant at p<0.05. 
 
7.3 Results 
7.3.1 Caco-2 ferritin response to unleavened flatbread (chapatti) samples- 
simulated digestion experiments 
Results obtained with 1g of flatbread (Figure 7.3.1) showed that there was 
significantly more ferritin produced by cells treated with Riband white flour bread in 
the presence of AA than from Riband or Rialto wholemeal flours (p<0.0005 and 
p=0.001 respectively). There were no significant differences between the two 
wholemeal or white flour cultivars.  
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Figure 7.3.1 Ferritin concentration in Caco-2 cells exposed to digests prepared from 
unleavened flatbread made out of Rialto and Riband white and wholegrain flours in 
the presence of 132µM AA, expressed as ferritin concentration (ng/mg total protein). 
Cell ferritin response to control (blank) was 6.2 ±SD 1.8. Data represent mean ±SD 
(n=6). Bars without a common letter (a, b, c) are significantly different, p<0.05. 
 
The cell ferritin response (143.1 ±SD 18.5 and 106.0 ±SD 12.7ng/mg total protein) 
to positive control treatments (8µg Fe as FeCl3+AA or MFP+AA respectively) was 
significantly higher (p<0.0005 for all comparisons) than any other treatment. Initially, 
no ferritin response was observed from the wholemeal flour breads (Rialto or 
Riband) therefore a further increase from 1g to 3g in sample quantity was 
implemented (Figure 7.3.2).  
When 3g of sample were used (Figure 7.3.2) cells exposed to white flatbreads 
(Rialto and Riband) produced significantly more ferritin than cells exposed to 
wholemeal products (p<0.0005 in both instances). Cells exposed to Riband white 
flatbread produced significantly more ferritin than cells exposed to any other 
flatbreads (p<0.0005 in all instances). 
Rialto or Riband wholemeal flour breads again resulted in very low cell ferritin 
formation (significantly lower than blank (7.5 ±SD 0.6ng/mg total protein; p=0.001 
and p<0.0005 respectively). One potential explanation for this observation may be 
that phytate present in wholemeal flours is inhibiting residual/contaminant iron 
present in the samples resulting in lower ferritin levels than in the blanks. To ensure 
that the cells were responsive positive controls (8ug FeCl3+AA and MFP+AA both in 
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presence of 132µM AA) were also included in this experiment and resulted in a high 
ferritin response (437.9 ±SD 33.5 and 166.9 ±SD 19.4ng/mg total protein). 
 
Figure 7.3.2 Ferritin concentration in Caco-2 cells exposed to digests prepared from 
unleavened bread made out of Rialto and Riband white and wholegrain flours in the 
presence of 132µM AA expressed as ferritin concentration (ng/mg total protein). 
Data represent mean ±SD (n=6). Bars without a common letter (a, b, c) are 
significantly different, p<0.05. 
In order to increase the cell response further all flour samples were supplemented 
with ferrous sulphate with 30mg Fe/kg prior to the production of flatbread (Figure 
7.3.3). There was a significantly higher cell ferritin response to samples from Rialto 
or Riband white flatbreads than wholemeal flours (p<0.0005 for all comparisons). 
Cells exposed to Riband wholemeal flatbread produced significantly more ferritin 
than cells exposed to Rialto wholemeal flatbread (p=0.001). Cell ferritin response to 
positive control (53.54µM FeSO4) was not significantly different from cell response 
to Riband white bread, but it was significantly higher than the response to Rialto 
white, wholemeal and Riband wholemeal (p=0.049; p<0.0005 and p<0.0005 
respectively). It is also worth mentioning that the cell response to flatbread made out 
of Rialto wholegrain flour was not significantly different to the blank (17.7 ±SD 
2.5ng/mg total protein). 
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Figure 7.3.3 Ferritin concentration in Caco-2 cells exposed to digests prepared from 
unleavened bread made out of Rialto and Riband white and wholegrain flours in 
presence of 132µM AA and 53.54µM FeSO4 expressed in ferritin concentration 
(ng/mg total protein). Data represent mean ±SD (n=6). Bars without a common letter 
(a, b, c, d) are significantly different, p<0.05. 
When the above experiment was repeated (data not shown) similar results were 
observed, the only difference being that cells exposed to FeSO4+AA produced 
significantly more ferritin that cells treated with Riband white flour (p=0.001). 
 
7.3.2 Cell ferritin response to iron (II), iron (III) or MFP treatments with NA, 
AA, DMA or NA and AA 
The results presented in this Section focus on iron availability in the presence of NA, 
DMA and/or AA.  
It has to be noted that AA was present in the treatments (Figure 7.3.4) at a ratio of 
≈1:9 (Fe:AA) whereas DMA and/or NA were present at a ratio of 1:1 (Fe:NA and/or 
DMA).  
Cell ferritin response to iron in the presence of NA (Figure 7.3.4) was significantly 
higher than to iron in the presence of DMA (p<0.0005) suggesting that NA is a more 
potent enhancer than DMA (at the tested molar ratio). Cell ferritin response 
significantly increased when AA was added to iron and DMA treatment (p<0.0005), 
but further addition of NA had no extra effect. However due to the absence of an 
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‘iron only’ treatment it is not possible to evaluate the enhancing effect of DMA on 
iron uptake by Caco-2 cells. The evidence indicates that DMA at 1:1 Fe to DMA 
molar ratio is not as effective as AA at 1:9 Fe to AA molar ratio. 
Interestingly, the cell ferritin response to MFP+AA was similar to ferrous 
chloride+AA, suggesting similar iron availability of both compounds. Also, further 
addition of NA to MFP+AA or to iron (II) chloride+AA significantly increased ferritin 
formation in cells (p<0.0005 in both instances).  
When the above experiment was repeated a lower ferritin response was obtained 
with MFP+AA.  
 
Figure 7.3.4 Ferritin concentration in Caco-2 cells exposed to 1.6µg of Fe(II)Cl, 
Fe(III)-DMA or MFP in presence of NA (at 1:1 Fe to NA ratio) and/or AA (at 1:9 Fe to 
AA ratio). Cell response expressed in ferritin concentration (ng/mg total protein). Cell 
ferritin response to control (blank) was 1.9±SD 1.3. Data represent mean ±SD (n=6). 
Bars without a common letter (a, b, c, d) are significantly different, p<0.05. 
 
The final experiment (Figure 7.3.5) was designed to investigate whether there was a 
dose-response effect of NA and to compare it with the most potent enhancer of iron 
uptake, namely AA.  
Cells exposed to iron in the presence of increasing NA concentrations (from 1:0.25 
Fe:NA molar ratio through 1:0.5 to 1:1 molar ratio) produced significantly more 
ferritin with every increase in NA (p<0.0005; p=0.001 and p=0.004 respectively). 
When a higher Fe:NA 1:4 molar ratio was used ferritin levels were not significantly 
different to those in cells exposed to 1:0.5 Fe:NA molar ratio. 
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The cell ferritin response was positively related to AA concentration (from 1:0.25 
Fe:AA molar ratio through 1:4 and 1:10 molar ratio, p=0.002; p<0.0005 and 
p<0.0005 respectively). Cells exposed to the highest 1:10 Fe to AA molar ratio 
produced ferritin at similar levels as cells exposed to the lowest 1:0.25 Fe to NA 
molar ratio suggesting that NA is a more potent iron enhancer than AA.  
When the experiment was repeated (data not shown), the only difference observed 
was that cells exposed to 1:4 Fe:NA molar ratio produced ferritin at significantly 
higher (p=0.019) levels than cells exposed to 1:1 Fe:NA molar ratio, indicating that 
NA continued to have an enhancing effect with increasing dose. 
 
Figure 7.3.5 Ferritin concentration in Caco-2 cells exposed to 3.11µg (13.88µM 
FeSO4) without or with NA (at following Fe:NA ratios: 1:0.25; 1:0.5; 1:1; 1:4) or AA 
(at following Fe:AA ratios: 1:0.25;1:4 and 1:10). Cell response expressed as ferritin 
concentration (ng/mg total protein). Cell ferritin response to control (blank) was 
4.0±SD 0.9. Data represent mean ±SD (n=6). Bars without a common letter (a, b, c, 
d, e, f) are significantly different, p<0.05. 
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7.4 Discussion 
Riband white flatbread delivered more available iron (in the presence of AA) than 
any other flatbread investigated despite having the lowest iron content of all samples 
(Figure 7.3.1; Figure 7.3.2 and Figure 7.3.3) when tested in the in vitro model. One 
potential explanation for this phenomenon may be the fact that Riband white 
flatbread also contained the lowest phytate content of all flatbreads tested (Table 
7.2.1). The results suggested that the cell ferritin response increased with the fall in 
phytate rather than the increased iron content. This observation suggests that 
phytate and not the iron content of the flours tested was the main determinant of iron 
bioavailability.  
When flatbreads were supplemented with additional iron at 30µg/g together with AA, 
(Figure 7.3.3) the same trend was observed. The cell ferritin response was inversely 
proportional to the concentration of phytate and iron in flatbreads tested. However it 
has to be noted that because the iron content of all samples differed, the AA:Fe 
molar ratios in the samples were not the same (Table 7.2.2), with the highest AA:Fe 
ratio found in the sample with the lowest iron (Riband white flatbread). The rationale 
for using equal amounts of AA across all samples provided by Tristan Eagling ( who 
prepared the samples) is that when AA is used in excess it should have a similar 
effect across all iron concentrations299.  
Since 1953, it has been mandatory in the UK to add iron to white and brown flour to 
restore it to the levels found in wholemeal flour (16.5mg kg-1)301, 70 The results 
reported in this Chapter suggest that most of the iron present in wholemeal products 
is not available, almost certainly due to the presence of phytate.  
The enhancing effect of DMA requires further investigation. The design of the 
experiment reported in Figure 7.3.4 had its limitations (including the lack of 
appropriate comparison; which would have been an iron only treatment) and has not 
explained the effect of DMA on iron uptake in the Caco-2 cell model. However, the 
enhancing effect of NA on iron availability was clear. NA is a more potent iron 
enhancer than DMA (Figure 7.3.4) or AA (Figure 7.3.5), as also reported by Zheng 
et al.66. NA at the lowest 1:0.25 Fe:NA molar ratio tested was similar to AA at a 1:10 
Fe:AA molar ratio (Figure 7.3.5).The most effective Fe:NA molar ratio observed in 
experiments reported in this work seems to be 1:1 or 1:4 (data not shown). Zheng et 
al.66 also specified a 1:1 Fe:NA molar ratio was the most effective when used with 
wild type rice and that a 1:4 Fe:NA molar ratio proved to be the most effective in a 
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transgenic rice grain that was tested. However these findings cannot be directly 
compared with those presented here as iron compounds were tested without a food 
matrix and the test materials were not subjected to a simulated digestion procedure.  
These results also indicate that MPF with AA may provoke a similar cell ferritin 
response to ferrous chloride with AA (when the experiment was repeated MFP with 
AA did not provide as much iron as ferrous chloride with AA, data not shown). 
Furthermore, when ferrous chloride was applied to the cells in the presence of AA 
and NA the ferritin response was significantly higher than when ferrous chloride was 
applied to the cells in the presence of AA or NA (p<0.0005 in both instances). 
Similarly, when MFP was applied to the cells in the presence of NA and AA, the cell 
ferritin response was significantly higher (p<0.0005) than when MFP was 
accompanied by AA alone. The above observations suggest an additive effect of NA 
and AA, which requires further investigation. 
Future research should include studies of iron availability from flour products (or 
flour samples) in the presence of NA in order to confirm that the positive effect of NA 
on iron uptake from rice65,66,302 and from iron compounds reported in this work is also 
present in food products made from wheat flours.   
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The overall aim of the research presented in this thesis was to investigate potential 
strategies for increasing iron availability in order to help address global issues of iron 
deficiency.  
When studying the effects of diet on iron bioavailability it is essential to take into 
account the iron status of study participants as this has a major impact on the 
efficiency of iron absorption. It is important to have tools to identify individuals most 
at risk of IDA who would benefit from iron supplementation or other strategies. The 
assessment of body iron, calculated from serum ferritin and soluble transferrin 
receptor concentrations, is the most informative as it allows individuals to be placed 
at a specific point in the iron status spectrum, rather than using a cut-off value. 
However, the body iron method is not valid in the presence of inflammation as it 
relies on ferritin measurements, and ferritin is an acute phase protein (see Section 
1.3 for more details).  
The presence of underlying conditions such as malaria, HIV, and obesity cause an 
inflammatory response and confound biomarkers of iron status (serum ferritin and in 
some cases soluble transferrin receptor) thus making it difficult to determine whether 
or not the anaemia is caused by insufficient iron supply. Probably one of the best 
approaches to deal with the confounding effect of inflammation on iron status is to 
include the use of inflammatory biomarkers in the analysis, namely CRP and AGP 
and to adjust the data accordingly (see Section 1.3.1 for more details).  
As mentioned at the beginning of this Chapter, research reported in this thesis 
focused on methods of delivering bioavailable iron to reduce the risk of iron 
deficiency. First, the use of food constituents (such as alginates, Chapter 3, 4, 5) 
was investigated to test if they could be used to protect a soluble form of iron 
through the digestion process and thus deliver iron in a more available form into the 
duodenum. For our preliminary investigations an in vitro Caco-2 cell line model was 
used. The Caco-2 system is recognised to be a valuable screening tool for ranking 
different iron sources in terms of potential bioavailability, and for investigating 
mechanisms of nutrient absorption in humans197,198. Initial experiments with alginate 
solutions and alginate beads were promising242 and provided justification for a 
human study. As reported in Chapter 4, contrary to previous in vitro findings 
(Chapter 3), alginate beads reduced iron absorption (measured by the plasma 
appearance method) when tested in human volunteers. Therefore, investigations 
into potential reasons for this discrepancy were undertaken and resulted in 
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identifying the following differences between the beads produced for in vitro and in 
vivo research:  
 Varying conditions of the loading bath in which alginate beads were soaked. 
The beads for in vitro investigations were prepared to minimise technical 
(weighing) errors, hence they contained less iron per 1g of beads, whereas 
for the human study investigations the aim was to load the beads with a 
maximal amount of iron in order to reduce the quantity of beads that the 
volunteers had to consume. 
 An additional washing step was introduced into the production of beads 
prepared for human consumption. In-house organoleptic tests of beads 
revealed a strong metallic taste, therefore in order to increase the palatability 
of the beads and to keep the volunteers blinded to treatments the additional 
washing step was added to the protocol. 
 Administration of beads in a test meal (cola jelly) in the human study. Again, 
after in-house organoleptic tests cola jelly was selected as a test meal in 
order to blind participants to the treatment and to increase palatability of the 
beads.  
All the above differences can be considered as limitations when trying to compare in 
vivo and in vitro experiments. Therefore, follow-up in vitro investigations were 
undertaken in order to address these limitations. Interestingly, when cola jelly was 
used in the cell model it inhibited iron uptake from both alginate bead and iron only 
treatments (Chapter 5). The possibility of jelly limiting iron absorption in vivo cannot 
be ruled out, but since it was added to all treatments, the differences in iron 
absorption reported in Chapter 5 were likely to be due to other test meal 
components (FeG alone or alginate beads). Since the beads used in the human 
study contained a considerable amount of calcium (Fe:Ca ratio 1 : 1.9), on the basis 
of published evidence (refer to Chapter 6 for details), the possibility of calcium being 
the main contributor to the observed inhibitory effect of alginate beads in vivo and in 
the in vitro model cannot be ruled out. It is also worth mentioning that beads 
containing iron and AA produced a greater ferritin response than iron alone, 
suggesting a synergistic effect between AA and alginate which warrants further 
investigation.  
In order to understand better the observed inhibitory effect of calcium on iron 
absorption in the human study, preliminary in vitro work investigating calcium and 
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iron interactions with the use of live cell imaging was undertaken (Chapter 6). If live 
cell imaging methods prove to be useful (i.e. sufficiently sensitive) for evaluating 
calcium and iron interactions, then further investigations could be undertaken with 
alginate solutions in the presence of iron and/or calcium, thus providing direct 
answers to the following issues: 
 to confirm (via a different empirical method) that iron enters Caco-2 cells in 
the presence of alginate, 
 to investigate if calcium, present in the media at standard concentrations 
(1.8mM calcium chloride), binds to alginate  
 to test whether additional calcium introduced into the experimental media 
binds to alginate.  
In addition, it would be beneficial to quantify inflammation proteins such as 
interleukin 6 or 8 in cell lysates in order to rule out the (unlikely) possibility that 
alginates induce an inflammatory state in cells, thus increasing ferritin 
concentrations unrelated to iron uptake. It also has to be emphasised that the use of 
ferritin as a surrogate marker of iron availability needs to be treated with caution due 
the fact that a single ferritin molecule can contain up to 4500 atoms of ferric iron85,96 
and to date there is no simple method to quantify the iron content of ferritin in Caco-
2 cells.  
In addition to exploring the possibility of using alginates to protect iron and provide a 
bioavailable food fortificant (as discussed above) a collaborative project with 
Rothamsted Research Institute was undertaken, in which iron availability from 2 
different wheat cultivars (Chapter 7) with varying iron and phytate content was 
investigated. This research revealed that the cell ferritin response increased as the 
concentration of phytate decreased and was not related to the iron content of the 
flatbreads. These findings suggest that not only iron, but also the phytate content of 
staple foods, should be taken into consideration when food fortification policies are 
introduced.  
Furthermore, the research revealed that monoferric phytate in the presence of AA is 
(at least, in part) available to be taken up by the cells. 
Finally, there was the interesting observation that NA is a more potent iron enhancer 
than AA (at much lower iron : NA ratio) and that DMA may also enhance iron uptake 
into the Caco-2 cell model, but its effect is not as strong as that of AA at 1:10 iron to 
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AA ratio. Future work should include dose response experiments with increasing 
DMA : iron and AA : iron ratios in order to elucidate the potential enhancing effect of 
DMA on iron uptake. These should also include studies of iron availability from flour 
products (or flour samples) in the presence of NA or DMA in order to confirm that 
the positive effect of NA/DMA on iron uptake from iron compounds reported in this 
work is also the case for food products made from wheat flours. 
The use of iron containing alginate beads as an iron fortificant in foods with high 
water activity was a novel approach and ultimately a lot of technical problems had to 
be overcome.  The conclusion from the work on alginates was that alginate beads 
with the use of calcium as a gelling agent is not an effective delivery vehicle for 
soluble iron compounds. However, these findings should not rule out the potential 
use of alginates. Building on findings reported herein future work should focus on 
the use of alginates with different gelling agents such as zinc, or with the addition of 
AA, as a delivery system for iron. Use of alginates in diets containing high levels of 
tannic acid and phytate where alginates may prevent binding of iron to tannic acid or 
phytate should also be investigated in future.  
Another tool for tackling iron deficiency is biofortification, and increasing the iron 
availability of staple crops, especially focussing on increasing NA and or DMA 
content of different varieties/cultivars appears to be a promising strategy.  
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Abstract  
IDA is prevalent in older age, particularly after the age of 80. Serum ferritin concentrations 
also decline, although there is no evidence to suggest that changes in iron stores are an 
inevitable consequence of ageing. Chronic inflammation is a common condition in older 
people, making the measurement of iron status difficult, and it is likely that elevated levels of 
circulating hepcidin are responsible for changes in iron metabolism that result in systemic 
iron depletion. Other contributory factors are poor diet and some medications, such as 
aspirin. Anaemia in older age has undesirable health outcomes, including increased 
susceptibility to falling and depression. However, there are concerns about possible adverse 
effects of iron supplements, either in relation to pro-inflammatory effects in the gut or 
inappropriate tissue iron deposition. Brain iron levels are increased with age-related 
degenerative diseases, but it is not known if this is the cause or a consequence of the 
disease, and genetic factors are likely to play a role. In order to maintain body iron within the 
normal range a personalised approach is required, taking into account all of the factors that 
may affect iron metabolism and the available strategies for preventing iron deficiency or 
overload. 
 
Aim of this review 
The objective of this narrative review was to summarise the latest information on changes in 
iron metabolism and status in the elderly population and consequent effects on health in 
order to provide the framework for studies on iron in an ECfunded project, NU-AGE (New 
dietary strategies addressing the specific needs of the elderly population for healthy ageing 
in Europe). Serum ferritin and soluble transferrin receptor will be measured in 1,250 male 
and female volunteers between the ages of 65-79 years from five different European centres 
(UK, Italy, France, Netherlands, and Poland). Half of the volunteers have been randomly 
assigned to a one-year ‘whole diet’ intervention centred on dietary guidelines specifically 
tailored for elderly people with the aim of reducing age-related inflammation. The other half 
have been asked to maintain their usual diet for the year. Iron status is being measured at 
the beginning and end of the intervention to determine if a reduction in inflammatory status, 
resulting from the dietary changes, has an impact on iron metabolism. In addition, dietary 
intake data will be analysed to identify factors that explain the variance in iron status in 
elderly men and women, using both crosssectional and longitudinal data. 
 
Background 
The adult human body contains 3-4 g of iron, approximately 70% of which is present in 
haemoglobin (Hb) in red blood cells and myoglobin in muscle. Iron is instrumental for the 
transport of oxygen around the body and is an essential component of many enzymes and 
cytochromes where it plays a role in electron transport, respiration and hormone synthesis. 
As a result of these multiple functions, iron is important for physical performance, immunity, 
cognitive development and function, thermoregulation, and thyroid metabolism. The body 
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efficiently recycles iron from degraded red blood cells so the daily requirement to replace 
endogenous losses from the gastrointestinal tract, skin, hair, sweat and menstrual blood loss 
in women is relatively low, at about 1-1.5 mg/d. 
Iron deficiency (ID) is the most common nutritional deficiency disorder in the world, defined 
as a lack of body iron stores, and usually caused by inadequate absorption and/or excessive 
iron losses. It is the result of an imbalance between iron supply and iron requirements of the 
erythroid bone marrow. The next stage of deficiency is iron deficient erythropoiesis, 
characterised by reduced transferrin saturation. Finally, Hb concentrations fall and 
hypochromic, microcytic anaemia (IDA) is observed; this affects over 1 billion people 
worldwide (WHO 2008). 
 
Measurement of iron status 
There are a number of biomarkers that reflect different aspects of iron metabolism and can 
be used singly or collectively to assess body iron status. An in-depth review of biomarkers of 
iron status is available on the Biomarkers of Nutrition for Development (BOND) website 
(www.nichd.nih.gov/global_nutrition/programs/bond). 
1. Bone marrow grading is the gold standard method of assessing iron deficiency but is 
highly invasive so rarely used. 
2. Serum iron concentration and transferrin saturation indicate the adequacy of the iron 
supply to developing red blood cells. Serum iron is less reliable as it is subject to diurnal 
rhythms and increases after the ingestion of iron-containing foods. A transferrin saturation of 
<15% generally indicates iron deficiency. 
3. Zinc protoporphyrin (ZPP). When there is an inadequate supply of iron, zinc is 
incorporated into the protoporphyrin ring of the haem structure. An elevated ZPP is 
characteristic of iron deficient erythropoiesis. 
4. Soluble serum/plasma transferrin receptor (sTfR). This binds diferric transferrin (Tf) on the 
cell surface. The main source of serum sTfR is bone marrow erythroid precursors (Flowers 
et al 1989). When intracellular iron supply is reduced, cell surface TfR1 expression is up-
regulated in order to acquire more iron, and it is down-regulated when there is sufficient iron. 
An elevated sTfR is a marker of tissue ID and increased bone marrow 
erythropoietic activity. The sTfR concentration increases in parallel with the severity of iron 
depletion and treatment of individuals with IDA results in a progressive fall in sTfR values 
(Skikne et al 1990). 
5. Serum/plasma ferritin concentration correlates closely with body iron stores, and values of 
<12 ug/L indicate depletion of liver iron stores. However it is an acute phase protein and is 
elevated in people with infection or inflammation (see below). In order to identify raised 
ferritin values that do not accurately reflect body iron stores, C-reactive protein (CRP) or 
alpha-acid-glycoprotein (AGP) are determined and if these are above the normal cut-off, 
ferritin concentration is not used as a biomarker of iron status. 
6. Body iron is not a quantitative measure of iron in the body but is a sensitive index that is 
useful for monitoring changes in iron status, for example resulting from interventions. It is the 
ratio of serum transferrin receptor to serum ferritin concentration. It is a relatively new 
epidemiological technique for monitoring iron status in population groups susceptible to iron 
deficiency in which inflammation is uncommon or has been excluded by laboratory 
screening. 
7. Hb concentration is a commonly measured biomarker but is not a specific measure of IDA 
as there are other causes of anaemia e.g. folate and B12 deficiency, and also the anaemia 
of chronic disease. It is not sensitive as the cut-off values and normal ranges vary according 
to sex, age, and ethnicity. Hypochromic microcytic appearance of red cells in blood film 
examination is used by clinician as suggestive of iron deficiency but requires a second 
biomarker (e.g. ferritin) to confirm the diagnosis of IDA. 
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Factors that affect biomarkers of status 
Hb concentration has been reported to decline with advancing age, even in the absence of 
demonstrable disorders. In one report this was calculated to be 0.53 g/L/y in men and 0.05 
g/L/y in women between the ages of 70 and 88 years (Nilsson-Ehle et al 2000) and in 
another the decline was 0.1 g/L/y in men and 0.09 g/L/y in women between the ages of 70 
and 80 years (Milman et al 2008). The decline appears to increase after the age of 80, 
particularly in men. It has been shown that growth hormone and/or insulin-like growth factor-
1 are positively and erythropoietin negatively correlated with Hb in elderly people (Nilsson-
Ehle et al 2005). Erythrocytes released from the bone marrow are less functional and 
partially damaged in aged individuals and as they are less able to protect themselves against 
stress which results in their early sequestration (Gershon & Gershon 1988). 
Differences in Hb concentration and ferritin levels have been noted between ethnicities 
(Patel et al 2007). For example, anaemia is reported to be more common amongst black 
American compared to white American adults. However, there is evidence that the Hb 
distribution curve is shifted towards lower values in blacks (Perry et al 1992) which has led to 
the debate about race-specific criteria for defining anaemia (Beutler & Waalen 2006). Cross-
sectional data from the second National Health and Nutrition Examination Survey show that 
serum ferritin concentrations increase with age until the sixth decade of life at which time 
they reach a plateau (Yip 1994). In a cross-sectional study of 441 men and women aged 60-
93 y, serum ferritin concentration was reported to be positively associated with increasing 
age in women (p=0.0223) but not in men. 
However, in a longitudinal study undertaken in a sub-set of 125 people there was no 
significant change in iron stores over the 10 y monitoring period (Garry et al 2000), 
suggesting that changes in serum ferritin (and iron stores) are not an inevitable consequence 
of ageing. Chronic inflammation, a common condition in older people, alters iron metabolism 
and haematopoiesis and can lead to anaemia (Lee 1983), but it is difficult to determine 
whether or not the cause of anaemia is insufficient iron supply because indices of iron status 
(notably serum iron, ferritin and transferrin) are modified by the inflammatory state. It has 
been observed that malnutrition, not uncommon in the elderly, can exacerbate the effect of 
inflammation on biomarkers of iron status. Nevertheless, it is possible to differentiate 
between pure IDA, anaemia of chronic disease, and anaemia of chronic disease with co-
existing iron deficiency using the sTfR and sTfR/log serum ferritin index (Jain et al 2010; 
Hanif et al 2005). Rimon et al (2002) undertook tests for anaemia in consecutive patients 
admitted to an acute geriatric ward who were older than 80 years. Bone marrow examination 
confirmed IDA in 49 individuals but the routine laboratory tests identified only 8, whereas the 
transferrin receptor-ferritin index identified 35, demonstrating that this is a more sensitive and 
specific method for diagnosing IDA in the elderly when bone marrow aspirates are not 
feasible. Karlsson et al (2010) compared bone marrow iron status with various biomarkers of 
iron status in 50 elderly patients. The sTfR assay correctly identified 87% of iron deficient 
individuals; the specificity was 74%. With ferritin cut-offs of 20 ug/L for men and 7 ug/L for 
women this biomarker was 100% specific for iron deficiency but only 35% sensitive. When a 
ferritin cut-off point of 40 ug/L was used, the specificity fell to 88% but the sensitivity 
increased to 100%. The sTfR-ferritin index with a cut-off point of 3.0 gave a sensitivity of 
100% and specificity of 43%. Acute inflammation is another condition that affects iron 
metabolism. Cunietti et al (2004) monitored changes in biomarkers through an acute 
inflammation episode identified by raised CRP (≥ 30 mg/L) in 39 older hospitalised patients 
(median age 79 years). All haematological indices measured, except for MCV and % 
transferrin saturation, were rapidly disrupted by the acute inflammation and followed differing 
time courses. ZPP and sTfR were not measured. The effects of a short period of 
inflammation. 
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The regular intake of aspirin, a commonly used antiplatelet agent in both primary and 
secondary prevention of cardiovascular diseases, is associated with lower serum ferritin. In 
916 elderly people (aged 67-96 y) participating in the Framingham Heart Study, those who 
took >7 aspirins/week has a significantly lower serum ferritin (p=0.004), and the effect was 
more marked in diseased than healthy subjects (Fleming et al 2001). The authors suggested 
that the effect could be related to increased occult blood loss and possibly a cytokine-
mediated effect on serum ferritin in individuals with inflammation, infection or liver disease. 
Although samples with a CRP >6 mg/L were excluded, it is possible that mild inflammatory 
states were not detected due to the low sensitivity of the CRP assay employed. 
Obesity may complicate the interpretation of biomarkers of iron status. The observed 
hypoferraemia of obesity may be due to both true iron deficiency and inflammatory mediated 
functional iron deficiency. For example, in a cross-sectional study examining the iron status 
of 234 obese adults compared with 172 non-obese adults attending an outpatient clinic, the 
obese patients had a higher prevalence of iron deficiency defined by sTfR and serum iron 
but not by ferritin (Yanoff et al 2007). An increase in sTfR was reported to be associated with 
central obesity in men with hyperferritinemia (Freixenet et al 2009). Tussing-Humphreys et al 
(2010) measured serum hepcidin in obese premenopausal women to investigate the reason 
for iron depletion in obesity. They proposed that hepcidin was expressed in response to 
inflammation rather than changes in iron status, and concluded that the iron deficiency of 
obesity is true body iron deficit caused by a reduction in iron absorption rather than 
maldistribution of iron due to inflammation. If this is confirmed, sTfR may serve as an 
accurate biomarker of iron status in obese and overweight individuals. 
 
Dietary intake 
Good food sources of iron include meat and meat products which contain haem iron, 
especially red meat and offal and also dark poultry meat; oily fish such as tuna and sardines; 
cereal products such as fortified breakfast cereals; eggs; pulses; and dark green vegetables. 
Vegetarians avoid meat so do not consume any haem iron unless they eat fish; their main 
sources of iron are fortified cereals, soybeans, tofu, lentils, kidney beans, chickpeas, baked 
beans, dark green vegetables. Bread, potatoes and dried fruit are also a useful source of 
iron. In elderly people, obtaining an adequate supply of iron may be a challenge due to 
impaired absorption, reduced food intake associated with lower physical activity, and 
changes in dietary patterns that result in a more limited diet. 
There are special challenges associated with collecting dietary information from elderly 
people, including fading memory and poor eyesight. A systematic review (Ortiz-Andrellucchi 
et al 2009) selected 33 papers and categorised the studies into short-term (<7 day) or long-
term (>7 day) intakes. The quality of each validation study was assessed using a scoring 
system, which provides a measure of accuracy of the method, and hence give some 
confidence to the evaluation that was undertaken. 
The correlations between the different methods are summarised below, where very good is 
>0.70, good is 0.51-0.70, and acceptable is 0.30-0.50. It should be noted that the degree of 
correlation is dependent on the accuracy of the two methods being assessed 
 FFQ vs. diet history: very good 
 FFQ vs. weighed record: good 
 Diet history vs. estimated record: good 
 Diet history vs. weighed record: good 
 FFQ vs. 24-h recall: acceptable 
 Videotaped assessment vs. 24-h recall: acceptable 
Declining short-term memory makes the 24-hour recall method less appropriate for this age 
group. Diet history is a good method but extended diet history interviews should be avoided 
in the very old as they can take an excessively long time and concentration levels may fall. 
Instead these should be replaced with modified (shorter) questionnaires. Similarly, FFQs 
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with a large number of items should be refined to reduce the number of foods. The 
relationship between iron intake and iron status is complicated by variations in the efficiency 
of iron absorption, but a systematic review of randomised clinical trials show a positive time-
dependent association between iron intake from supplemental iron and serum ferritin 
(Casgrain et al 2012). 
In the Framingham Heart Study, cross-sectional data of recognised modifiers of iron 
bioavailability were analysed in 1,401 elderly men and women aged 67-95 y and positive 
associations with serum ferritin were observed for haem iron, supplemental iron, vitamin C 
and alcohol, whereas coffee intake had a negative association (Fleming et al 1998). A study 
in 358 elderly Danish men and women evaluating iron status and its relationship with diet 
and supplement use (Milman et al 2004) reported a positive correlation between serum 
ferritin and intakes of dietary iron (p=0.03), meat (p=0.013), alcohol (p<0.001), and BMI (in 
men only, p=0.025), and a negative correlation with tea consumption (p=0.017), but no 
association between supplement use and iron status. Although individual dietary enhancers 
and inhibitors identified from single meal absorption studies (Hurrell & Egli 2010) may have a 
significant impact on iron absorption and hence status, it is more important to use data on 
iron absorption from whole diets to predict iron status (Collings et al, AJCN, accepted). 
 
Anaemia in the elderly 
In the US, it has been estimated that approximately 11% of men and 10% of women aged 65 
and above are anaemic, and that these figures double at the age of 85, with prevalence 
rates reaching 50-60% in residential/nursing homes (Price et al 2011). Although one of the 
conclusions from the Framingham Heart Study, initiated in 1948- 1950, with a cohort of 
~6000 adults living in Framingham MA, was that free-living elderly white American eating a 
Western diet are more likely to have high iron stores, not iron deficiency (Fleming et al 
2001a), iron supplement use and high intakes of vitamin C and red meat were shown to be 
important determinants of iron status. The English Longitudinal Study of Ageing, a 
prospective study of 3,816 community dwelling men and women (mean age 65.4 ± 9.0 y), 
reported that 5.2% were anaemic, and these individuals were older, less likely to drink 
alcohol, had a higher prevalence of morbidity, higher CRP (indicating anaemia of chronic 
disease) and demonstrated poorer performance on cognitive and physical function tests 
(Hamer & Molloy 2009). 
Large epidemiological studies report that in 30% of older people with anaemia the aetiology 
is unknown and the patient is diagnosed as having ‘unexplained anaemia of aging’ (Guralnik 
et al 2004). An investigation into reasons for anaemia in 190 patients aged 65 and over 
recruited from a haematology clinic, reported that 12% had IDA, and half of these individuals 
normalised Hb in response to therapeutic iron (Price et al 
2011).The ones who did not respond had malignancies (12%), renal disease (4%), or 
unexplained anaemia (35%). The latter had significantly higher inflammatory markers 
(hepcidin and ferritin, but not IL-6) than the non-anaemic controls. 
 
Causes of IDA 
Anaemia in the elderly may be caused by a number of individual or combined factors, 
including poor diet, reduced efficiency of iron absorption, occult blood loss, medications, and 
chronic disease (Lopez-Contreras et al 2010). Results from crosssectional studies 
measuring the prevalence of ID and IDA in elderly people are therefore very variable. 
Annibale et al (2001) examined 668 outpatients with IDA, aged 21-94 y, and were able to 
identify the underlying reason for anaemia in 85% of patients. Diseases associated with 
bleeding were found in 37%, including colon cancer, gastric cancer, peptic ulcer,hiatus 
hernia with linear erosions, colonic vascular ectasia, colonic polyps and Crohn’s disease. 
Causes not associated with bleeding were found in 51%, including atrophic gastritis, celiac 
disease, and H. pylori. The authors concluded that gastrointestinal diseases not associated 
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with bleeding are frequently associated with IDA in patients without gastrointestinal 
symptoms or other potential causes of gastrointestinal bleeding. The diseases observed in 
older patients were hiatus hernia, gastric cancer, colon cancer, and colonic vascular ectasia. 
Helicobacter pylori infection has been implicated as a risk factor for iron deficiency, but this 
may be a strain-related effect (Yokata et al 2012). A study in 220 Australian men and women 
aged 65 years or older reported no difference in median serum ferritin concentrations (or Hb) 
between H. pylori infected and uninfected individuals but serum ferritin concentrations were 
significantly lower in infected women who took low-dose aspirin (p-0.04) (Kaffes et al 2003). 
The authors conclude that it may the combination of H. pylori infection and use of low-dose 
aspirin that impact on iron stores. 
Institutionalisation is another known risk factor. In 252 institutionalised elderly Spanish men 
and women, aged 65-96 years, 4-day weighed food records were collected and iron status 
measured (Lopez-Contreras et al 2010). The prevalence of anaemia was 25.4% using a Hb 
cut-off of <130 g/L for men and <120 g/L for women (WHO 2001), but only 3.6% had serum 
ferritin below the cut-off of 15 ug/L. There was a high prevalence of inflammation/infection as 
illustrated by the fact that 41% of individuals had raised CRP values (>5 mg/L), and there 
was a significant correlation between CRP and ferritin (p=0.023) but not with Hb. Diet was 
not one of the principal causes of anaemia in their study, except for folate intake, but it 
appears that infection/inflammation was a key component. In another study in Spain 
(Vaquero et al 2004) in which elderly people living in retirement homes were consuming an 
Atlantic-Mediterranean diet (rich in meat products, fish, vegetables, fruit, olive oil and dairy 
products, but poor in cereals), the prevalence of anaemia was only 6.7%, but there were no 
measurements of infection/inflammation. 
 
Consequences of iron deficiency 
Anaemia is associated with numerous health implications, including a decline in physical 
performance, cognitive impairment, increased susceptibility to falling, frailty, and mortality 
(reviewed by Price et al 2011). 
A study in 1,156 community-dwelling Italian people aged 65 years and older showed a clear 
association between anaemia and disability, poorer physical performance and lower muscle 
strength (Penninx et al 2004) but there is no proof of causality in crosssectional 
epidemiological studies. In a 4-year prospective study in men (~30%) and women (~70%) 
aged 71 y and older (Penninx et al 2003) various physical performance tests were 
undertaken at baseline and after 4 y and the individuals classified for anaemia using Hb and 
MCV values. The number of volunteers who undertook both sets of tests was 1, 146. At 
baseline 5.9% had anaemia (Hb<130 g/L men, <120g g/L women), and 15% had borderline 
anaemia (Hb 130-140 g/L men, 120-130 g/L women). Those with anaemia were older and 
performed significantly worse on the baseline physical performance battery. There was a 
predicted fall in the physical performance score (p for trend 0.002), which was most marked 
in the anaemic group (p=0.003) followed by the borderline anaemic group (p=0.02). The 
results of this study suggest that anaemia in old age is an independent risk factor for decline 
in physical performance. 
The association between serum iron status, cardiovascular disease and all-cause mortality 
was examined in 336 elderly Taiwanese men and women (aged >65 y) living in long-term 
care facilities (Hsu et al 2013). The degree of iron deficiency was defined according to serum 
iron, but it should be noted that serum iron is affected by inflammation, as commonly present 
in cardiovascular disease, and it is not a good 1 measure of iron deficiency. Although there 
was a positive association between low serum iron, cardiovascular disease and all-cause 
mortality, causality cannot be inferred. The authors propose several mechanisms for the link 
between iron deficiency and cardiovascular disease. Firstly, iron deficiency is associated 
with cancer, renal failure and chronic inflammation, which are generally accompanied by 
higher mortality; an iron deficient state may reflect undiagnosed conditions. Secondly, iron 
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deficiency may be a surrogate marker for malnutrition, for which there is a link with mortality. 
Thirdly, iron deficiency may promote oxidative damage, for example, as illustrated by 
elevated serum malonyldialdehyde production in iron deficiency anemia (Coghetto Baccin et 
al 2009). Mørkedal et al (2011) assessed sex-specific associations of iron status with 
ischaemic heart disease (IHD) mortality in a prospective study of 640,798 healthy Norwegian 
adults. Low iron status, particularly in the early stages of follow-up, was associated with 
increased risk of death from IHD, but the limited range of biomarkers of iron status (serum 
iron, transferrin saturation, and total iron binding capacity) were measured in non-fasting 
blood samples, and it is possible that low iron status was a late sign in the pathogenesis of 
IHD or that underlying disease influenced the results. A smaller prospective study was 
undertaken in Finland in which 361 men and 394 women aged 65-99 years were followed for 
up to 10 years (Marniemi et al 2005), Individuals in the highest tertile for baseline serum iron 
had a reduced risk of acute myocardial infarction (AMI) (RR 0.544, 95% CI 0.35, 0.88) and 
those in the middle tertile had a reduced risk of stroke (RR 0.474, 95% CI 0.25, 0.89). There 
was an increased risk of stroke in those in the highest tertile of serum transferrin (RR 1.67, 
95% CI 1.07, 2.61), but no effect of blood Hb on either AMI or stroke. When the relationship 
with serum iron was analysed taking into account additional coronary heart disease risk 
factors the RR of AMI and stroke were still significant (p=0.016 and 0.047 respectively). In 
contrast, however, when the relationship between nutritional status and all-cause mortality 
was investigated in a prospective study of 405 community-dwelling Scottish men and women 
aged 75 y and older, no association was found between iron status and mortality (Jia et al 
2007). Racial variation in the relationship of anaemia with mortality and mobility disability 
among older adults has been observed. In a group of 1,018 black and 1,583 white US adults, 
aged 71-82 years, anaemia was associated with higher mortality in white but not black 
people. Anaemia was significantly associated with increased risk of death and mobility 
disability in community-dwelling older whites, whereas older blacks were not at risk of 
adverse events. The authors suggest that the criteria for defining anaemia may need revising 
(Patel et al 2007). 
A cross-sectional study in 1,875 men and women aged 65 y and older (enrolled in the 2005 
Health Survey for England) was undertaken to examine the relationship between iron status 
(defined according to biochemical criteria) and symptoms of depression (Stewart & Hirani 
2012). Anemia (Hb <130 g/L in men, <120 g/L in women) was present in 10.8% of 1,833 
samples analysed, low ferritin (< 45 ug/L) in 21.6% of 1,851 samples analysed, moderately 
raised sTfR (>2.3 g/L) was present in 7.6% of the 
1,875 samples analysed. Depressive symptoms were significantly higher in participants with 
anaemia, low ferritin and high sTfR, after adjustment for age, sex, social class, multivitamin 
intake, smoking status and BMI, but the association was reduced substantially after further 
adjustment for physical health status (chronic illness). There was a significant association 
between higher number of depressive symptoms and lower Hb and higher sTfR but not with 
ferritin, which suggests that the association with anaemia is accounted for by physical health 
status and thus may primarily reflect anaemia of chronic disease. Onder et al (2005) also 
found an association between anaemia and depression in 986 older adults from the 
InCHIANTI study, a prospective population-based study of community-dwelling men and 
women (mean age 75 y). Anaemia was present in 15% of the participants with depression 
and in 8% of the participants without depression (p<0.001), and the risk of anaemia 
progressively and significantly increased with severity of depression. 
 
Adverse effects of iron 
Concern has been expressed about potential adverse effects of moderately elevated iron 
stores in middle-aged and older people in that they may be associated with increased risk of 
several chronic diseases, such as heart disease, cancer and type 2 diabetes mellitus. 
Increased tissue iron stores have been implicated in risk of diabetes mellitus and decrease in 
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insulin sensitivity, but the mechanism is uncertain (Sung et al 2012). Iron has well-described 
pro-oxidant effects in vitro, and may have proinflammatory effects. For example, Sung et al 
(2012) reported that in 12,033 Korean men (mean age 41.2 y in the group with no coronary 
artery calcium and 47.7 y in those with coronary artery calcium) ferritin was independently 
associated with the presence of coronary artery calcium, a biomarker of preclinical 
atherosclerosis. Those in the highest quartile for ferritin (>257 ug/L) had a higher score for 
coronary artery calcium than the lowest quartile (<128 ug/L). However, the relationship with 
transferrin saturation was weaker, suggesting that there may be another contributory factor, 
unrelated to high iron status, e.g. inflammation or metabolic stress. 
The explanation for the presence of high iron stores was sought in a study of 614 elderly 
Americans participating in the Framingham Heart Study. After excluding individuals with 
raised CRP (>6 mg/L, n=45), infection (diagnosed from white blood cell count, n=40) and 
other confounding factors (n=69), 11.4% of the remaining 460 participants were reported to 
have elevated iron stores (serum ferritin >300 ug/L in men, and >200 ug/L in women). 
Dietary factors associated with high iron stores included use of iron supplements (≥30 mg/d), 
>3 servings of fruit or fruit juice/d, and >4 servings of red meat/week. High intakes of 
wholegrain (>7 servings/week) were inversely associated with risk of having high iron stores 
(Fleming et al 2002). Three prospective studies reported an association between moderately 
elevated serum ferritin concentration (>200 ug/L) and risk of acute myocardial infarction 
(Salonen et al 1992, Tuomainen et al 1998, Klipstein-Grobusch et al 1999), but the 
association was not observed in other prospective studies (Manttari et al 1994, Frey et al 
1994, Magnusson et al 1994). Furthermore, in a matched, nested case-control study (252 
cases and 499 controls) drawn from the Copenhagen City Heart Study and the Copenhagen 
General Population Study, markers of iron overload (high serum iron and transferrin 
saturation) were associated with reduced risk of a near-term (4 years onset) myocardial 
infarction; conversely there was an association between low serum iron and transferrin 
saturation and increased risk of a near-term myocardial infarction in this apparently healthy 
population (Nordestgaard et al 2010). 
A few early epidemiological studies indicated a weak positive association between very high 
body iron levels and risk of cancer e.g. colorectal cancer (Knedt et al 1994), possibly related 
to free radical tissue damage caused by iron released from degradation of tissue ferritin. The 
UK Scientific Advisory Committee on Nutrition has concluded that there are insufficient data 
to reach a clear conclusion about high iron levels and risk of cancer (Scientific Advisory 
Committee on Nutrition 2010). There may, however, be an interaction between high body 
iron levels and lipids (either high VLDL-cholesterol or low HDL-cholesterol) that promotes 
oxidative stress (Mainous 3rd et al 2005). There is emerging evidence to suggest that 
luminal iron in the gut may be pro-inflammatory and iron supplements given to treat IDA, 
common in irritable bowel disease and other gut disorders associated with faecal blood loss, 
may exacerbate the inflammatory processes by stimulating the production of reactive oxygen 
species and inflammatory cytokines (Weiss 2011). The form of iron appears to be important, 
for example chelated forms of iron are better tolerated than ferrous sulphate, presumably 
because it generates a lower concentration of soluble iron in the lumen (Liquori 1993). In 
healthy individuals brain iron levels increase with age (Bartzokis et al 1994) and abnormally 
high brain iron levels are observed in age-related degenerative diseases. For example, in 
Alzheimer’s Disease hippocampal iron is increased beyond levels of non-demented controls 
(Pankhurst et al 2008). The hippocampus is the key region in memory function that is 
severely affected in ageing and dementing disorders. 
Although there is no proof of a causal relationship, the fact that elevated levels have been 
observed in preclinical disease (Smith et al 2010) has generated the hypothesis that an 
accelerated trajectory of brain iron accumulation, and the associated oxidative damage, may 
occur during the transition from healthy ageing to dementia. Bartzokis et al (2011) measured 
hippocampal iron in healthy older people (aged 55 to 76 y) of mixed racial origin and found 
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that in men, but not women, there was a significant decrease in memory function with 
increase hippocampal ferritin iron (p=0.003), and independent of gender, worse verbal 
working memory performance was associated with higher basal ganglia iron (p=0.005) in 
individuals without the H63D and TfC2 gene variants. The authors suggest a combination of 
genetic and MTI biomarkers may be useful for identifying high risk groups for primary 
prevention clinical trials. 
 
 
Iron requirements in the elderly 
Although physiological iron requirements do not differ between adult and elderly men and 
post-menopausal and elderly women there is growing evidence that iron metabolism is 
affected by the ageing process. Chronic low-grade inflammation leads to less efficient 
absorption through hepcidin regulation. Identifying iron deficiency becomes more of a 
problem because of age-related changes in Hb, effects of medication prescribed for age-
related disorders and diseases, and increased ferritin concentrations associated with 
inflammatory states. The sTfR-ferritin index appears to be the most useful method for 
detecting iron deficiency in older people. There is sufficient evidence linking iron deficiency 
with adverse health effects to justify correcting it through diet or iron therapy, but at the same 
time it is important to ensure that the risk of high body iron stores is not increased as this 
may have detrimental effects on the brain. 
 
Future work 
One of the most challenging problems with studies of iron metabolism in older people is 
measuring iron status in the presence of inflammatory conditions, such as obesity and age-
related chronic and degenerative diseases. Therefore the development of improved 
biomarkers of iron status must be given high priority. This would enable the relationships 
between anaemia and iron deficiency and chronic diseases to be characterised more 
accurately and causality clarified, and would also facilitate research on the potential links 
between iron and dementia. There is still some uncertainty about iron requirements in the 
elderly, confounded by effects of inflammation on iron status, which better biomarkers would 
help address. Finally, there is virtually no information about how ageing of the GI tract affects 
iron absorption, and this is urgently required for calculating average requirements for iron 
(using the factorial method) to derive dietary reference values and develop dietary 
recommendations for elderly populations. 
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Abstract 
This is the first published report examining the combined effect of diet and genotype on body 
iron content using a classical twin study design. The aim of this study was to determine the 
relative contribution of genetic and environmental factors in determining iron status. The 
population was comprised of 200 BMI- and age-matched pairs of MZ and DZ healthy twins, 
characterised for habitual diet and 15 iron-related candidate genetic markers. Variance 
components analysis demonstrated that the heritability of serum ferritin (SF) and soluble 
transferrin receptor was 44% and 54% respectively. Measured single nucleotide 
polymorphisms explained 5% and selected dietary factors 6% of the variance in iron status; 
there was a negative association between calcium intake and body iron (p=0.02) and SF 
(p=0.04).  
 
Introduction 
Levels of iron in the body are tightly regulated through changes in the efficiency of 
absorption to ensure sufficient iron is available for vital functions but at the same time to 
avoid the accumulation of excessive iron. It is well established that genetics plays a 
significant role in iron overload, the most common example being hereditary 
hemochromatosis which, in spite of its low penetrance, is attributable to mutations in the 
hemochromatosis gene, HFE (Feder et al 1996), but the detailed role of genetics in 
determining body iron status remains largely unexplained. Iron absorption is also dependent 
on dietary composition as a number of food constituents render luminal iron more or less 
available for duodenal uptake by the iron transport protein, DMT1 (Hurrell & Egli 2010). 
Estimates of the relative contribution of diet and genotype to iron status vary widely 
according to data from different studies, but they have not yet been studied simultaneously in 
the same population group. The aim of the present study was to assess the role of dietary 
and genetic factors in determining iron levels using a classical twin study design, and to 
quantify the relative contribution of each by including specific nutritional factors and 
candidate genes.  
Materials and methods 
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A sample of 100 MZ and 100 DZ female healthy twin pairs was selected from a group of 
around 3,500 twins enlisted in the TwinsUK registry. The key inclusion criteria were data on 
body mass index (BMI), dietary intake and genotype, together with a serum blood sample. 
The sample size was chosen to provide power of 90% and type-I error rate of 0.05 (Visscher, 
2004) in detecting a heritability of approximately 30%. The sample was selected at random 
but weighted in favour of premenopausal twins as their iron requirements are higher and 
hence they are more sensitive to environmental modulators. MZ and DZ pairs were also age- 
and BMI-matched in the selection process to achieve balance between the zygosity groups. 
All participants gave written, informed consent, and the Guy’s and St Thomas’ Hospital 
ethics committee approved the study (REC ref. EC04/015).  
Dietary information was collected from a validated 131-item food frequency questionnaire 
(FFQ), previously developed for the European Prospective Investigation into Cancer and 
Nutrition Study (Bingham SA et al, 2001), from which nutrient intakes were determined using 
an established database (Teucher et al, 2007). Individuals completed questionnaires that 
included information on menopausal history. Intakes of dietary constituents that might 
influence iron status, by modifying the quantity of iron absorbed, were calculated: iron, 
calcium, dietary fibre (non-starch polysaccharide), vitamin C, and frequency of red meat 
(beef, pork, lamb) intake. 
Blood samples were collected at approximately the same time as the FFQ and other 
questionnaires and stored at -80ºC. As part of other on-going research, some of the samples 
had been analysed for C-reactive protein, (data shown in Table 1). Analysis of serum ferritin 
(SF) and soluble transferrin receptor (sTfR) were performed using enzyme immunoassays 
(Spectro ferritin and TfR respectively, Ramco USA). Two additional standards (10ng and 
100ng) were included in addition to the standards provided in the SF kit to increase the 
assay accuracy. A WHO reference reagent (recombinant soluble transferrin receptor, NIBSC 
code: 07/202) was run in duplicate on every sTfR plate at 30μg and 90μg/L to standardise 
the immunoassay (average CV 5.7%). The sTfR value was calculated from the WHO 
conversion (Thorpe et al, 2009). Duplicates were analysed in 30% of SF samples (average 
CV 6.5%) and in 20% of sTfR samples (average CV 5.2%). Body iron, widely accepted as a 
good measure of iron status, was calculated from the sTfR/log SF index (Cook et al, 2003). 
Single nucleotide polymorphisms (SNPs) selected for this analysis were from genes known 
to be involved in iron metabolism (http://www.micronutrientgenomics.org/index.php/Iron). 
The list was filtered to include only SNPs with a minor allele frequency (MAF) >5%. The 
pairwise linkage disequilibrium was examined and where r
2
 >0.2, the SNP with the greater 
MAF was retained. A total of 15 iron related SNPs were included in the analysis. 
The twin model partitions variance in a trait into genetic and environmental components. The 
contribution of genetic and environmental factors was assessed through variance component 
analysis implemented in SOLAR v4 (Almasy & Blangero 1998). The quantitative age- and 
BMI-adjusted phenotype (y) was modelled as a linear function of a polygenetic genetic effect 
(g) and a random environmental component (e) (Model 1). This was extended to examine 
the influence of 5 individual nutrients (Model 2), and the 15 candidate SNPs (Model 3) 
Model 1:         
Model 2:                   
Model 3:                  
SOLAR models the covariance among phenotype values  ) using the kinship coefficient 
matrix (   derived from the family structure,       
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where   
  and   
 are the variances of the polygenic and environmental effects and I is the 
identity matrix. The trait heritability was estimated from   
  
 
  
    
  in Model 1. The significance of 
individual covariates was assessed by examining the change in model likelihood after the 
covariates were omitted. Measures of genotypic association were tested under an additive 
model. 
To account for multiple testing, the Benjamini-Hochberg adjustment was applied to p values 
using the p.adjust function in R, assuming a 10% false discovery rate. The proportional 
contribution of measured nutritional factors and measured SNPs to overall variance was 
estimated from the variance of            and          in Models 2 and 3 respectively. 
 
Results and discussion 
Phenotypic data for the twins and the SF and TfR concentrations are shown in Table 1. 
There were no significant differences between MZ and DZ twins for any of the measured 
variables, including factors that might affect iron metabolism such as smoking status 
(assessed in all individuals) and C-reactive protein, a measure of inflammatory status 
(measured in some of the twins). Parity was similar in MZ and DZ twins, with an average of 
1.6 pregnancies. Iron supplements were reported to have been used by only 5 MZ and 4 DZ 
individual twins, all of whom were premenopausal, and had SF concentrations that were 
below the overall mean (mean 39.2μg/L). These individuals were retained in the analysis. SF 
concentrations <12μg/L (depleted iron stores) were present in 18% of the total sample; the 
proportion was similar in MZ and DZ groups. However, none of the twins had been clinically 
diagnosed as iron deficient. 
The heritability of iron status (Model 1) was calculated to be 46 (95% CI 28, 65)% for SF, 54 
(95% CI 40, 67)% for sTfR, and 44 (95% CI 26, 61)% for body iron.  
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Table 1. Characteristics of the twins. Values are means ± SD (min, max) 
 All MZ twins DZ twins 
No of individuals 400 200 200 
Post-menopausal 
(%) 
64 (16) 32 (16) 32 (16) 
Age (y)  43.3  (25.6, 69.8) 44.6  (25.6, 69.5) 45.1 (30.5, 
69.8) 
BMI (kg/m
2
)
 
 24.9 ± 24.8 
(16.5, 44.4) 
24.8 ± 4.6 
(17, 44.4) 
24.9 ± 5.2 
(16.5, 43. 5) 
Smoking status: 
Never (%) 
Former (%) 
Current (%) 
 
249 (62.3) 
107 (26.8) 
  44 (11.0) 
 
136 (68.0) 
  45 (22.5) 
   19  (9.5) 
 
113 (56.5) 
  62 (31.0) 
  25 (12.5) 
C-reactive protein 
(mg/l)  
(n=136 MZ, 140 
DZ) 
2.83 ± 4.37 
(0.16, 34) 
2.34 ± 2.93 
(0.16, 20.9) 
3.31 ± 5.39 
(0.16, 34.0) 
Dietary calcium 
(mg/day) 
1074 ± 328 
(232, 2119) 
1070 ± 324 
(232, 2010) 
1078 ± 333 
(232, 2119) 
Dietary fibre 
(g/day)  
19.1 ± 7.1 
(5.3, 51.0) 
19.3 ± 6.9 
(5.3, 51.0) 
18.9 ± 7.2 
(5.4, 50.5) 
Dietary vitamin C 
(mg/day)  
154.9 ± 77.9 
(31.0, 561) 
160.4 ± 77.1 
(41.2, 515) 
149.4 ± 78.5 
(31.0, 561) 
Meat consumption 
(times/week)  
2 ± 1.72 
(0, 11.5) 
1.9 ± 1.5 
(0, 8.75) 
2.2 ± 1.9 
(0, 11.5) 
 
The overall contribution of the selected dietary factors to variance in iron status was 6% 
(Model 2). There was a negative association between calcium intake and body iron 
(p=0.004) and SF (p=0.008) which remained significant (p=0.02 and 0.04 respectively) after 
taking multiple testing into account.  The contribution of the 15 SNPs examined to variance 
in iron status was 5% (Model 3). Three were significant for one or more measures of iron 
status (rs960748 CYBRD1, rs9366637 HFE, rs4434553 TFR2) (Table 2) although none 
remained significant after taking into account multiple testing. 
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Table 2. Contribution from SNPs to body iron, serum ferritin (SF) and soluble transferrin 
receptor (sTfR): *unadjusted p values  
SNP Gene Gene name Body iron SF sTfR 
rs960748 CYBRD1 cytochrome b 
reductase 1 
0.008 0.079 0.168 
rs2304704 SLC40A1 solute carrier family 
40 (iron-regulated 
transporter), 
0.783 0.566 0.623 
rs8177190 TF transferrin 0.565 0.558 0.294 
rs1799852 TF transferrin 0.420 0.174 0.228 
rs3811647 TF transferrin 0.990 0.753 0.237 
rs1049296 TF transferrin 0.805 0.796 0.466 
rs1115219 TF transferrin 0.367 0.948 0.424 
rs3817672 TFRC transferrin receptor 
(p90, CD71) 
0.892 0.949 0.105 
rs9366637 HFE human 
hemochromatosis 
protein  
0.063 0.028 0.516 
rs1572982 HFE human 
hemochromatosis 
protein  
0.281 0.167 0.115 
rs4727457 TFR2 transferrin receptor 
protein 2 
0.627 0.191 0.863 
rs4434553 TFR2 transferrin receptor 
protein 2 
0.465 0.945 0.034 
rs829021 SLC11A2 solute carrier family 
11 (proton-coupled 
divalent metal ion 
transporters), 
member 2 
0.093 0.613 0.154 
rs149411 SLC11A2 solute carrier family 
11 (proton-coupled 
divalent metal ion 
transporters), 
member 2 
0.718 0.686 0.976 
rs7251432 HAMP hepcidin antimicrobial 
peptide 
0.507 0.927 0.174 
*Adjusted p values were all >0.05 
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This is the first published report examining the combined effect of diet and genotype on body 
iron content using a classical twin study design. The results demonstrate that there is a 
substantial genetic contribution to iron status, which agrees with Whitfield et al (2000) who 
reported that 47% of the variance in SF in twins was explained by additive genetic factors. 
However, in their study sTfR was not measured, therefore body iron could not be calculated, 
nor was there any assessment of the dietary impact on iron stores. 
Our study provides evidence to support a contribution for genes known to be involved in iron 
metabolism. In particular, three (rs960748 CYBRD1, rs9366637 HFE, rs4434553 TFR2) are 
worthy of further investigation. These genes have also emerged in other studies. In a multi-
ethnic population of iron-deficient and normal iron status adults SNPs in the TR and HFE 
genes were identified that were associated with at least one iron phenotypic measure 
(McLaren et al, 2011). In a Genome Wide Association Study (GWAS) in MZ twins and their 
siblings 40% of the genetic variation in serum transferrin concentration was explained by a 
combination of three SNPs in the transferrin (TF) gene and the HFE C282Y mutation, but the 
proportion of phenotypic variance in SF and other measures of iron status could not be 
explained by SNPs other than C282Y (Benyamin et al, 2009). In a meta-analysis of 5 GWAS 
Oexle et al (2011) found that sTfR concentration was associated with HFE and TMPRSS6 
genes and the PCSK7 locus. The involvement of these genes suggests that they might have 
a role in screening for susceptibility to iron deficiency. However, a substantial proportion of 
genetic variation remains unexplained, justifying the pursuit of more detailed genetic analysis 
in large scale genome wide studies.  
Among the potential environmental factors influencing iron status, this study identified 
calcium as being negatively associated with iron status, which agrees with its reported 
inhibitory effect on iron absorption in single meal studies, for example, Minihane & 
Fairweather-Tait (1998). Data from calcium supplementation studies are inconsistent 
(Lonnerdal, 2010), and there are conflicting reports about the threshold dose of calcium that 
affects absorption from a 5 mg dose of iron, ranging from as low as 165 mg (Hallberg et al 
1991) up to 800 mg (Gaitán et al 2011). One of the proposed mechanisms of action for the 
acute effect of calcium is that it internalises DMT1, thereby limiting iron transport across the 
apical membrane of the mucosal cell (Thompson et al, 2010). It could be argued that the 
consequence of this would be a compensatory increase in DMT1 expression when the cells 
are next exposed to digestive chyme, but the degree to which this is achievable is dependent 
on the dietary supply of available iron. It was notable that the selected dietary factors 
accounted for only 6% of the overall variation in iron status in this group. This may in part be 
a reflection of the relatively narrow range of dietary intakes in this group of healthy female 
twins. Nevertheless, as they are typical of the adult UK population, our findings suggest that 
modifications in a Western diet are not required to maintain iron status, with the possible 
exception of calcium intakes in individuals at high risk of iron deficiency, although it is 
possible that calcium intake in the twins was a proxy measure of differences in dietary 
patterns and/or intakes of other dietary modulators of iron absorption.  
Whitfield et al (2003) reported that the combined effect of age, menopausal status and 
magnitude of blood loss accounted for up to 18% of the variance in SF, and Harvey et al 
(2005) found that menstrual loss accounted for 11.5% in the variance in SF. They reported 
that diet was responsible for a further 6.7%, a figure that agrees well with our estimate of 
6%. Our analysis took age into account but we could not examine the effect of menstrual 
blood loss, although this is known to have a high degree of heritability (Rybo & Hallberg, 
1966). It is also conceivable that interactions between diet and genes might account for part 
of the unexplained variation. However, gene environment interactions cannot be addressed 
in these data and would require a substantially larger sample size.  
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The results of our study quantify heritability of iron status using the most appropriate 
measures of body iron. With the classical twin study design we have been able to gain a 
unique insight into the effect of environmental factors and genotype on iron status, and 
demonstrated that they make an approximately equal contribution.  
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Abstract: Background: Zinc deficiency is often associated with nutritional iron deficiency 
(ID), and may be exacerbated by low selenium status. Aim: To investigate risk of iron and 
zinc deficiency in women with contrasting selenium status. 
Methods: In a cross-sectional study, 1-day diet composites and blood samples were 
collected from self-selected Malawian women aged 18−50 y from low (Zombwe) (n=60) and 
high-plant-available soil selenium (Mikalango) (n=60) districts. Diets were analyzed for trace 
elements and blood for biomarkers. Results: Zinc deficiency (>90%) was greater than ID 
anemia (6%), or ID (5%), attributed to diets low in zinc (median 5.7 mg/d) with high 
phytate:zinc molar ratios (20.0), but high in iron (21.0 mg/d) from soil contaminant iron. 
Zombwe compared to Mikalango women had lower (p<0.05) intakes of selenium (6.5 vs. 
55.3 µg/d), zinc (4.8 vs. 6.4 mg/d), iron (16.6 vs. 29.6 mg/d), lower plasma selenium (0.72 
vs. 1.60 µmol/L), higher body iron (5.3 vs.3.8 mg/kg), although plasma zinc was similar (8.60 
vs. 8.87 µmol/L). Body iron and plasma zinc were positive determinants of hemoglobin. 
Conclusion: Risk of zinc deficiency was higher than ID and not shown to be associated with 
selenium status. Plasma zinc was almost as important as body iron as a hemoglobin 
determinant.  
 
Introduction 
Iron deficiency is recognized as the most common micronutrient deficiency in low income 
countries. Women of child bearing age are especially at risk because pregnancy entails a 
high demand for iron. A major factor contributing to iron deficiency in these settings is 
inadequate intakes of bioavailable iron. Such deficits arise because diets are predominately 
plant-based, and intakes of readily available heme iron from flesh foods are generally low. 
These dietary patterns are also likely to be inadequate in absorbable zinc because zinc and 
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iron have a similar distribution in the food supply and are affected by many of the same 
dietary absorption modifiers [1]. Indeed, low iron stores have been identified as a risk factor 
for suboptimal zinc status [2]. Furthermore, a compromised zinc status may have a negative 
impact on hemoglobin concentrations, independent of iron status, as has been reported 
previously among pregnant women in Ethiopia [3]. Deficiencies of iron and zinc can have 
numerous adverse effects on women’s health, including impairments in physical work 
capacity [4], cognitive function [5], poor pregnancy outcomes [6,7], and increased risk of 
morbidity and mortality [8]. 
  
An additional factor with the potential to compromise the zinc status of Malawian women is a 
low selenium status. Our earlier cross-sectional study reported low levels of selenium in the 
diets and plasma of rural Malawian women living in a region where plant-available selenium 
content of soils and concentrations in staple foods are low [9]. There is accumulating 
evidence that selenium interacts with zinc by several mechanisms [10-12]. Therefore in this 
study, we have determined the risk of zinc deficiency in two groups of rural Malawian women 
of child-bearing age living in district with contrasting plant-available selenium concentrations 
in the soil. We used two recommended indicators for assessing population zinc status: the 
prevalence of inadequate zinc intakes and low plasma zinc concentrations [13]. In addition, 
we have examined the risk of iron deficiency in these women, using hemoglobin, mean cell 
volume, and total body iron calculated from plasma ferritin and soluble transferrin receptor in 
an effort to provide a more accurate reflection of the prevalence and severity of nutritional 
iron deficiency among these rural Malawian women. We also explored possible determinants 
of plasma ferritin, total body iron, hemoglobin, and plasma zinc. 
 
Subjects and Methods 
Study site and subjects. 
The women were a convenience sample recruited in March 2011 from six rural villages 
situated in a district with low available selenium acidic soils in the Extension Planning Area 
(EPA) of Zombwe (n=60) in Mzuzu Agricultural Development District in the north, and six 
villages in Mikalango EPA (n=60), a district with high available selenium calcareous soils in 
the Shire Valley in the south of Malawi. December to the end of March is the preharvest and 
rainy season in Malawi, when most of the farming activities take place and food intakes are 
lowest. Women (non- pregnant) aged 18 to 50 years, apparently healthy with no evidence of 
acute or chronic illnesses, and with an initial hemoglobin > 80 g/L, were eligible to 
participate. Only one woman per household was recruited. The sample size was sufficient to 
detect a difference in the prevalence of zinc deficiency of 15% between the women in the 
two EPAs with a confidence level of 95% [14].  
 
The study protocol was approved by the National Health Sciences Research and Ethics 
Committee, Malawi. Verbal informed consent was obtained from the traditional authorities in 
the villages and from the participants. After recruitment, the women were interviewed in their 
homes by trained research assistants using a pretested questionnaire to obtain demographic 
and socio-economic data, and information on the health and family characteristics of the 
women. From these data, a socio-economic status (SES) index was developed based on a 
total possible maximum score of 14 [15].  
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Anthropometry  
Weight and height were measured using standardized techniques and calibrated equipment 
with participants wearing light clothing and no shoes, from which body mass index (BMI) 
(wt/ht
2
), and the proportions with height-for-age Z scores <−2SD and height <145cm were 
calculated.  
 
Collection of duplicate diet composites 
Trained research assistants collected 1-d weighed duplicate diet composites (including 
drinking water) from the women in their homes using digital scales accurate to ±1g (Salter, 
UK); details are described in Hurst et al. [9]. Research assistants also recorded the types of 
foods consumed. Weekend and weekdays were proportionately represented to account for 
any day-of-the-week effects on food and/or nutrient intakes in the group. Diet composites 
were transported chilled to a central laboratory in Lilongwe for processing. Women were 
instructed not to change their normal dietary pattern during the diet-composite day, and were 
reimbursed for the cost of the food. 
  
Analyses of diet composites  
The weighed diet composites were blended to a homogenous slurry, after which aliquots 
were withdrawn into trace-element free polyethylene containers, frozen at –20
٥
C, and then 
shipped on dry ice to the University of Nottingham, where they were freeze-dried to constant 
weight. The diet composites were microwave digested, and the digests analyzed for Fe, Zn, 
Se, Ca, Al, Ti by inductively coupled plasma mass spectrometry (ICP-MS) (Thermo Fisher X 
Series 
(II)
 model) in the laboratory of SY, as described elsewhere [9]. Analysis of phytate (as 
inositol penta-(IP5) and hexa-(IP6) phosphates) was performed by high performance liquid 
chromatography in the laboratory of RSG using the method of Lehrfeld [16], as modified by 
Hotz and Gibson [17]. Molar ratios of phytate:zinc were calculated for each diet composite 
from the analyzed values. Accuracy and precision of the diet composite assays were 
established using certified reference materials for the minerals [9] and an inter-laboratory 
comparison for phytate [17].  
 
 
Calculation of the prevalence of inadequate intakes of zinc 
The distribution of observed intakes of zinc based on the analyzed 1-d diet composites were 
adjusted to usual intakes by using PC-SIDE (PC software for intake distribution estimation) 
in conjunction with the intake, monitoring, assessment and planning program (IMAPP)[18]. 
An external variance component ratio for zinc (0.6993) calculated from dietary data for 
pregnant Malawian women [19] was used for this step because only 1-d diet composites 
were collected. The prevalence of inadequate intakes of zinc, a recommended indicator for 
population risk of zinc deficiency [13] was calculated using the Estimated Average 
Requirement (EAR) cut-point method and the EAR for an unrefined cereal-based diet set by 
the International Zinc Consultative Group [20]. The prevalence of inadequate intakes of iron 
was not estimated in view of the uncertainty about the bioavailability of iron in these diets 
[21]. 
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Laboratory assessment 
Fasting morning venipuncture blood samples were drawn into trace-element free heparinized 
evacuated tubes (Becton Dickinson, UK Ltd, Plymouth, UK) from all the women in the sitting 
position. Blood samples were stored in cooler boxes with ice packs as soon as possible after 
collection, and transported to the laboratories of the nearby district hospitals, where one 
aliquot of whole blood was analyzed for a complete blood cell count performed by an 
electronic counter. A second aliquot was separated by centrifugation using trace-element-
free techniques based on the recommended procedures of the International Zinc Nutrition 
Consultative Group (IZiNCG) [20], and the plasma stored frozen at –80
o
 C in trace-element-
free polypropylene vials. The frozen plasma samples were shipped to the UK on dry ice for 
analysis.  
 
Plasma ferritin, soluble transferrin receptor (sTfR), α-1-acid glycoprotein (AGP), and C-
reactive protein (CRP) were analyzed in duplicate in the laboratory of SFT by enzyme 
immunoassays using commercial kits manufactured by Ramco Laboratories (Houston, TX) 
for ferritin and sTfR, and R&D Systems (Minneapolis, MN, USA) for the inflammatory 
biomarkers. Plasma zinc and selenium were analyzed using ICP-MS (Thermo Fisher X 
Series 
(II)
 model) in the laboratory of SY, as described previously [9]. A pooled plasma 
sample together with manufacturer’s controls (for Hb, ferritin, AGP and CRP) or certified 
reference materials (for plasma zinc, and selenium) [8] were used to check the precision and 
accuracy of the analytical methods. The WHO international reference material (Recombinant 
sTfR, ANIBSC code: 07/202) was used for the sTfR assay [22]. The between-assay CVs for 
serum ferritin, sTfR, CRP, AGP, zinc and selenium were 10 %, 4 %, 7 %, 6%, 1.3%, and 
1.9%, respectively. Values for the controls fell within the certified ranges for plasma ferritin, 
sTfR, AGP, CRP, zinc and selenium. 
 
Plasma concentrations of AGP > 1.0 g/L and CRP > 5 mg/L were used to indicate the 
presence of chronic and acute inflammation, respectively [23] and to adjust the ferritin values 
for subclinical inflammation [24]. Anemia was assessed by Hb <120 g/L [23], microcytic 
anemia by mean cell volume (< 82 fL), depleted iron stores as plasma ferritin <12 µg/L 
(adjusted for inflammation) in the absence of anemia [23], and iron deficiency (ID) as total 
body iron < 0 mg/kg, adjusted for inflammation [25]. The algorithm of Cook et al. [25] was 
used to calculate total body iron because the ratio sTfR to ferritin was measured using the 
Ramco assays [26]. Iron deficiency anemia (IDA) was defined as iron deficiency concurrent 
with anemia. Zinc deficiency was defined as plasma zinc <10.7 µmol/L [20, 27]. No universal 
interpretive criteria are available for plasma selenium because they vary markedly with 
geographic location [28]. In this study, plasma selenium concentrations were considered low 
when below the level of optimal activity of at least one of the selenoproteins (i.e., < 0.82 
µmol/L) [29].  
 
Statistical Analysis 
All p values are 2-sided and not adjusted for multiple testing. Distribution of data was 
checked for normality using the Shapiro-Wilkes test. For consistency and comparability with 
earlier data, intakes of iron and zinc are reported as medians (1
st
, 3
rd
 quartiles). Values for 
ferritin (adjusted for inflammation), sTfR, CRP, and AGP were log transformed to normalize 
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their distributions and expressed as geometric means (95
th
 Confidence Interval). Differences 
in median intakes, arithmetic or geometric mean (ferritin, CRP and AGP) biomarker 
concentrations in the two EPA’s were assessed using the Mann Whitney-U test and 
Student’s two sample t tests, respectively, whereas differences between the two EPAs for 
the proportion with storage iron depletion, ID, IDA, iron sufficiency, non-iron deficiency 
anemia, and zinc deficiency were examined using Fisher’s exact test. Spearman’s rank 
correlation coefficients were used to explore associations between socio-demographic 
variables, hemoglobin, and the plasma biomarkers. 
 
Multiple regression analysis was used to examine the independent predictors of adjusted log 
ferritin, adjusted total body iron, hemoglobin, and plasma zinc. The explanatory variables 
investigated in the regression models were those that were known or suspected [13] to be 
biologically important. Dietary intake data could not be included in the models because they 
were based on one day intakes per person [30]. There was no evidence in the multiple 
regression models of multiple colinearity for the independent variables.  Statistically 
significant differences are indicated by p < 0.05. All statistical analyses were carried out 
using STATA-11.0 (Stata Corp, College Station, TX).  
 
Results 
Socio-demographic characteristics of study population  
All women approached agreed to participate in the study and were predominantly 
subsistence farmers. Significantly more women from the high selenium EPA (i.e., Mikalango) 
had little or no primary education, were classified into the two lowest SES categories (i.e., 
SES score 1-3 and 4-7), and had a lower mean age and height than the women from the low 
selenium EPA (i.e., Zombwe) (p <0.05). In contrast, there were no significant differences in 
the mean number of persons per household, body weight, and BMI of the women in the two 
districts, with <15% in each district with a BMI below 18.5 (termed “mild underweight”) (Table 
1). Of the women, less than 10% were stunted, with very few (< 5%) with a height below 145 
cm, the critical height to limit the risk of delivery complications as a result of cephalo-pelvic 
disproportions [31].  
Table 1: Selected socio-demographic and anthropometric characteristics of Malawian 
women with a low-plasma selenium (Zombwe) and high-plasma selenium (Mikalango) status  
 
 
Zombwe    Mikalango     p 
Household  are subsistence 
farmers 
2
 (%) 
53/60 88 46/60 77 0.249 
Respondents with no or only 
primary education 
2
(%) 
6/60 10 19/60 32 0.049 
Household SES score 5 or 
less on scale of 1-14
2
 (%) 
16/60 27 35/60 58 0.002 
Number of persons in 
household
1,3
 
4.8 1.6 4.7 1.6 0.610 
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Age (y)
 1,3
 39.0 11.0 34.8 9.6 0.026 
Height, cm
1,3
 156.5 5.5 152.8 5.9 0.001 
Weight, kg
1,3
 55.4 11.6 52.8 8.0 0.173 
BMI, kg/m
2  1,3
 22.5 4.1 22.5 3.3 0.977 
BMI less than 18.5
2
 (%) 6/53 11 4/55 7 0.523 
Stunted (HAZ < −2.0)
2
 (%) 4/53 8 5/55 9 0.524 
Height less than145 cm
2
 (%) 2/53 4 3/55 5 0.518 
 
1 
Values are mean and standard deviation 
2
 Fisher’s exact test 
3
Students t-test 
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Intakes from analyzed diet composites  
Maize was the dominant cereal in Zombwe whereas in Mikalango, sorghum and millet 
replaced maize. Consumption of both cellular animal protein and dairy products were low in 
both groups, with the exception of a small amount of milk consumed with tea. Indeed, during 
the diet composite collection day, milk was consumed in tea by the women in Mikalango on 
only one of the nine tea-drinking- occasions compared to eight of the 51 tea-drinking-
occasions in Zombwe. Median (1
st
, 3
rd
 quartile) analyzed intakes (Table 2) were significantly 
higher (p<0.05) for iron, zinc, selenium, titanium, phytate, and molar ratios of phytate:zinc in 
Mikalango compared to Zombwe, although median intakes of aluminium were not 
significantly different in the two EPAs.  
 
Biochemical status 
 In those women with elevated CRP levels indicative of acute inflammation (CRP >5 mg/L, 
17.5%; 21/120), higher concentrations of log plasma ferritin (p=0.048) and a tendency for 
lower values for plasma zinc (p=0.061) were observed; hemoglobin, plasma sTfR and 
plasma selenium did not differ. Elevated AGP concentrations had no significant association 
with plasma ferritin or zinc. 
 
In Zombwe, the mean plasma selenium was lower (p < 0.001) as noted earlier [9], whereas 
the mean cell volume, geometric mean ferritin, mean total body iron (mg/kg) (both adjusted 
for inflammation), and the geometric mean for CRP (but not AGP) were higher (p < 0.05) in 
Zombwe, although the proportions of women with elevated CRP and AGP levels in the two 
districts were not significantly different (Table 3). 
 
The overall prevalence of anemia and iron deficiency anemia was 21% (25/119) and 6% 
(7/115), respectively, with no significant differences between the two districts (Tables 3 & 4). 
Of the anemic women, 14% (17/119) had a low mean cell volume (i.e., < 82 fL). Both storage 
iron depletion and iron deficiency (in the absence of anemia) were low in both districts (Table 
4). Low plasma zinc concentrations were observed in 92% and 95% of the women Zombwe 
and Mikalango, respectively, with no significant differences between the two districts. As 
expected, 82% of women in Zombwe compared to none in Mikalango had plasma selenium 
concentrations < 0.82 µmol/L.  
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Table 2: Intakes of iron, zinc, selenium, phytate, molar ratios of phytate: zinc, aluminium, and 
titanium based on analyzed diet composites for Malawian women with a low- plasma 
selenium (Zombwe) and a high-plasma selenium (Mikalango) status  
 
Zombwe  (n=55)          Mikalango  (n=58) 
 
 Median (1,3
rd
 Q) Median (1,3
rd
 Q)     P
1
 
Iron (mg/d)   16.6 (10.9, 26.0) 29.6 (15.9, 49.3) <0.001 
Zinc (mg/d) 4.8 (3.5, 6.4) 6.4 (4.4, 8.5) 0.003 
Selenium (µg/d)   6.6 (4.5, 10.1) 55.3 (31.4, 89.8) <0.001 
Phytate (mg/d) 846 (525, 1197) 1564 (1094, 2236) <0.001 
Phytate:zinc
2
 17 (14,20) 24 (20,31) <0.001 
Aluminium (mg/d) 15.6 (11.3, 27.6) 16.7 (10.0, 29.3) 0.827 
Titanium (mg/d) 0.18 (0.12, 0.31) 0.32 (0.22,0.44) <0.001 
             
(1,3rd Q): 1st, 3rd Quartile 
         
1
Mann Whitney-U test
 
        
         2
Molar ratiovery complications as a result of cephalo-pelvic disproportions [31 
The prevalence of inadequate intakes of zinc was 54% in Mikalango EPA and 89% in 
Zombwe EPA, based on an EAR set for unrefined cereal-based diets [20].  
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Table 3: Plasma biomarkers, hemoglobin and mean cell volume for Malawian women with a 
low-plasma selenium (Zombwe) and a high-plasma selenium (Mikalango) status 
 
Zombwe Mikalango 
                Mean (95% CI) Mean (95% CI) p 
Zinc, µmol/L
1,4
 8.60 (8.22, 8.99) 8.87 (8.55, 9.19) 0.289
1
 
Zinc < 10.7 µmol/L, 
n (%)
5
 
55/60 (92%) 57/60 (95%) 
0.464 
   
 
Selenium, µmol/L
1,4
 0.72 (0.68, 0.75) 1.60 (1.52, 1.68) <0.001 
Selenium < 0.82 
µmol/L
5
, n (%) 
49/60 (82%) 0/60 (0%) <0.001 
   
 
Hemoglobin, g/L
1,4
 138.9 (132.4,145.4) 132.8 (128.6, 137.0) 0.119 
Hemoglobin < 120 
g/L
5
, n (%) 
14/60 (23%) 11/59 (19%) 
0.530 
   
 
MCV, fL
1,4
 90.2 (87.6, 92.9 85.3 (82.3, 87.9) 0.009 
MCV <  82 fL
5
, n 
(%) 
14/60 (23%) 24/59 (41%) 
0.042 
   
 
Ferritin, µg/L
2,3
 38.6 (30.6, 48.7) 26.3 (20.5, 33.8) 0.027 
Ferritin < 12.0 
µg/L
5
, n (%)  
5/60 (8%) 11/56 (20%) 
0.078 
   
 
Body iron (mg/kg)
1,4
 5.3 (4.3, 6.4) 3.8 (2.7, 4.9) 0.046 
Body iron<0 mg/kg
5
, 
n (%) 
6/60 (10%) 8/56 (14%) 
0.479 
   
 
CRP, mg/L
2,4
 1.6 (1.1, 2.4) 0.7 (0.5, 1.1) 0.004 
CRP > 5 mg/L
5
, n 
(%) 
13/60 (22%) 8/60 (13%) 
0.230 
   
 
AGP, g/L
2,4
 0.5 (0.5, 0.6) 0.6 (0.5, 0.6) 0.326 
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MCV: Mean cell volume; CRP: C-reactive protein; AGP: α-1-acid glycoprotein 
1
Values are arithmetic means 
2
Values are geometric means 
3
Ferritin values are adjusted for inflammation [24] 
4
Students t-test
 
5
Fisher’s exact test  
AGP >1 g/L
5
, n (%) 6/60 (10%) 4/59 (7%) 0.527 
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Table 4: Prevalence of depleted iron stores, iron deficiency, iron deficiency anemia, iron 
sufficiency, and non-iron deficiency anemia for Malawian women with a low- plasma 
selenium ( Zombwe) and a high-plasma selenium (Mikalango) status  
 
Hb: Hemoglobin 
1
Ferritin values are adjusted for inflammation [24] 
2
Fisher’s exact test  
 
Interrelations among biomarkers and socio-demographic variables  
Significant Spearman’s rank correlations were observed between values for all the women 
for adjusted log ferritin and hemoglobin (r=0.245, p=0.008), log sTfR and hemoglobin 
(r=−0.320; p=0.005), adjusted total body iron and hemoglobin (r=0.388, p < 0.001), adjusted 
log ferritin and log sTfR (r=−0.554, p<0.001), and plasma zinc and hemoglobin (r=0.291, 
p=001). No significant relationships were observed between plasma biomarkers and the 
socio-demographic or anthropometric characteristics of the women 
Stages of iron deficiency 
Zombwe Mikalango  
n (%) n (%) p
2
 
Storage iron depletion
1,2
 
  
 
Ferritin < 12 ug/L+ Hb 
> 120 g/L 
2/60 (3%) 5/55 (9%) 0.269 
   
 
Iron deficiency 
1,2
 
  
 
Body iron<0 mg/kg + Hb > 120 g/L 4/60 (7%) 2/55 (4%) 0.683 
   
 
Iron deficiency anemia
1,2
  
  
 
Body iron<0 mg/kg + Hb < 120 g/L 2/60 (3%) 5/55 (9%) 0.269 
   
 
Iron sufficient (non-anemic)
1,2
 
  
 
Body iron >0 mg/kg + Hb > 120g/L 
42/60 
(70%) 
43/55 
(78%) 
0.699 
   
 
Non-iron deficiency anemia
1,2
   
  
 
Body iron >0 mg/kg + Hb < 120g/L 
12/60 
(20%) 
5/55 (9%) 
0.196 
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In view of the very large differences in the plasma selenium concentrations in the two EPAs 
[9], associations between plasma selenium and other biomarkers were examined separately 
for each EPA. In the low-selenium Zombwe EPA, the Spearman’s rank correlation between 
plasma selenium and zinc was positive (r=0.253, p=0.052, n=60), whereas in the high-
selenium Mikalango EPA the correlation was negative (r=–0.273; p=0.035, n=60).  Plasma 
selenium was not associated with any of the other biomarkers or the socio-demographic 
variables of the women in each EPA. 
 
Determinants of plasma ferritin, total body iron, plasma zinc and hemoglobin  
Plasma CRP (but not AGP) was a significant and positive determinant of unadjusted log 
ferritin (p=0.004; R
2
=0.10) based on linear regression analysis. Neither age, household 
socio-economic status, education level of the respondent, BMI, or district were significant 
determinants of adjusted log ferritin or adjusted total body iron, and for plasma zinc when log 
CRP or log AGP was also included as an additional independent variable in the regression 
analysis. In the multiple regression model for hemoglobin, total body iron adjusted for 
inflammation had the largest standardized beta coefficient, followed closely by plasma zinc; 
neither log AGP, household SES score, age or district (high or low selenium status area) 
was significant (Table 5).  
 
Table 5:  Multiple linear regression analysis with hemoglobin as the dependent variable 
Independent variable β coefficient (95% CI) Standardized β p>t 
Total body iron, mg/kg
1
 0.183 (0.095, 0.272) 0.354 0.000 
Plasma zinc, µmol/L 0.007 (0.003, 0.011) 0.293 0.001 
Log AGP, g/L −0.642 (−1.478, 0.195) −0.126 0.131   
Household SES score −0.090 (−0.325, 0.145) −0.069 0.448 
Age, y −0.026 (−0.061, 0.009) −0.126 0.148 
District code −0.682 (−1.482, 0.118) −0.159 0.094 
    
n=115, R
2
 = 0.252 
1
Plasma ferritin adjusted for inflammation [24]  
 
Discussion 
A striking feature of the results is the very high prevalence of zinc deficiency which was 
independent of their selenium status, and the contrasting much lower prevalence of iron 
deficiency among these Malawian women.  This result was unexpected in view of the low 
intakes of readily available heme iron from cellular animal protein and the high phytate : iron 
molar ratios in the diets. Furthermore, the multiple regression results with hemoglobin as the 
dependent variable emphasized that the zinc status of these women was almost as 
important as total body iron (mg/kg body weight) as a determinant of hemoglobin.  
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Zinc status 
 In this study the prevalence of inadequate intakes of zinc was high, especially among the 
women from Zombwe, suggesting that dietary-induced zinc deficiency most likely contributed 
at least in part to the high prevalence of zinc deficiency noted here, a finding consistent with 
earlier reports of rural Malawian pregnant women [15].  This finding is not unexpected as the 
diets of the women in both EPAs were low in zinc with high phytate-to-zinc molar ratios, and 
the inhibitory effect of phytate on zinc absorption in adults is now thought to be much larger 
than previously estimated [32]. Moreover, there is no evidence of an adaptive response to 
habitual high phytate intakes on zinc absorption [33]. Nevertheless, the predicted risk of zinc 
deficiency based on low plasma zinc concentrations was higher than predicted from zinc 
intakes. Several factors may account for this lack of concordance, including the existence of 
tropical enteropathy, which has been reported earlier to exacerbate risk of zinc deficiency 
among Malawian children [34].  
 
The prevalence of low plasma zinc concentrations among the women was unexpectedly high 
in the two districts, with a difference of only 3% , despite their contrasting plant-available soil 
selenium concentrations. Our sample size was too small to detect whether this was a 
significant difference in the prevalence of zinc deficiency.   
 
Iron status 
Less than 15% of the women had iron deficiency (defined by total body iron <0 mg/kg), 
despite the high prevalence of zinc deficiency (i.e., > 90%) in both EPAs. Indeed, total body 
iron for the Zombwe women, unlike the women in Mikalango EPA, was very comparable to 
that for US women of child bearing age (20 to 49 y) in the US National Health and Nutrition 
Examination Survey 2003−2006 [35]. A lack of concordance between the prevalence of iron 
and zinc deficiency has also been reported earlier among pregnant women in Ethiopia 
whose diets, like those reported here, contained negligible amounts of readily absorbable 
heme iron but high levels of non-heme iron [3].  Contaminant iron from soil was probably 
responsible, at least in part, for the high iron content of the Malawian diets, as reported 
earlier in Ethiopia [36, 37]. This suggestion is supported by the high concentrations of 
aluminum and titanium in the analyzed diet composites, well recognized markers of soil 
contamination [38], and their positive correlation (p<0.05) with the iron concentration of the 
diet composites. These findings highlight the importance of assessing iron intakes from 
analyzed duplicate diet composites in this setting. In Malawi, iron contamination from soil 
may be from cereals being threshed under the hooves of cattle. During threshing, soil 
adheres to the outer surface of the cereal grains, especially those with small grains such as 
sorghum and millet, the major cereals consumed in the Mikalango EPA .  
  
The low prevalence of depleted iron stores, especially among the Zombwe women (i.e., 3%), 
even after adjusting ferritin for inflammation, suggests that at least some of the contaminant 
iron may have joined the common nonheme iron pool (i.e. is exchangeable) and thus been 
available for absorption as postulated in Ethiopia [36], although we recognize that predicting 
the exchangeability of contaminant iron is difficult [39]. Moreover, the low prevalence of iron 
deficiency anemia overall (i.e., 6 %) suggests that the few women identified with low iron 
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stores may have upregulated iron absorption from their predominantly cereal-based diets to 
preserve hemoglobin mass.   
 
The women in the high selenium EPA – Mikalango – had significantly higher  intakes of total 
iron compared to those in the low selenium EPA, yet significantly lower (P < 0.05) adjusted 
values for plasma ferritin and total body iron (Tables 2 and 3). Several factors may account 
for this discrepancy, including the significantly higher phytate (Table 2), and probably higher  
polyphenol content of the finger millet and brown sorghum consumed in Mikalango, 
compared to the maize in Zombwe, which has a low polyphenol content [40].  Both phytate 
and polyphenols inhibit absorption of the non-heme iron intrinsic to food as well as any 
exchangeable contaminant iron [1, 39].  Consumption of polyphenol-containing tea was not 
an additional inhibitory factor because the women in Mikalango consumed less tea than 
those in Zombwe. 
 
It is also possible that the proportion of exchangeable contaminant iron was lower in the 
diets in Mikalango than Zombwe due to differences in soil mineralogy.  Mikalango EPA is 
characterized by areas of calcareous Eutric Vertisols (median pH = 7.8), whereas in Zombwe 
EPA soils have a low pH (median 5.2) [9]. Certainly, the proportion of soil contaminant iron 
that is available for absorption is said to vary widely [39]. Reduction in iron absorption as a 
consequence of inflammation [41] is unlikely to be responsible for the discrepancy because 
there were no differences in the prevalence of elevated concentrations of CRP and AGP in 
the two EPAs. 
 
 Determinants of plasma ferritin, total body iron, hemoglobin, and plasma zinc  
We were unable to explore the role of the dietary intakes as determinants of iron, 
hemoglobin, or zinc status of the women in our multiple regression models because only 
one-day diet composites were collected. Of the dependent variables investigated, only 
significant determinants of hemoglobin were identified. These were adjusted total body iron 
and plasma zinc, with plasma zinc being almost as important as total body iron (based on 
the absolute values of the standardized ß-coefficients). Furthermore, there was no significant 
correlation linking these two independent variables (i.e., total body iron and plasma zinc) 
(data not shown), confirming that a comparable distribution of iron and zinc in the food 
supply was not responsible for the positive association between zinc and hemoglobin noted 
here.  
 
Both dietary and non-dietary factors probably contributed to the positive relationship 
observed here between adjusted total body iron and hemoglobin. As emphasized earlier, 
total iron intakes were unexpectedly high, in part due to contaminant iron from soil, although 
the extent to which the contaminant iron is exchangeable is uncertain. Consequently, we did 
not calculate the prevalence of inadequate intakes of iron.   
 
It is of interest that 15% of the cases of anemia overall among these Malawian women were 
not attributable to iron deficiency (Table 4). Other factors, not investigated in this study, that 
have been reported in earlier studies to play a role in anemia in Malawi include deficiencies 
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of vitamin B-12 and vitamin A [42], as well as malaria, glucose-6-phosphate dehydrogenase  
deficiency (G6PD), α-thalassemia,  and sickle cell disease [43]. Most of these factors were 
not investigated in this study with the exception of macrocytosis (i.e., mean cell volume > 99 
fL) [44], a characteristic of vitamin B-12 deficiency, which was seen in 8% of the women.  
 
Plasma zinc was found to be an important determinant of hemoglobin in an earlier study of 
pregnant Ethiopian women [3]. Several mechanisms exist whereby zinc has a role in 
hemoglobin concentrations. For example, hemoglobin synthesis depends on several zinc-
dependent enzyme systems, specifically aminolevulinic acid dehydrase [45] and thymidine 
kinase and DNA polymerase [46], whereas a zinc finger transcription factor-- GATA-1-- is 
essential for normal hematopoiesis [47]. Zinc may also play a role in stabilizing red cell 
membranes and in increasing plasma IGF-1 levels, which may in turn stimulate 
erythropoiesis [48].  
   
Despite the tendency for plasma zinc and selenium to be positively correlated among women 
in the low selenium district of Zombwe and negatively correlated in the high selenium district 
of Mikalango, district was not a significant determinant of plasma zinc in our multiple 
regression model. The reason for these findings is uncertain. 
 
Strengths and weaknesses of study  
We believe this study has several strengths. The analysis of the duplicate diet composites 
improved the estimates of trace element and phytate intakes, and confirmed the presence of 
contaminant iron from soil, although because the diet composites were based on only one 
day, the data could not be included in the multiple regression models.  Furthermore, our 
estimates for the prevalence of inadequate zinc intakes were calculated from the distribution 
of usual intakes, whereas that of iron deficiency was based on total body iron adjusted for 
inflammation to provide a more accurate reflection of the true prevalence and severity of 
nutritional iron deficiency [49]. Finally, analysis of plasma zinc and selenium as well as 
multiple iron biomarkers allowed the assessment of inter-relationships among these 
micronutrients in Malawian women, which has not been possible in earlier reports. 
 
Nevertheless, we were not able to assess the presence of malaria parasitemia or  genetic 
hemoglobin disorders, all of which also have been implicated in anemia in Malawi [43] and 
also have the potential to confound total body iron assessment by elevating sTfR in 
response to an increased rate of erythropoiesis [49,50]. Further, we used the correction 
factors of Thurnham et al. [24] to adjust for the effect of subclinical inflammation on ferritin 
and body iron because our sample size was too small to yield reliable estimates based on 
internally generated correction factors.  
 
We also recognize that our results are based on a convenience sample of women and 
therefore not representative of women of child-bearing age living in Zombwe and Mikalango 
EPAs of Malawi.  However, in an effort to minimize bias, women from six villages in Zombwe 
EPA and six villages in Mikalango were approached, all of whom were eligible and agreed to 
participate in the study. A further limitation is that our small sample size may have accounted 
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for our inability to both detect any difference in the prevalence of low plasma zinc among the 
women in the two districts and explain none of the variance in ferritin, total body iron, and 
plasma zinc concentrations.  Nonetheless, some of the nutritional status variables reported 
here were comparable to those reported in the same geographical areas in the 2010 
Malawian Demographic and Health Survey [51]. For example, in Zombwe and Mikalango 
EPAs, both the mean BMI (Zombwe, 22.4 vs. 22.5; Mikalango, 21.6 vs. 22.5) and the 
proportion with BMI <18.5 (Zombwe, 5.6 vs. 10%; Mikalango, 7.8 vs. 15% were reasonably 
comparable to those reported here. Likewise, for Zombwe, the prevalence of anemia in the 
DHS survey was similar (26 vs. 23%), although higher for the DHS survey in Mikalango 
(37%) than that reported in this study (19%). Finally, because our study was observational, 
we cannot exclude the possibility of unmeasured confounding.  
 
Conclusion 
Risk of zinc deficiency among these Malawian women was much higher than that of iron 
deficiency in both districts. This finding was attributed to diets low in absorbable zinc but with 
a high total iron content due in part to contaminant iron from soil. We were unable to show 
any differences in the prevalence of zinc deficiency among the women living in districts with 
low and high plant-available soil selenium concentrations. Plasma zinc was almost as 
important as total body iron as a determinant of hemoglobin.  Our findings suggest that at 
least some of contaminant iron from soil was exchangeable and thus available for 
absorption, and highlight the utility of analyzing diet composites to assess total iron intakes in 
this setting.  
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 CONSORT 2010 checklist of information to include 
when reporting a randomised trial* 
Section/Topic 
Item  
No Checklist item 
Reported 
on page 
No 
Title and 
abstract 
   
 1a Identification as a randomised 
trial in the title 
n/a 
 1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific guidance 
see CONSORT for abstracts) 
n/a 
Introduction    
Background 
and objectives 
2a Scientific background and 
explanation of rationale 
72-101 
 2b Specific objectives or hypotheses 102 
Methods    
Trial design 3a Description of trial design (such 
as parallel, factorial) including 
allocation ratio 
103; 105- 
106 
 3b Important changes to methods 
after trial commencement (such 
as eligibility criteria), with reasons 
n/a 
Participants 4a Eligibility criteria for participants 104-105 
 4b Settings and locations where the 
data were collected 
107 
Interventions 5 The interventions for each group 
with sufficient details to allow 
replication, including how and 
when they were actually 
administered 
110-111 
115-116 
Outcomes 6a Completely defined pre specified 
primary and secondary outcome 
measures, including how and 
when they were assessed 
117-120 
 6b Any changes to trial outcomes 
after the trial commenced, with 
reasons 
n/a 
Sample size 7a How sample size was determined 120 
 7b When applicable, explanation of 
any interim analyses and 
stopping guidelines 
n/a 
Randomisation:    
Sequence 
generation 
8a Method used to generate the 
random allocation sequence 
109 
 8b Type of randomisation; details of 
any restriction  such as blocking 
and block size) 
n/a 
 Allocation 
Concealment 
mechanism 
9 Mechanism used to implement 
the random allocation sequence 
(such as sequentially numbered 
109 
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containers), describing any steps 
taken to conceal the sequence 
until interventions were assigned 
Implementation 10 Who generated the random 
allocation sequence, who 
enrolled participants, and who 
assigned participants to 
interventions 
107-109 
Blinding 11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care providers, 
those assessing outcomes) 
and how 
105 
 11b If relevant, description of the 
similarity of interventions 
106 
Statistical 
methods 
12a Statistical methods used to 
compare groups for primary 
and secondary outcomes 
120-121 
 12b Methods for additional analyses, 
such as subgroup analyses and 
adjusted analyses 
n/a 
Results    
Participant flow 
(a diagram is 
Strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
103 
 13b For each group, losses and 
exclusions after randomisation, 
together with reasons 
103 
Recruitment 14a Dates defining the periods 
of recruitment and follow-up 
106 
 14b Why the trial ended or was 
stopped 
n/a 
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
123 
Numbers 
analysed 
16 For each group, number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups 
129 
Outcomes and 
estimation 
17a For each primary and secondary 
outcome, results for each group, 
and the estimated effect size and 
its precision (such as 95% 
confidence interval) 
120-121; 
129 
 17b For binary outcomes, 
presentation of both absolute and 
relative effect sizes is 
recommended 
129 
Ancillary 
analyses 
18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing pre-specified from 
exploratory 
129 
Harms 19 All important harms or n/a 
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unintended effects in each 
group (for specific guidance 
see CONSORT for harms) 
Discussion    
Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
131; 133- 
134 
Generalisability 21 Generalisability (external validity, 
applicability) of the trial findings 
134 
Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence 
131-134 
Other    
Registration 23 Registration number and name of 
trial registry 
102 
Protocol 24 Where the full trial protocol can 
be accessed, if available 
102 
Funding 25 Sources of funding and other 
support (such as supply of drugs)  
73 
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Manchester, 17.08.2011  
 ‘Estimation of iron status in Malawi’, Seventh DRINC Dissemination Event 12-
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 Joint poster with IFR ‘Enhancing delivery of minerals using multifunctional carriers – 
II’ prepared for Forth DRINC dissemination event, 27-28
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 April 2010. 
 Poster ‘Interactions between iron and alginates in Caco-2 cell model’ presented at 
Bioavailability 2010 conference 26-30
th 
September and Fifth DRINC dissemination 
event 20-21
st
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 Joint poster with IFR ‘Preparation of multifunctional carriers for the site directed 
delivery of iron’ (co-author) prepared for Sixth DRINC Dissemination Event, 13-14
th
 
April.2011.  
 Poster ‘Challenges of estimating iron status in Malawi’ PGR student conference, 
University of East Anglia, Norwich, 29
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